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Abstract
Alzheimer’s disease was first discovered in 1906 by Alois Alzheimer. It is a neurodegenerative disease characterized
by the buildup of toxic amyloid plaque and intracellular neurofibrillary tangles, which results in the progressive loss of
cognitive function and memory. Since its discovery, the disease has become a growing health concern, particularly in the
developed world, where the ageing demographics have contributed to an increase in its prevalence and incidence. The
earliest research into the disease focused on neurochemical analyses and resulted in the formulation of the cholinergic
hypothesis. The mechanism of disease was explained as the degeneration of the cholinergic system and a reduction in
acetylcholine. While much data supports this hypothesis, it fails to explain the accumulation of amyloid plaque, a hallmark of the disease. Analysis of the genetic factors in familial Alzheimer’s disease, and the discovery of the higher risk
for Alzheimer’s disease amongst individuals with Down’s syndrome led to the more comprehensive amyloid cascade
hypothesis.The failure of both amyloid centric drugs and cholinesterase inhibitors to have a significant impact on disease
progression has caused some to have rejected both these hypotheses to focus on other possible causes. However,
there is undoubtedly a wealth of data in support of both the cholinergic hypothesis and the amyloid cascade hypothesis.
Understanding the functional relationship between the cholinergic system and the formation of beta amyloid plaques
may lead to a greater understanding of the mechanism of disease and provide a target for more effective therapy.
Introduction
Alzheimer’s disease was first identified by Alois Alzheimer in
1906. However not until the 1970’s did it become a major and
significant area of research. Since that time much has been
discovered about the mechanisms of the disease, however the
precise biological processes in the disease are mostly unknown
and the large variance in its progression amongst patients with
the disease needs to be better understood.
Alzheimer’s disease is a neurodegenerative disease that effects
memory, behavior and eventually leads to death within an average of 8 years of diagnosis, the last three of which are typically
spent with full time care or in an institution.
The changing demographics worldwide and with the baby boom
generation reaching ages 70 and beyond has led Alzheimer’s
disease to become one of the biggest healthcare concerns in
the developed world. This greater prevalence and incidence of
Alzheimer’s disease, the largest cause of dementia, has created a
huge burden on society.
Millions of Americans have Alzheimer’s disease and other forms
of dementias. An estimated 5.4 million Americans of all ages had
Alzheimer’s disease in 2016. One in nine people aged 65 years
or older and about one third (32%) of people aged 85 and older
have the disease (Herbert et al., 2013).
The future projections for Alzheimer’s disease are equally bleak.
Approximately 476,000 people will develop the disease in the
United States in 2016, with the numbers increasing dramatically
with age. There will be 63,000 new cases among people aged 65
to 74 and 241,000 new cases among people aged 85 and older.
Because of the ageing demographics in the United States, these
numbers are projected to double by 2050 (Herbert et al., 2001).

Alzheimer’s disease is one of the leading causes of both mortality and morbidity in the United States. It is currently the sixth
leading cause of death for those 65 years and older. According
to data from the National Center for Health Statistics of the
Centers for Disease Control and Prevention (CDC), 84,767
people died from it in 2013. These numbers only consider
those who have cause of death listed as Alzheimer’s disease on
their death certificate. Death certificates for individuals with
Alzheimer’s disease often list other acute conditions, such as
pneumonia, as the primary cause of death and therefore death
due to Alzheimer’s is most likely underreported.
The cost of the disease is very substantial, both in terms of the
value of the unpaid caregiving for Alzheimer’s disease which has
been estimated at $221.3 billion in 2013, and the total payments
made which in 2016 was estimated at $236 billion. Overall the
cost of healthcare, long term care and hospice care for individuals with the disease makes it one of the costliest chronic
diseases to society (Hurd et al., 2013).
Alzheimer’s disease is characterized by a gradually worsening
ability to remember new information. This occurs because the
first neurons to be damaged and destroyed are in the area of
the brain responsible for creating new memories. As the disease
causes the destruction of neurons in other regions of the brain,
symptoms worsen and individuals experience other difficulties
such as challenges in problem solving and planning, confusion
with time and place, decreased and poor judgement, and withdrawal from social activities and work.
There are about 100 billion neurons in the adult healthy brain.
During the development of Alzheimer’s disease, the connections and synapses between neurons is hindered and the overall
number of neurons decrease. The destruction of neurons and
the disruption of the cellular neuronal circuits lead to many of
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the symptoms. The brains of people with advanced Alzheimer’s
disease show inflammation, dramatic shrinkage from cell loss
and widespread debris from dead and destroyed neurons. Some
of these brain changes can begin 20 years prior to the onset of
symptoms for the disease (Villemagne et al., 2013).
No simple test currently exists for diagnosis of Alzheimer’s disease, rather an individual’s physician together with the help of a
neurologist will use a variety of methods to assist in a diagnosis.
These include obtaining a family history and medical history of
the patient which may include psychiatric, cognitive and behavioral histories. In addition, diagnosis is often aided by conducting
cognitive tests and physical and neurological examinations. Finally,
a physician will typically use blood tests and brain imaging to rule
out other possible causes of behavioral and memory changes
such as tumor formation or nutrient deficiencies.
Much research has focused on a potential precursor to
Alzheimer’s disease known as Mild Cognitive Impairment (MCI).
An individual with Mild Cognitive Impairment will experience
mild but measurable changes in thinking abilities that are noticeable to friends and families of the affected person but that
do not affect the person’s ability to carry out normal everyday
functions and activities (Roberts & Knopman, 2013). It is estimated that about 20% of people over the age of 65 have Mild
Cognitive Impairment. Recent studies have shown that an average of 32% of people with MCI will develop Alzheimer’s disease
within 5 years. However, some with MCI will see their cognitive
decline stabilize, and in some cases, they may even return to
normal cognition (Ward et al., 2013).
In a small percent of those diagnosed with Alzheimer’s disease
the development of the disease can be attributed to genetic
mutations.Three genes have been implicated in its development.
These are the genes which encode for the amyloid precursor
protein (APP), the genes for presenilin-1 and for presenilin-2.
Mutations in both the APP gene and the presenilin-1 gene result
in guaranteed development of the disease, while a mutation in
the presenilin-2 gene leads to a 95% chance of its development.
Individuals with mutations in any of these three genes will usually develop symptoms as young as age 30, unlike the vast majority
of Alzheimer’s cases, which are late onset where symptoms typically develop at age 65 and over (Bekris et al., 2010).
People with Down syndrome are born with an additional copy
of chromosome 21 and have a greater risk of developing all
forms of dementia including Alzheimer’s disease. Studies have
found that more than 75% of people with Down Syndrome
aged 65 and over have Alzheimer’s. While the exact relationship
between Down Syndrome and Alzheimer’s is not entirely clear,
one possible explanation might be that the gene that codes for
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amyloid precursor protein is located on chromosome 21 and
the additional copy of this gene increases the likelihood of the
development of the plaques associated with the amyloid precursor protein. By age 40 most people with Down Syndrome have
high levels of beta amyloid plaques in their brains, a marker for
Alzheimer’s disease (Lott & Dierssen, 2010).
Besides for the genetic factors in Alzheimer’s disease much research has been conducted on the effects of environmental and
modifiable risk factors. Studies have shown that regular physical
activity, and management of cardiovascular risk factors such as
obesity, smoking and high blood pressure reduce the risk of the
development of Alzheimer’s disease and dementia. There is also
evidence that a healthy lifestyle and diet as well as continued
engagement in learning can prevent cognitive decline in old age
(Baumgart et al., 2015).
Current treatment options for Alzheimer’s disease are limited.
None of the pharmacological treatments available cures or
stops the damage the disease causes to the brain. The six drugs
that have thus far been approved by the U.S Food and Drug
Administration (FDA) focus primarily on increasing the levels
of neurotransmitter present in the brain. While this helps deal
with the symptoms of Alzheimer’s disease such as memory loss
and reduced cognitive capacity, these drugs don’t deal with the
underlying issues in the disease, and their effectiveness is limited
to the early stages of the disease.
This paper attempts to review some of the complex molecular
mechanisms involved in Alzheimer’s disease. It will explore the
current research on the molecular mechanisms in Alzheimer’s
disease to better understand the development of the disease
and the wide variance in disease progression, and explain possible areas of future research in the development of more effective therapeutic agents.

Methods
This study was performed through the analysis of various original and peer reviewed articles which were accessed using databases such as the Touro Database, PubMed, and Google Scholar.
The research collected in this study was used to understand the
molecular processes in Alzheimer’s disease, and to evaluate the
various hypotheses postulated in the formation of the disease.

Discussion
Since the systematic biochemical analysis of patients with
Alzheimer’s began in the early 1970’s much knowledge has been
acquired concerning the possible mechanisms responsible for
the disease.The earliest research into neurochemical abnormalities that are present in Alzheimer’s disease led to the formulation of the cholinergic hypothesis.

Molecular Mechanisms of Alzheimer’s Disease

Cholinergic Hypothesis
Acetylcholine was the first neurotransmitter to be identified
and is the neurotransmitter used in all cholinergic neurons. It is
fundamental in both the central nervous system (CNS) and the
peripheral nervous system (PNS).
Successful neurotransmission of acetylcholine is dependent on
proteins needed for its synthesis, transport, degradation and reuptake. Acetylcholine synthesis takes place in the cytoplasm of
cholinergic cells. The enzyme, choline acetyltransferase (ChAT)
catalyzes the combination reaction of dietary choline and AcetylCoA, generated by the mitochondria, to form the product acetylcholine. Three forms of the ChAT enzyme have been found in
humans. Formation of acetylcholine is followed by its transfer to
the synaptic vesicles before release.This step is enabled by the vesicular acetylcholine transporter (VAChT). When the cholinergic
neurons are depolarized, acetylcholine is released by exocytosis
into the synaptic cleft. On the post synaptic neuron, acetylcholine
can activate both muscarinic and nicotinic receptors. Nicotinic
ACh receptors are ion gated channels which are selective for
cations including sodium, potassium, and calcium. Nicotinic receptors are made up from a combination of five different subunits.
The large variance in the properties and functions of the different
nicotinic receptors is a direct result of the many different possible
combinations of subunits that form each receptor. In the PNS the
activation of these receptors results in the transmission of the
signal to ganglion cells and the innervation of muscles and glands.
In the CNS the role of nicotinic receptors is regulatory rather
than purely the transmission of excitatory or inhibitory signals.
In the PNS the nicotinic receptors are mostly located on the
post synaptic neuronal membrane, where they are activated by
acetylcholine and facilitate the transmission of signals. However,
in the CNS the receptors are mostly located on the pre-synaptic
neuronal membrane where their activation regulates the release
of acetylcholine and other neurotransmitters into the synapse.
The activation of these receptors results in an increase in calcium
levels in the presynaptic neuron, which is a crucial step in the
exocytosis of neurotransmitters such as GABA, glutamate, dopamine and serotonin into the synapse. Muscarinic receptors are
G-protein coupled receptors, and unlike the nicotinic receptors,
their role is largely in the transmission of signals. Five isoforms of
the receptor have so far been identified. M1, M3 and M5 are excitatory receptors and their activation results in the formation of
second messengers by phospholipase C which results in closure
of K+ channels enabling the greater depolarization of the cell
and the transmission of signal down the axon. M2 and M4 are
inhibitory and their activation has the opposite effect.They result
in the inhibition of adenylyl cyclase which leads to lower levels
of cyclic adenosine monophosphate (cAMP) and promotes the
inhibition of [Ca]++ channels diminishing cell excitability.

In the synaptic cleft acetylcholine is broken down to its components Acetyl-CoA and choline by the enzyme acetylcholinesterase (AChE). AChE is one of the most kinetically effective
enzymes. It is able to catalyze the breakdown of 5000 molecules
of acetylcholine per second. The choline transporter, CHT1, facilitates the uptake of choline, that is produced by the breakdown of acetylcholine by AChE, into the presynaptic neuron.
This transporter is also the source of the choline used in acetylcholine synthesis and it therefore plays a crucial role in the
recycling of acetylcholine (Fig. 1, Ferreira Vieira et al., 2016).

Figure 1 Schematic representation of biological aspects involving
acetylcholine neurotransmission. (Ferreira Vieira et al., 2016)
Early research into Alzheimer’s disease showed reduced activity of choline acetyltransferase in the amygdala, hippocampus
and cortex of patients with the disease. In one such study, the
levels of the enzyme responsible for acetylcholine synthesis in
patients with the disease was found to be lower than 10% of the
normal activity seen in the control group. Similarly, the levels of
acetylcholinesterase in the same brain regions were markedly
lower in patients with Alzheimer’s disease (Davies & Maloney
1976).
Further studies showed that in addition to the decreased activity of the enzymes responsible for acetylcholine synthesis, the
levels of acetylcholine uptake by neurons in the frontal cortex
and in the hippocampus, were significantly lower in patients
with Alzheimer’s disease. In the frontal cortex, the transport
of choline into synaptosomes was reduced by 50% and an even
greater reduction of 80% was seen in the hippocampus. Further
evidence of the loss of cholinergic function in the uptake of
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choline in Alzheimer’s disease is seen in the lower densities of
the presynaptic high affinity choline uptake carrier (HACU) in
both the cortex and hippocampus (Rylett et al., 1983; Pascual
et al., 1991).
Other studies have shown there to be a reduction in the number of nicotinic and muscarinic M2 acetylcholine receptors in
Alzheimer’s disease brains and there is evidence for the disruption of the M1 receptors and their G-proteins which effects the second messenger systems and transmission of signals
(Whitehouse et al., 1988).
The cholinergic hypothesis of Alzheimer’s disease was also evidenced by the reduction in the amount of acetylcholine released
from neurons in the brains of affected patients. An experiment
conducted on brain tissue of both controls and patients with
the disease collected with short post mortem delay, showed
a significant reduction in tritium (3H-acetylcholine) release
during potassium stimulation, as compared with the controls
(Nilsson et al., 1986).
In addition, the loss of cholinergic neurons as a result of the
neurodegeneration caused by Alzheimer’s has further implicated the cholinergic system in the etiology of the disease. In
particular, the selective degeneration of neurons in the nucleus
basalis of Meynert, a significant source of neurons which are
fundamental in the cholinergic innervation of the cerebral
cortex, explains the reduction in the levels of acetylcholine in
individuals with Alzheimer’s disease (Whitehouse et al., 1982).
It has also been demonstrated that the cholinergic system plays
a role in memory and in learning. The loss of the neurons in
the nucleus basalis of Meynert has been correlated with the
impaired memory and cognitive abilities seen in patients with
Alzheimer’s disease. The effects on the cholinergic system has
also been shown to result in the many behavioral and psychological symptoms seen in individuals with the disease. Emotional
processing deficits associated with Alzheimer’s disease may
be caused by loss of cholinergic function in the areas of the
amygdala and frontal cortex. Apathy and depression as well as
disturbance in sleep cycle are symptoms commonly found in
patients with Alzheimer’s disease. It has been postulated that
the degeneration of cholinergic neurons and the resulting loss
of regulation of neurotransmitters, including dopamine and serotonin, is responsible for the many psychiatric symptoms observed. Moreover, cholinesterase inhibitors, the primary focus
of the current pharmacologic agents available for the treatment
of Alzheimer’s disease have shown to improve many of the psychiatric symptoms. Clinical trials conducted on affected patients,
reported reduced delusions, stress, apathy and depression in the
treated group (Ferreira et al., 2016; Pinto et al., 2011).
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There is much research that shows the link between the cholinergic system and Alzheimer’s disease.The neurodegeneration of
neuronal cells critical in the cholinergic system, the reduction in
the enzymes responsible for the synthesis of acetylcholine, and
lower levels of proteins that facilitate choline uptake in neuronal cells that is seen in the brains of patients with Alzheimer’s
disease, together with the role that the cholinergic system plays
in memory and learning have contributed to the formulation of
the cholinergic hypothesis. However there remains some inconsistencies in this hypothesis that suggest the role of the cholinergic system in the disease needs to be better understood.
Although cholinergic loss seems to correlate with cognitive
impairment, other factors such as loss of synapses and pyramidal cells may also be responsible for the cognitive decline.
Additionally, some patients with Alzheimer’s disease do not
show the large decreases in ChAT activity that would be expected. Moreover, patients with inherited olivopontocerebellar
activity have levels of ChAT which are reduced to similar levels
as those seen in Alzheimer’s patients yet they don’t experience
the decline in cognition and memory that would be expected.
An expectation of the cholinergic hypothesis would be that
drugs that restore cholinergic function to the brain regions effected by Alzheimer’s disease would improve and reverse the
cognitive symptoms seen in the disease. Five drugs have been
approved by the FDA for Alzheimer’s disease. Four of these
drugs are cholinesterase inhibitors and one is a receptor antagonist. The cholinesterase inhibitors have shown limited success
in clinical trials and are mostly able to merely delay the progression of the disease. The failure of the cholinesterase inhibitors
to cure Alzheimer’s disease was seen by some as the strongest
evidence against the cholinergic hypothesis.
Many researchers have continued to explore the role of neurotransmission in the disease because of the acetylcholine
dysfunction seen in the brains of Alzheimer’s disease patients.
However, the inconsistencies with the cholinergic hypothesis
have resulted in a shift in the focus of much of the more recent research towards two of the hallmarks of the disease, the
buildup of beta amyloid plaques in the extracellular space, and
the intracellular formation of neurofibrillary tangles (Craig et al.,
2011; Francis et al., 1999).

Amyloid Cascade Hypothsis
The origins of the Amyloid Cascade Hypothesis lie in the sequencing of the Aβ extracted from cerebral blood vessels
and the brain parenchyma of Alzheimer’s disease patients. The
identification of the Aβ sequence led to the sequencing of the
amyloid precursor protein gene (APP). This gene located on
chromosome 21 encodes the holoprotein that is cleaved first by
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the β-amyloid cleaving enzyme and then by γ-secretase to form
the Aβ peptide. (Masters et al., 1985; Kang et al., 1987; Hussain
et al., 1999). The essence of the amyloid cascade hypothesis is
that the increased production or decreased clearance of the
Aβ peptides causes the disease. Aggregation of the hydrophobic
Aβ40 and Aβ42 peptides results in the formation of insoluble
plaque which triggers a cascade of changes ultimately resulting
in cell death and the symptoms of the disease.
Human APP belongs to a family of type I transmembrane glycoproteins that also includes the similar amyloid precursor like
proteins 1 and 2 (APLP1 and APLP2). These proteins are functionally the same as the APP but they lack the Aβ sequence. The
APP gene is highly conserved and several alternatively spliced
isoforms of APP have been identified in humans. Invertebrates
such as the fruit fly D. melanogaster and the worm C. elegans
contain paralogs of the amyloid precursor protein, amyloid protein precursor-like (APPL) and APP-like 1, (APL-1). The zebrafish genome encodes two variants of APP, Appa and Appb. All of
these proteins share domains that are highly conserved in both
the large extracellular domains and in the shorter cytoplasmic
domain (Nicolas & Hassan, 2014).

Figure 2 The domain structure of APP family members in model
organisms. All APP homologs contain the extracellular domains E2, an
acidic domain (Ac), a copper binding domain (CuBD), and a heparin
binding domain (HBD). A kunitz protease inhibitor domain (KPI) is
found only in the APP and APLP-2 forms of the protein and the Aβ
sequence is only present in APP. The most highly conserved domain
across species is the intracellular YENPTY domain (Nicolas & Hassan,
2014).
APP can undergo two types of processing depending on the
secretases that cleave it. In the non-amyloidogenic pathway APP
is cleaved within the Aβ sequence by α-secretase forming the
sAPPα extracellular protein and the membrane bound αAPPCT.The membrane bound protein is then cleaved by γ-secretase
forming P3 peptide and amyloid precursor protein intracellular
domain (AICD).
In the amyloidogenic pathway,APP is first cleaved by β-secretase
forming the soluble sAPPβ protein and the C-terminal membrane bound fragment βAPP-CTF. The subsequent cleavage of

the βAPP-CTF fragment by γ-secretase forms the Aβ peptide
and the amyloid precursor intracellular domain (ACID). The
release of the Aβ peptide by γ-secretase is thought to be fundamental to Alzheimer’s disease pathology, and the aggregation
of these insoluble and toxic protein fragments results in the formation of the senile plaque that is a hallmark of the disease. In
the earliest and most direct elucidation of the amyloid cascade

Figure 3 proteolytic processing of APP (Nicolas & Hassan, 2014).
hypothesis the aggregation of the Aβ peptide was explained as
critical event in the development of Alzheimer’s disease. The
accumulation of the peptide was seen as both a cause of cell
death and as a crucial step in the hyper-phosphorylation of Tau
proteins leading to the formation of intracellular neurofibrillary
tangles (Hardy & Higgins, 1992).
Critical evidence for the ACH comes from human genetics. The
observation that the Aβ peptide deposited in elderly Down’s
syndrome patients, was the same as that found in patients with
Alzheimer’s suggested that a gene on chromosome 21 was
central to the development of the disease (Glenner & Wong,
1984a). Later studies on a family with a history of early onset
Alzheimer’s provided further evidence for a genetic link in the
disease, and was the basis for much of the research that followed. These studies revealed a missense mutation in the APP
gene that resulted in a V717I amino acid substitution in the
protein product. The position of the substitution, just upstream
from the carboxyl terminal cleavage site of the Aβ peptide, provided further evidence for the role of Aβ peptide in the etiology
of the disease (Goate et al., 1991).
The link between mutations in the presenilin 1 and presenilin 2
genes, that encode a part of the γ-secretase mutiprotein complex, and the development of the disease has likewise provided
support for the amyloid cascade hypothesis.
There are now hundreds of mutations to the PSEN-1, PSEN-2
and APP genes that are known to cause early onset familial AD
(FAD).These mutations effect the formation and accumulation of
amyloid plaque in several ways. Some of these mutations result in
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the extension of the C-terminal side of the Aβ peptide, others increase the overall ratio of the longer less soluble Aβ peptides to
the shorter more soluble forms, and some are directly responsible for an increase in the aggregatory properties of the protein.
In addition to the effects of these three genes on familial
Alzheimer’s disease, there are also genes that are connected
to sporadic Alzheimer’s disease (SAD). There are three major
alleles of the APOE gene in the human population (Nickerson et
al., 2000).These are APOE2, APOE3 and APOE4. A heterozygous
APOE4 carrier has a four-fold increased risk for the disease
as compared with the homozygous APOE3 genotype. The homozygous APOE4 genotype has an even more drastic 12 fold
increase in risk. Conversely, a carrier of the APOE2 gene has
a reduced risk of the disease (Verghase et al., 2011). The ApoE
protein is believed to have a role in the deposition of the amyloid plaques. Furthermore, there are specific mutations in the
APP gene that result in the protection against Alzheimer’s disease, with the evidence suggesting that they disrupt the ability
to form the Aβ peptides.

Figure 4 Amyloid precursor proteins. The diagram shows both the
β- secretase and γ-secretase cleavage sites and protective and
pathogenic mutations (Karran & De Strooper, 2016).
While many of the above studies have shown a link between the
genes involved in the formation of the Aβ peptides and the development of the disease, like the cholinergic hypothesis there
remain some inconsistencies and unanswered questions. These
questions have led many to believe that rather than being the
central mechanism in the development of Alzheimer’s disease,
the formation of amyloid plaque may just be one of several factors that contribute to its development.
Much to the frustration of the proponents of the ACH, the amyloidocentric drugs have failed to produce the results that would
have been expected according to the hypothesis.The phase three
clinical trials of 6 of these drugs have provided disappointing
results. Triampirosate, a small molecule drug that prevents the
aggregation of Aβ peptide showed no significant effect on cognition and memory during the clinical trials. Similarly no significant
effect on primary outcomes were seen in the trials of Tarenflurbil,
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a γ-secretase modulator that reduces the ratio of aggregatory
Aβ peptide to the shorter more soluble form. The only limited
success in this class of drug for the treatment of Alzheimer’s disease, was Solanezumab, a monoclonal antibody directed at the
amyloid plaque protein. In its phase three clinical trials there was
a significant improvement in cognitive abilities. In an extension
trial, these positive effects on cognition were sustained over a
two-year period raising hope and providing some evidence for a
disease modifying effect (Karran & De Strooper, 2016).
A central tenet of the amyloid cascade hypothesis is that the
accumulation of the Aβ peptides causes both cell death and
the intracellular neurofibrillary tangles. Tissue studies in vitro
have shown the toxic nature of Aβ peptide and Aβ42. Many
early studies showed that the addition of the peptide to cell
culture resulted in neuronal death and apoptosis as well as
synaptic and dendritic loss. In vivo studies produced similar
results, when these deleterious effects were seen in mouse
brains injected with the peptide. However, the relationship
between the formation of amyloid plaque and the tangles remains unclear. The aggregation of plaque initially takes place
in the frontal cortex, before spreading throughout the cortex
as the disease progresses. Neurofibrillary tangles first appear
in the limbic system, in the hippocampus and dentate gyrus.
This spatial discrepancy together with further studies that
have shown that the tangles appear before the accumulation
of plaque, and are more closely correlated with disease progression and severity have contributed to the re-evaluation of
the ACH (Braak & Braak, 1998).
An analysis conducted to determine the correlation between
cognitive abilities and some of the neurochemical and structural measurements in 15 patients with Alzheimer’s disease
further questions the relationship between amyloid plaque
and cognitive impairment. In this study, there were only weak
correlations between plaque and tangles and performance
on psychometric tests. In contrast, the density of the cortical
synapses was found to be strongly correlated with the psychological assessments of the patients (Terry et al., 1991). Mouse
models of Alzheimer’s disease have shown the accumulation
of plaques without the observed cognitive impairments. In
addition, neuroimaging analysis have shown the presence of
plaques in cognitively healthy people.
The amyloid cascade hypothesis dominates the field of
Alzheimer’s research as the most complete and evidenced
hypothesis about the causes of the disease. However, it is not
without its flaws, which has led to some reassessing the hypothesis and to others dismissing its significance altogether.
The genetic link to Alzheimer’s disease was considered the central evidence for this hypothesis. Mutations in APP, PSEN1 and
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PSEN2 are associated with familial Alzheimer’s disease and the
EPOE4 allele is a risk factor for sporadic AD. The fact that these
genes are involved in the processing of APP and the formation
of Aβ peptide has provided strong evidence for the role of amyloid plaque in disease progression. The mutations associated
with APP are all located in the proximity of the cleavage sites of
Aβ peptide, suggesting that the plaque formed by the peptide is
central to the development of the disease. However, the mutations in the presenilin genes, which encode γ-secretase, occur
throughout the protein, and not just the sites that are involved
with Aβ formation. This has led to the belief that defective APP
processing may in fact be the actual cause of the disease, and
that the formation of the Aβ peptide and plaques might just be
a secondary effect. This belief is supported by the weak correlation between plaque formation and density and cognition.While
the ACH is the best defined and most widely accepted view, the
data both for and against this hypothesis is significant. Many still
strongly support the ACH and others have dismissed it entirely
to focus on other hypotheses.

Alternative Hypotheses
Analysis of the relationship between mitochondrial function
and Alzheimer’s disease has resulted in the proposition of
the mitochondrial cascade hypothesis (MCH). The fundamental principle of the MCH is that Alzheimer’s disease is
a usual if not inevitable consequence of ageing. Support for
this hypothesis comes from the undoubted evidence of mitochondrial damage in the brains of patients with the disease. Mitochondria are critical in the regulation of cell death
and mutations in mitochondrial DNA and oxidative stress
both contribute to ageing and neurodegenerative diseases
(Lin & Beal, 2006). Studies using flourodeoxyglucose positron
emission tomography (PET) imaging, as a measure of oxygen
uptake, showed deficits in the brains of Alzheimer’s disease
patients (Jack et al., 2012). There is also strong evidence of
free radical damage in AD brains (Sonnen et al., 2008). These
findings suggest that dysfunctional and altered mitochondria
is central in the disease. Experimental evidence for the MCH
comes from studies conducted on cybrid cells- cells that
contains mitochondria from a different cell. Studies on cybrid cells which were induced to take up mitochondrial DNA
from platelets of patients with Alzheimer’s disease, showed
increased production of beta amyloid peptide (Khan et al.,
2000). This data provides support for the MCH, by showing that mitochondrial deficiency is the cause of the amyloid
plaques and central to disease development. Despite this
data, the MCH fails to explain the full array of Alzheimer’s disease pathology. In addition, genome wide association studies
have failed to show links between mitochondrial genes and
proteins and the disease. The cybrid experiments show that
mitochondrial dysregulation in Alzheimer’s disease leads to

increases in beta amyloid production. However, they do not
account for the mutations in APP and PSEN which increase
the ratio of insoluble Aβ peptide to the smaller soluble form,
or the mutations that result in an increase in aggregatory
properties.
Another hypothesis that deserves mention is the metabolism
hypothesis. According to this hypothesis, the underlying cause
of AD is hypometabolism of glucose in the brain. The basis of
this hypothesis was experiments on a rat model injected with
streptozotocin, which effects insulin production, and resulted
in decreased glucose metabolism in the brain, and learning
and memory impairments (Lannert & Hoyer 1998). Further
studies showed that the insulin signaling pathway is significantly depressed in many brain regions in Alzheimer’s disease
(Steen et al., 2005). Clinical experiments also have linked
insulin with Aβ peptide buildup. Incretin mimetics injected
in mice resulted in significant reductions in Aβ plaque load
(Mcclean & Hölscher, 2014), and there is also data that suggests that Aβ oligomers disrupt the insulin pathway leading
to an increase in glycogen synthase kinase 3β (GSK 3β), a Tau
kinase, and the formation of neurofibrillary tangles (Morgen
& Frölich, 2015). As with the mitochondrial hypothesis, no
data from genome wide association studies have confirmed
this link between Alzheimer’s disease and insulin signaling.
However, this hypothesis does provide several targets for
possible therapeutic intervention.
A more generalized proposition is the cell cycle re-entry
hypothesis. This view examines Alzheimer’s disease from
the perspective of age related DNA damage. Neurons are
post mitotic and therefore must maintain integrity long
term. Brain cells have a very high energy requirement and
therefore are particularly susceptible to DNA damage.
Mitogen kinases have increased expression in the brains
of Alzheimer’s disease patients, and have been posited to
stimulate the neurodegenerative pathways and effect cell
repair mechanisms (Arendt et al., 1995). Later studies on
differentiated neurons that were infected with the oncogenes, c-myc and ras resulted in DNA duplication and
hyperphosphorylated and unusually folded Tau proteins,
similar to those observed in Alzheimer’s disease. However,
the disrupted DNA repair mechanisms does not adequately
explain the formation of Aβ plaques, and as before there is
little support for this hypothesis from genome wide association studies.
The observation that the Alzheimer’s disease brain has a
much-reduced capillary and vascular network has led to the
formulation of the vascular hypothesis. There is much evidence linking the brain’s vascular network and the disease.
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Research has found that hypertension and diabetes, which
both have vascular effects, significantly increase the risk
of the development of the disease (Prince et al., 2014). In
one study, it was discovered that the formation of 85% of
the amyloid plaques in AD brains were either centered or
proximal to vasculature (Kumar & Singh et al., 2005). A
study of several different forms of dementia including AD
revealed substantial reductions in microvasculature (Buee
et al., 1994). Although there appears to be a credible link
between the disease and the vasculature, it is not entirely
clear if AD causes damage to the vasculature or if a vascular
insufficiency promotes deposition of Aβ plaque (Karran &
De Strooper, 2016).
One final hypothesis to consider is the Aβ oligomer hypothesis (AβOH). This theory is a variation of the original ACH.
The main traction behind this theory is that it provides possible explanation as to why the density and amount of amyloid plaques does not correlate with the symptoms of AD.
According to the AβOH the oligomers act at a distance from
the plaques and mediate their effects. There is a large amount
of data in support of this view. These include the treatment of
cells with Aβ oligomers to induce neuronal death, the impact
of the oligomers on insulin and nicotinic receptors, and the
injection of these oligomers in rat brains which induced impaired memory and cognition. The AβOH would also explain
why amyloidocentric drugs have had little success (Karran &
De Strooper, 2016).
The cholinergic hypothesis and the amyloid cascade hypothesis clearly are supported by the strongest evidence. The earliest experiments demonstrating the reduction in cholinergic
function provided the basis for much of the later research
into Alzheimer’s disease. Studies have consistently shown
reductions in the levels of enzymes responsible for acetylcholine synthesis, and loss of receptor activity disrupting its
uptake into neurons. This together with the degeneration
of cholinergic neurons has provided the basis for this hypothesis. The genetic studies into familial Alzheimer’s disease
and the link between the disease and Down’s syndrome laid
the path for the formulation of the ACH which is the most
comprehensive hypothesis in Alzheimer’s disease. The cholinergic hypothesis fails to explain the mutations in APP in
familial Alzheimer’s disease, the formation of the Aβ peptide,
amyloid plaques and neurofibrillary tangles. The Amyloid cascade hypothesis too has its inconsistencies and unanswered
questions. However, rather than rejecting the undeniable data
in support of each of these hypothesis, understanding the
links and interactions between the two may provide a clearer
picture of the mechanism of disease and provide a target for
more effective therapy.
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The connection between the cholinergic system and APP
processing has been established. In one study, human embryonic kidney (HEK) cell lines were transfected with muscarinic acetylcholine receptors. As mentioned earlier there
are five isoforms of muscarinic receptors; M1, M2, M3, M4
and M5. Cells transfected with M1 and M3 receptors showed
significant increase in the release of APPα the product in the
non-amyloidogenic pathway, when exposed to Carbachol a
muscarinic receptor agonist. These cells also released lower
levels of Aβ (Nitsch et al., 1992). Similar effects were seen in
rat cerebral cortex slices that were exposed to M1 receptor
agonists (Pittel et al., 1996). In addition to the effect the cholinergic system has on APP processing, Aβ peptides appear
to modulate cholinergic function. Picomolar and nanomolar
concentration of the beta amyloid peptide inhibit acetylcholine release from neurons in studies conducted on rat
hippocampus and cortex sections. The exact mechanism by
which the Aβ adversely effects acetylcholine release remains
unclear. However, it appears that the Aβ peptides inhibit uptake of choline in the presynaptic neurons. The activity of
choline acetyltransferase (ChAT) appears to be unaffected,
while high affinity choline uptake is decreased by 20 minutes
after incubation with Aβ (Kar et al., 2004). Further studies on
rat septal neurons found that Aβ42 reduces the levels of acetylcholine by inhibiting the activity of the enzyme pyruvate
dehydrogenase (PDH). The inhibition of pyruvate dehydrogenase results in a reduction in the biosynthesis of Acetyl-CoA,
which is critical for acetylcholine synthesis. Aβ peptides have
also been shown to disrupt cellular signaling and secondary
messengers activated by muscarinic receptors.
Aside from the disruption to the various cellular processes Aβ exposure is also toxic to neurons in the long term.
Differentiated cholinergic cell lines were the most susceptible to the toxic effects of beta amyloid, while GABAergic and
serotonergic cells were more resistant. As stated above Aβ
peptide appears to effect choline uptake in neurons. Under
conditions of choline depletion, cells synthesize acetylcholine using membrane phosphatidylcholine. Therefore, a severe
choline depletion may result in regulated membrane turnover being disrupted and eventually lead to cell death.
Aβ has also been shown to have a role in the hyper-phosphorylation of Tau. Hyper- phosphorylated Tau can no longer associate with microtubules, effecting both cell structure and vital
mechanisms of transport. In cholinergic cell lines, aggregated
Aβ peptide induced the phosphorylation of Tau proteins. The
exact mechanism is unclear but it is most likely a result of an
increase in kinase activity as Aβ peptides have been shown to
increase the activity of both MAP kinase and GSK3β.
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Figure 5 Targets of Aβ that modulate cholinergic transmission: (1)
Aβ reduces activity of pyruvate dehydrogenase, an enzyme that
generates acetyl coenzyme A (CoA) from pyruvate; (2) Aβ reduces
high-affinity uptake of choline; (3) long-term or high-dose exposure to
Aβ reduces activity of the choline acetyltransferase (ChAT) enzyme;
(4) Aβ reduces acetylcholine (ACh) content; (5) Aβ reduces ACh
release from synaptic vesicles (SV); (6) Aβ impairs muscarinic M1-like
signalling. AChE = acetylcholinesterase, Ch U = site of choline uptake,
M2 = presynaptic muscarinic M2 receptor, N = presynaptic nicotinic
receptor, PtdCho = phosphatidylcholine. (Kar et al., 2004).

Conclusion
With the wealth of evidence in support of both the cholinergic
hypothesis and the amyloid cascade hypothesis, an attempt at
fully understanding the mechanism of disease will require better
understanding of the link between Aβ peptides and the cholinergic system. The cholinergic system has been shown to play a
significant role in the regulation of APP processing. Reciprocally,
studies have found that the accumulation of Aβ peptides disrupts
the muscarinic and nicotinic receptors on cholinergic neurons
while also having a downstream effect on the signaling pathway
and secondary messengers. In addition, Aβ inhibits synthesis
of acetylcholine in a variety of ways and cholinergic neurons
are particularly susceptible to the toxic effects of Aβ peptide.
Genetics provides the basis of support for the amyloid cascade
hypothesis, and while the amyloid plaque density may not correlate well with cognitive impairment in Alzheimer’s disease, its
interactions with the cholinergic system may be responsible for
the symptoms of AD. The exact mechanism of that interaction
needs to be better elucidated, as that understanding provides
the greatest potential for more effective and targeted therapy.
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Abstract
Alzheimer’s disease is a major cause of dementia in the elderly and is a global health concern. However, researchers are
not sure what causes the characteristic amyloid-β plaque accumulation and neurofibrillary tangles in the brain. Several
model mechanisms have been proposed to answer this question. This paper examines three of these possibilities.
Research suggests that a particular allele of the apoE gene is responsible for the neurodegeneration found in Alzheimer’s
disease. Another hypothesis is that the mechanism of Alzheimer’s is related to prion-mediated protein misfolding. Other
studies indicate that certain environmental factors can cause the neuropathology of Alzheimer’s. Specifically, this paper
will investigate the effects of a neurotoxin produced by cyanobacteria. Each of these possibilities is backed by supporting
evidence, and there is probably not just one cause. Alzheimer’s is a complex disease caused by a combination of interacting factors that may include these models, as well as others that have not been focused on in this paper. The more
that is discovered about the multiple possible causes of Alzheimer’s, the closer we are to developing ways of preventing
these pathways in the hope of a cure.
Introduction
Alzheimer’s disease is the most common cause of dementia in the
elderly (Seeley, Miller 2015) and a devastating disease for those affected and their families.According to the Alzheimer’s Association,
Alzheimer’s disease affected 5.4 million American people in 2016.
Age is a major risk factor for developing Alzheimer’s, and the risk
increases the longer a person lives past age 60. A person over
the age of 65 has a one in nine chance of having the disease.
These numbers will only increase in the future years. Because of
advancing science and better treatments, people are living longer, therefore increasing the chances of developing this disease.
The average cost of caring for a person with Alzheimer’s is over
$50,000 a year, creating an emotional and financial burden on
caregivers and family members (Seeley, Miller 2015).
Alzheimer’s disease progresses in stages, and the first symptoms
noted are generally memory related. The disease is usually diagnosed in the “mild” stage, where memory loss becomes more
apparent and the patient exhibits other cognitive impairments
(NIH). It is important to note that these are not symptoms of
normal aging; this is evidence of a disease state in the brain (CDC).
As the disease progresses to moderate and severe Alzheimer’s,
the patient gradually loses language ability, reasoning, sensory
processing and conscious thought. The disease culminates in the
patient being completely uncommunicative and bedridden, wholly
dependent on a caregiver (NIH).The disease usually lasts for 8-10
years and ends in death from secondary factors, such as malnutrition or pneumonia. This pattern of degeneration is patterned by
the atrophy of brain tissue, which begins in the medial temporal
lobes, then affecting the lateral parietal, medial parietal and temporal lobes before spreading to the lateral frontal cortex, as seen
by brain imaging of Alzheimer patients (Seeley, Miller 2015).
The brain tissue of an Alzheimer patient exhibits significant shrinkage and characteristic amyloid plaques and neurofibrillary tangles
(Seeley, Miller 2015). Amyloid plaques consist of beta-amyloid
oligomers that stick together.These beta-amyloid fragments arise
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from a transmembrane protein called amyloid precursor protein
(APP). Different enzymes called alpha-secretase, beta-secretase,
and gamma-secretase can cleave the APP protein in different places causing different results. In a healthy pathway, alpha-secretase
will cleave off a fragment called sAPPα, which may be beneficial
to the neuron. The rest of the APP fragment is cleaved with gamma-secretase and released. In the harmful pathway, APP is cleaved
with beta-secretase which releases sAPPβ. The residual fragment
is cleaved with gamma-secretase and is released as amyloid-β.
These amyloid-β fragments accumulate and become the damaging amyloid plaques found in Alzheimer patients (NIH).
Another feature of Alzheimer’s disease is the neurofibrillary tangles caused by the protein tau, which normally helps support the
internal structure of the neurons. Neurons contain microtubules,
which support them and help in transporting nutrients. Attached
to these microtubules are the tau proteins that aid in stabilization.
In Alzheimer’s the tau proteins are hyperphosphorylated, which
causes the tau proteins to separate from the microtubules and
tangle together with other tau threads. The microtubules break
down which causes the neuron’s transport system to fail, compromising the neuron’s ability to communicate (NIH).
These misfolded proteins cause the degradation of neurons in
Alzheimer’s and the subsequent brain atrophy.The causes and possible treatments for the accumulation of beta-amyloid and the neurofibrillary tangles are the subjects of ongoing research.This paper explores three different current ideas as to what causes these plaques
and tangles to form, and by what mechanism they cause disease.

Methods
Articles and studies researched in this paper were obtained
through the Ebsco and AccessMedicine databases with access
provided by Touro College Library. Pubmed and Google Scholar
were used to find other research articles. Several papers were
obtained by use of the Touro College interlibrary loan system.
Some of the research articles were kindly provided by Dr. Zev
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Leifer, who has an interest in the topic. In addition, references
in these articles were used as additional sources of information.

The Effect of apoE on the Development of Senile
Plaques
Several possible causes of Alzheimer’s disease are currently
under investigation. Recent research has been done to study genetic factors of the disease. It has been found that the apolipoprotein E (apoE) gene exists in several alleles, and one, in particular, contributes to the biochemical mechanism of Alzheimer’s
disease (Liraz et al., 2013). Alzheimer’s disease is characterized
by the formation of senile plaques composed of amyloid-β, a
40-42 amino acid long peptide derived from amyloid precursor
protein. Another feature is the neurofibrillary tangles that arise
from the hyperphosphorylated protein tau, which leads to a
compromised cytoskeleton and cell death. The apoE gene encodes for the apoE protein, which is produced by astrocytes in
the brain. It is an important cholesterol carrier which is involved
in the transport of lipids and injury repair. ApoE exists as three
alleles: apoE2, apoE3, and apoE4. ApoE is a 299 amino acid protein, and the difference between the isoforms is at amino acid
112 and 158, where either a cysteine or arginine is present (Lui
et al., 2013). This slight difference is enough to cause a change
in the protein’s tertiary structure, which affects its ability to
bind lipids, receptors, and amyloid-β. ApoE3 is the most common allele, and apoE2 is associated with a decreased risk of AD
(Simonovitch, et al., 2016). ApoE4 is a hypolipidated version of
the protein, and it has been linked to an increased risk of developing Alzheimer’s. A greater percentage of the apoE4 allele has
been noted in families with late-onset and sporadic Alzheimer’s.
In sporadic AD, the frequency of apoE4 is greater than 50%, and
each copy of the allele decreases the disease onset 7-9 years.
Patients with a higher percentage of apoE4 have been found to
have a higher level accumulated amyloid-β and hyperphosphorylated tau, as well as a decreased neural plasticity and neuropathology (Liraz et al., 2013).The fact that amyloid-β accumulation
is increased in apoE4 positive patients led researchers to believe
that the two pathways interact with each other, and cross-talk
between them causes the pathological effects. The presence of
the apoE4 allele adversely affects the binding of apoE4 to lipids,
leading to the proposal that the disease is caused by lipid-related mechanisms (Liraz et al., 2013).

Impaired Autophagy in Alzheimer’s Disease
Additional research on how apoE4 is related to Alzheimer’s
disease has shown how other factors can also play a role in
the disease process. Besides causing the formation of senile
plaques, the apoE4 protein can also impede the body’s means of
removing it. Amyloid plaques and neurofibrillary tangles are usually removed from the brain through the process of autophagy
(Simonovitch et al., 2016, p. 917). Autophagy clears out cellular

debris such as dysfunctional organelles, old proteins, and aggregated proteins. Normally astrocytes produce apoE in the central
nervous system, which protects the brain from harmful protein
buildup. However, the mechanism becomes faulty as the disease
progresses, and impaired autophagy may become harmful because the accumulated protein can cause synaptic degeneration
in hippocampal neurons. In 2016, an experiment was done to
connect the presence of the apoE4 gene to the accumulation of
amyloid-β buildup by the process of decreased autophagy. This
experiment used knock-in mice with either apoE3 or apoE4
human cell lines and 5XFAD mice to replicate the disease
process. 5XFAD mice have a phenotype similar to Alzheimer
disease and exhibit many comparable characteristics such as
amyloid plaques (Alzforum). Astrocytes were isolated from the
apoE3 and apoE4 mice and cultured with frozen coronal brain
sections from the 5XFAD mice. The experimental results were
based on the ability of the astrocytes to clear the amyloid-β
plaques from the brain slices. Brain slices with no astrocytes
were used as a control. Amino acid deprivation was used to
induce autophagy, and results were measured at the first, second and fourth hours of starvation. Results were calculated by
means of the LC3 and p62/SQSTM1 proteins. LC3-I becomes
a lipidated form, LC3-II, during autophagy and becomes associated with the autophagosomal membrane. P62 is a protein
that is associated with LC3 and is degraded during autophagy. By looking at the LC3-II/LC3-I ratio, the rate of activation
of autophagy can be monitored and measured. A higher ratio
indicates greater autophagic activation, which in turn indicates
more autophagy and more clearing of the amyloid plaques. This
ratio was significantly higher in the apoE3 astrocytes compared
to the apoE4 astrocytes. In addition, the levels of p62 decreased
more rapidly in the apoE3 astrocytes compared to the apoE4
astrocytes following starvation. This evidence suggests that the
initiation of autophagy in apoE4 astrocytes is somehow impaired in Alzheimer’s disease (Simonovitch et al., 2016).
To test this hypothesis, the researchers examined the autophagy
levels of the astrocytes when an autophagy inducer and inhibitor were added in separate experiments. Rapamycin was used
as an autophagy inducer, and chloroquine was used as an inhibitor. In these sets of experiments, the apoE3 and apoE4 astrocytes were treated with rapamycin and chloroquine in separate
trials. The results were measured with the LC3-II/LC3-I ratio
and the rate of p62 degradation. The results showed that with
treatment with rapamycin, the apoE3 cells were even more effective at clearing the amyloid-β plaques, and while it was more
effective than the apoE4, the apoE4 was still more effective than
the non-treated apoE4 cells. In contrast, treatment with chloroquine entirely prevented autophagy in both apoE3 and apoE4
cells (Simonovitch et al., 2016) This research highlights how the
apoE gene can be connected to the buildup of the amyloid-β
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plaques in Alzheimer’s disease. It demonstrates that the presence of the apoE4 allele affects the body’s mechanisms of naturally clearing protein buildup through the process of autophagy
and that the problem is probably at the beginning of the process
when autophagy is first induced. This research shows that not
only is Alzheimer’s disease caused by the buildup of misfolded
proteins but also that the body’s normal mechanism of clearing
it away is also adversely affected.

ABCA1 Lipidates ApoE
Knowing how the function of apoE4 is different from apoE3
is valuable for possible therapeutic strategies. If apoE4 can be
made to function like apoE3, many of the symptoms and pathologies of Alzheimer’s disease can potentially be reversed.
Although the full pathological process of apoE4 is not yet fully
understood, evidence suggests that it is connected to lipid-related mechanisms (Boehm-Cagan et al., 2016). ApoE lipidation
is controlled by the ATP-binding cassette transporters ABCA1
and ABCG1. ABCA1 triggers the efflux of cholesterol and phospholipids onto the apoE acceptor, and ABCG1 has a similar
function. Studies have shown that apoE4 is less lipidated than
apoE3 and is less effective at stimulating the efflux of cholesterol and phospholipids in a cell culture. These proteins are regulated by the retinoid X receptor transcription regulating system.
If this system can be activated by some means, the pathological
effects of apoE4 may be alleviated.

CS-6253 Can Activate ABCA1
CS-6253 is a non-toxic peptide derived from the carboxyl terminal of apoE (Boehm-Cagan et al., 2016). It has been shown to
interact with and stimulate ABCA1 to activate cholesterol and
phospholipid efflux. A study was done to see what effect CS6253 has in vivo on the neuropathology and cognitive decline
in apoE4 mice. ApoE3 and apoE4 mice were injected intraperitoneally with CS-6253 every 48 hours for 6 weeks. A control
group was injected with saline. They were then subjected to
a series of cognitive tests to measure learning and memory.
During the novel object recognition test, mice were placed in
an arena with no objects. Then, two objects were introduced.
24 hours later the mice were replaced in the arena with one
familiar object, and one new one. Their behavior and interactions with the objects were monitored and measured. During
the Morris maze test, the mice were placed in a circular pool
of cloudy water with a submerged hidden platform. The test
examined the mice’s memory by measuring the time it took
the mice to reach the platform after being placed in the pool
previously. After the experiment, the mice were euthanized and
the brains were removed to be stained and studied (BoehmCagan et al., 2016).
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The results of this experiment showed many important findings on the effect of CS-6253. Treatment with CS-6253 significantly lowered the buildup of amyloid-β in the test apoE4
mice compared to the untreated mice. The levels of amyloid-β
in the treated apoE4 mice brains became similar to the untreated apoE3 mice, who were unaffected by the treatment.
Treatment with CS-6253 also had an effect on the buildup of
phosphorylated tau. The tested apoE4 mice showed a marked
decrease of phosphorylated tau compared to the untreated
apoE4 mice. Injections of CS-6253 also affected the results
of the cognitive tests. Before treatment, apoE4 mice took a
significantly longer time to reach the platform in the Morris
maze test compared to the apoE3 mice. After treatment, the
performance of the treated apoE4 mice was similar to the
apoE3 mice. The treated apoE4 mice also scored similarly to
the apo3 mice during the novel item recognition test after they
were treated with CS-6253. The experimental findings show
that CS-6253 can successfully activate ABCA1 to reverse the
hypolipidation of apoE4, decrease the levels of accumulated
amyloid-β and phosphorylated tau, and reverse the cognitive
deficiencies of apoE4 mice. These results indicate that ABCA1
can be an important therapeutic target in treating Alzheimer’s
disease (Boehm-Cagan et al., 2016).

Alzheimer’s Nay be Linked to Prion Diseases
Many characteristics of Alzheimer’s disease are similar to prion
diseases, suggesting that there may be a connection between
the two (Castellani et al., 2004). Prion diseases are characterized by the buildup of misfolded prion proteins (PrP) that
can propagate themselves by causing other healthy protein to
misfold in the same way (Prion Alliance). Prion diseases can
affect humans and animals. The five human prion diseases are
Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker
syndrome, fatal familial and sporadic insomnia, kuru, and new
variant Creutzfeldt-Jakob disease. Alzheimer’s disease is similar
to these prion diseases in that both have an age requirement for
the symptoms to become apparent, both usually occur sporadically although there is a genetic component in some cases. Most
prion diseases appear in middle age to older patients, and that
is the age demographic that is affected by Alzheimer’s. There
is significant overlap between the two diseases’ characteristics.
In both diseases, there is allelic segregation, with an allele that
makes a person susceptible to getting the disease. In prion disease, this gene is the PRNP gene, and in Alzheimer’s disease, it
is ApoE and presenilin 1 genes. Furthermore, in a certain type
of Gerstmann-Straussler-Scheinker syndrome, prion plaques in
the gray matter also have tau protein with neurofibrillary tangles, amyloid-β accumulation, and gradual memory loss over a
longer span of time than typical prion diseases, more similar to
the pattern seen in Alzheimer’s disease (Castellani et al., 2004).

Possible Causes of Alzheimer’s Disease

The word prion comes from “proteinaceous infectious particle” (Jeffrey 2013). These particles are neither bacteria nor
virus, but they cause transmissible diseases. Prion diseases
are also known as “transmissible spongiform encephalopathies” because they are neurodegenerative and ultimately
fatal. Amyloid plaques are frequently present in these diseases,
which leads to the possibility that Alzheimer’s disease may be
related. Prions are caused by a pathogenic form of cellular
prion proteins (PrPc), which are encoded by the host’s PRNP/
prnp gene (Jeffrey 2013). PrPC is an endogenous, cell surface
glycoprotein of unknown function (Elezgarei, Biasini 2016). In
prion diseases, this normal protein undergoes a conformational change and is called a “scrapie form of PrP,” or PrPSc.
This misfolded isomer accumulates in the central nervous
system of affected individuals. PrPSc, or prions, are capable
of propagating themselves by binding to normal PrPC proteins and forcing their conformational change to new PrPSc,
thereby perpetuating a cycle that leads to a buildup of misfolded proteins, which causes neurodegeneration and cell death
(Elezgarei, Biasini 2016). PrPSc changes PrPC into prions by
affecting the tertiary structure of the protein. Normal PrP is
made up of 209 amino acids and the tertiary structure is 40%
alpha helix with minimal beta sheet. PrPSc however, is made of
40% beta sheet and 30% alpha helix (Castellani et al., 2004).
Research shows that the prions are formed when alpha helixes
are converted into beta sheets. This change causes PrPSc to
be insoluble and resistant to proteolytic enzymes (Castenelli
et al., 2004).

Similarities Between Amyloid-β and Prions
Amyloid-β oligomers in Alzheimer’s disease have similarities to
prions. Soluble amyloid-β oligomers affect the neuronal synapse
in Alzheimer’s disease, causing synaptic abnormalities and neurodegeneration (Elezgarei, Biasini 2016). These oligomers are
different from the insoluble amyloid-β that builds up in the brain.
There is evidence that the amyloid-β oligomers bind to PrPC in
a similar manner to prions, and cause a cascade that leads to cell
death (Laurén et al., 2009). PrPC can act as a receptor site on
the cell membrane of neurons, which have been shown to bind
amyloid-β and mediate the pathological effect. Suppression of
these receptors may, in fact, have therapeutic benefit for people
suffering from the disease (Laurén et al., 2009) PrPC-amyloid-β
complexes occur in the brains of Alzheimer patients, which is
further evidence that this prion-like mechanism is implicated
in Alzheimer’s disease. PrPC is not necessarily involved in all
cases of Alzheimer’s; Amyloid-β can cause neural damage without PrPC (Elezgarei, Biasini 2016). This fact demonstrates the
complexity of the disease and that the cause may be due to
several factors.There are several similarities between amyloid-β
precursor protein (AβPP) in Alzheimer’s disease and PRNP in

prion diseases (Castenelli et al., 2004). Mutations in both of
these genes can cause a buildup of their respective proteins
with increased beta sheet structure.

Disease Transmission
Classic prion diseases are transmissible from one affected individual to another. They are able to be passed from person to
person, from animal to person, and from person to animal. PrPSc
initially forms in sporadic diseases by nucleation. The initial formation of the protein is kinetically less favorable; however, once
it overcomes the activation barrier it is able to propagate, changing PrPC to PrPSc very easily (Beekes et al., 2014). Once you
have an initial prion “seed,” it can quickly proliferate and corrupt
other proteins (Figure 1). However, prions are not infectious in
the typical sense; you cannot “catch” a prion disease through
direct contact (Weissmann et al., 2002). Transmission of prions
occurs perorally and perenterally. The kuru epidemic that occurred in Papua New Guinea in the 1900’s was spread through
cannibalism. A greater concern is the spread of prions to humans iatrogenically. Prion contaminated cadaver-derived human
growth hormone gonadotrophin has caused Creutzfeldt-Jakob
disease in people in the past, and surgical instruments that have
been used on affected people have caused the disease in others, even after being properly sterilized. If Alzheimer disease is
so similar to prion diseases, can Alzheimer’s be spread through
such means? Studies were done where amyloid-β taken from
the brain tissue of Alzheimer’s patients was injected into mice
(Kane et al., 2000). This resulted in the stimulation of amyloid-β
deposition in mice that were genetically predisposed to the formation of such plaques. Amyloid-β deposition was recovered
past the site of injection, similar to prion spreading. Inoculation
of amyloid-β in wild-type mice initiated amyloid-β build up in
brain tissue at the site of injection, and in certain species, in
distant areas of the brain as well. However, none of the mice
developed cerebral neurodegeneration or cognitive decline
(Beekes et al., 2014). Similar experiments were done with the
protein tau (Sanders et al., 2014). The protein was able to replicate itself with high fidelity in a prion-like manner and cause an
increase of hyperphosphorylated tau in the mouse brain tissue.
Nevertheless, this buildup of tau did not cause cognitive decline
or severe disease in these mice. Epidemiological studies investigated the transmission of Alzheimer’s disease between humans
in real life (Beekes et al., 2014). Available data indicates that
Alzheimer’s disease is not likely to be spread between people.
Blood transfusions do not cause a risk of Alzheimer’s in the recipient, and neither does plasma protein therapy for hemophilia. Another study examined the risk associated with receiving
cadaveric human growth hormone, derived from the pituitary
gland of the deceased. Such growth hormone has caused over
200 cases of iatrogenic Creutzfeldt-Jakob disease because of
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PcPSc seeds that contaminated the hormone and caused the
prion disease in the recipient. In this study, researchers found
small amounts of amyloid-β in the pituitary glands of the recipient. Yet, none of the recipients studied developed Alzheimer’s
disease. Based on these studies, as similar as Alzheimer’s disease is to prion diseases, there is an essential difference when
it comes to disease transmission. Although seeding effects of
Amyloid-β can somewhat cause neurotoxicity, it does not cause
the neurodegenerative a cognitive impairment characteristic of
Alzheimer’s (Beekes et al., 2014).

Environmental Effects on Neurodegenerative
Disease: Mystery Disease in Guam is Similar to
Alzheimer’s
The environment can have a role in the development of neurodegenerative diseases such as Alzheimer’s. On the Island of
Guam, many of the native villagers, known as Chamorros, suffer
from a debilitating neurodegenerative disease with symptoms
similar to Alzheimer’s disease, amyotrophic lateral sclerosis
(ALS), and Parkinson’s disease (Cox et al., 2016). The illness
caused paralysis, shaking, and dementia at 50-100 times the incidence of ALS worldwide (Holtcamp 2012). This disease was
first described in the 1950’s by US Army physicians, who called
it amyotrophic lateral sclerosis/Parkinsonism dementia complex
(ALS/PDC). Amyloid-β plaques and neurofibrillary tangles were
present in the brains of Chamorros who developed this mystery disease. Although in some villages a quarter of adults died
from this disease, no distinct pattern of heredity was apparent.
Because outsiders who adopted the Chamorro lifestyle were
also affected, the cause of this disease seemed likely to be an
environmental toxin (Cox et al., 2016).

The BMAA Hypothesis
There was difficulty in determining the exact nature of the
toxin because symptoms could appear years after the exposure. However, researchers were able to isolate the neurotox-

Figure 1: Mechanism of prion mediated misfolding of protein.
(Sanders 2015
in β-N-methylamino-L-alanine (BMAA) from the cycad seed,
which the Chamorros use to make flour, a staple in their diet. In
the 1980’s, BMAA was fed to macaques which caused acute neurological symptoms. However, these results were disregarded
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when it was shown that a human would have to consume an
inordinate amount of cycad seed flour to ingest a comparable
dose (Cox et al., 2016). Paul Alan Cox, an ethnobotanist, arrived
in Guam in the 1990’s and revived the hypothesis that BMAA
causes ALS/PDC seen in the natives (Holtcamp 2012). With
his colleague Sandra Banack, he was able to show that BMAA
was produced by a symbiotic cyanobacteria living in specialized
cycad roots. BMAA accumulates in the gametophytes of the
cycad seeds that are ground and eaten by the villagers. Cox then
showed that animals such as flying foxes, feral deer, and pigs all
feed on the cycad seeds, which are then eaten by the Chamorro
people. BMAA is biomagnified in these mammals 10, 000 times
that which is produced by the cyanobacteria. This process of
biomagnification allows a sufficiently toxic amount of BMAA
to accumulate in the food chain that it can cause neurological
symptoms in the Chamorro people. This problem is not limited
to Guam. BMAA producing cyanobacteria live in many marine
ecosystems that biomagnify BMAA up the food chain, accumulating in sharks, bottom-dwelling fish, and shellfish (Cox et al.,
2016). People who eat these organisms are at risk of BMAA
ending up in their brain tissue.

Mechanism of Toxicity of BMAA
BMAA is readily able to cross the blood-brain barrier into
the brain and central nervous system. It is mistaken for
L-serine by the cellular mechanism and misincorporated into
proteins, leading to misfolding, aggregation, and apoptosis of
the cell (Cox et al., 2016). In normal proteins, the hydrophilic
part is on the outside of the structure and the hydrophobic
part is on the inside. However, because of protein misfolding
due to the incorporation of BMAA, the hydrophobic part can
end up on the outside, exposed. These hydrophobic areas are
sticky and tend to clump together forming the characteristic
aggregates of neurodegenerative plaques. These small aggregates end up forming larger ones that prevent the cells from
functioning properly (Holtcamp 2012). A misincorporation
rate of even 1 in 10,000 has been shown to have a neurodegenerative effect in laboratory animals. BMAA can also result
in phosphorylated tau by activating mGluR5, a metabotropic
glutamate receptor, which decreases the activity of protein
phosphatase 2A (PP2A). PP2A is significantly decreased in
Chamorro ALS/PDC brains, resulting in an increase of phosphorylated tau (Cox et al., 2015).

Neuropathology Caused by BMAA in an
Animal Model
To further prove that BMAA is responsible for the neurodegenerative disease, Cox and his colleagues conducted an
experiment in which they attempted to show that chronic
exposure to BMAA causes neuropathology and that BMAA
can be re-isolated from the induced organisms. Vervets, a type
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of non-human primate, were the subject of this study. The
vervets in this experiment were exposed to L-BMAA in their
diets for 140 days, and then the brain tissue was examined for
tau and amyloid deposition. Sixteen juvenile vervets divided
into 4 cohorts of 4 were used in this experiment. The first
cohort of vervets was given a piece of fruit dosed with 651
mg of L-BMAA. Because L-serine has been shown to prevent
misincorporation of BMAA into proteins, a cohort was given
was given 651mg of L-BMAA and 651 mg of L-serine. A third
cohort was given just 651 mg of L-serine. Finally, a control
group was given a piece of fruit with 651 mg of rice flour as
a placebo. A second experiment was done using adult vervets,
also using four cohorts. The first cohort was given 987 mg of
L-BMAA. The second was given 98.7 mg of L-BMAA, a tenfold
reduction. The third was given 987 mg of L-BMAA, and 987 mg
of L-serine. The fourth, a control, had 987 mg of rice flour as a
placebo (Cox et al., 2016).
In the first experiment, the vervets that received L-BMAA
had neurofibrillary tangles and sparse amyloid-β plaque
buildup in many areas of the brain. In contrast, the cohort
that received L-serine and the control cohort did not show
signs of amyloid-β or tau inclusions. The cohort that received
an equal amount of L-BMAA and L-serine showed an 80-90%
reduction in amyloid-β plaques and neurofibrillary tangles.
In the second experiment, all BMAA exposed vervets developed hyperphosphorylated tau proteins and neurofibrillary tangles. The density of the neurofibrillary tangles in the
brain was clearly related to the dose of BMAA administered.
Besides for the control cohort, the low dose cohort had
the lowest median count of neurofibrillary tangle density; the
median density of the high dose cohort was more than twice
the levels of the low dose cohort. The cohort that received
both high dose BMAA and L-serine had a 50% decrease of
neurofibrillary tangles compared to the high dose cohort.
Exposure to BMAA also increased the chances of developing
amyloid-β deposits, which were not found in any of the control vervets (Cox et al., 2016).
This study shows that dietary exposure to BMAA can cause
the formation of neurofibrillary tangles and deposition of
amyloid-β (Figure 2). BMAA-producing cyanobacteria live
worldwide and can have an important effect on human
health. BMAA may possibly act as an initiator for sporadic
Alzheimer’s disease by triggering the formation of amyloid
plaques and neurofibrillary tangles. This study also indicates
that L-serine is able to reduce the risk of formation of the
characteristic plaques and tangles in the brains tissue of affected individuals, and that L-serine may have a possible therapeutic role in the treatment of mild cognitive impairment
and early Alzheimer’s disease (Cox et al., 2016).

Figure 2:Theoretical pathways of development of ALS/PDC and
Alzheimer’s disease neuropathology from dietary BMAA exposure
causing neurofibrillary tangles and amyloid-β plaques. (Cox et
al.,2016)

Conclusion
This paper investigated three seemingly unrelated mechanisms
that have been proposed to cause the neuropathology seen in
Alzheimer’s disease. Although the means of each method reviewed are very different, they have all been studied as a potential cause of the buildup of the characteristic plaques and
tangles present in the disease. Alzheimer’s disease is a public
health problem; it is the sixth-leading cause of death in the
United Stated, and fifth among people 65 and older (Alzheimer’s
Association). Therefore it is important to study various models
of the mechanism of the disease in the hope of gaining a better
understanding of it, and eventually finding a cure. These three
models may seem disconnected from each other, but in reality,
Alzheimer’s disease is a complex disease.There are multiple factors involved that cause a person to develop Alzheimer’s related
neurodegeneration; there is no one “correct” model. The three
mechanisms discussed are only part of the multipart picture,
and yet they are important to understand to get a complete
understanding of the various pathways that lead to this disease.
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By examining different routes, hopefully some light will be shed
on questions like; why, if two people have a genetic predisposition, does one develop Alzheimer’s and one does not? Only by
studying the causes will we ever discover a cure to the disease
that affects so many.
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Abstract
Alzheimer’s disease is a neurodegenerative condition which results in a significant decline in cognitive status. Novel
treatment approaches for Alzheimer’s are sorely needed, as current medications for the disease offer only marginal
clinical benefit. Research has discovered a connection between the pathology of Alzheimer’s and Type 2 Diabetes, two
serious and seemingly unrelated disorders. Clinical studies have shown that Alzheimer’s disease is associated with brain
insulin resistance similar to the pathology of Type 2 Diabetes. This observation has led to the notion that drugs developed for the treatment of Type 2 Diabetes may be beneficial in modifying the cognitive function and pathophysiology of
individuals suffering from Alzheimer’s disease. This paper offers a comprehensive review of the clinical studies demonstrating the potential of using diabetes medications as an effective therapeutic method for the prevention and treatment
of Alzheimer’s disease. Special focus is given towards the metabolic hormones insulin, amylin and leptin.
Introduction
Alzheimer’s and Type 2 Diabetes are two of the most common
diseases afflicting the elderly population today. A 2016 Report
by the Alzheimer’s Association found that of the 5.4 million
Americans with Alzheimer’s, an estimated 5.2 million people
are age 65 and older (Alzheimer’s Association, 2014). Similarly,
the American Diabetes Association reported that in 2012, of
the 29.1 million Americans with Diabetes, an estimated 11.8
million people were age 65 and older (American Diabetes
Association, 2012). The two conditions have traditionally been
treated as independent disorders. However, recent studies linking Alzheimer’s to Type 2 Diabetes have led to the proposal that
Alzheimer be referred to as “Type 3 Diabetes”. Discoveries of
common pathological mechanisms between these two diseases have given rise to novel clinical trials incorporating diabetes
therapies to treat Alzheimer’s disease.

Methods
A variety of literary reviews and research papers on the subject
were collected through use of the PubMed database. Keywords
such as Alzheimer’s disease, insulin resistance and Type 2 Diabetes
were used to search for relevant material. Access to PubMed was
provided by the Touro College online library system.

Pathophysiology of Alzheimer’s and Type 2
Diabetes
Alzheimer’s disease is a neurodegenerative condition, which
results in nerve cell death and tissue loss throughout the brain
(Li, Z et al., 2015). Scans of brains of individuals suffering from
Alzheimer’s demonstrate severe shrinkage of the hippocampus
and cerebral cortex, as well as the enlargement of the ventricles
(Querfurth et al., 2010).
The pathophysiology of Alzheimer’s disease is described by
the amyloid cascade hypothesis. Cleavage of amyloid precursor protein (APP) leads to the formation of the protein amyloid beta. Excessive cleavage of APP coupled with inefficient
removal of amyloid beta can lead to the formation of amyloid
beta plaques in the brain. These plaques damage and destroy

brain cells by blocking cell-to-cell signaling at synapses (Reitz,
2012). Amyloid beta plaques have also been shown to cause
apoptosis. The presence of amyloid plaques in the brain generates the production of harmful oxidative free radicals which in
turn activates the c-Jun N-terminal kinase (JNK) pathway. The
JNK pathway stimulates the transcription of several key target
genes, including the death inducer Fas ligand. The binding of
Fas ligand to its receptor Fas then induces a cascade of events
that lead to caspase activation and ultimately neuronal cell
death. (Yoshiyuki et al., 2001).
The tau protein also plays an important role in Alzheimer’s disease (Lasagna-Reeves CA et al., 2012). This protein is integral
to maintenance of internal support and transport systems between brain cells. Hyperphosphorylation, which is the addition
of phosphate to too many amino acids, leads to the collapse of
tau proteins into twisted strands referred to as neurofibrillary
tangles (Jack et al., 2013). Without the support of the tau protein, the transport system in the brain collapses. Consequently,
essential nutrients are unable to reach brain cells and cell death
ensues (Gong and Iqbal, 2008).
Diabetes is a metabolic disorder which develops when the body
does not make enough insulin or is unable to use insulin effectively. (Yarchoan and Arnold, 2014). If left untreated, diabetes can
cause many complications, including kidney failure, diabetic ketoacidosis, heart disease and stroke (Schnell et al., 2016). Type
2 Diabetes is characterized by an insulin resistant state which
is most commonly caused by obesity (Smith and Kahn, 2016).
In insulin resistance, muscle, fat, and liver cells do not respond
properly to insulin and thus cannot easily absorb glucose from
the bloodstream. As a result, the body needs higher levels of
insulin to help glucose enter cells. The pancreatic beta cells initially increase their insulin output but fail over time to keep up
with the body’s increased demands for insulin. Type 2 diabetes
develops when insulin production is inadequate to overcome
insulin resistance, resulting in the drastic rise in blood glucose
levels (Yarchoan and Arnold, 2014).
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Discovery of Insulin Resistance in Alzheimer’s
Disease
Insulin receptors are widely distributed in brain regions known to
be involved in memory function, including the hippocampus, cerebral cortex and cerebellum (Werther et al., 2015). Clinical studies
have found evidence for central insulin resistance in Alzheimer’s
brains. Post-mortem studies of brain tissues from people with
Alzheimer’s disease have discovered extensive abnormalities in
insulin and insulin-like growth factor signaling mechanisms in
the brain (Steen et al., 2005). A study of post-mortem human
hippocampus Alzheimer’s tissue was done by exposing the tissue
to different concentrations of insulin. This allowed researchers
to study the activation of insulin pathways in the brain tissue of
people with Alzheimer’s compared to the brain tissue of those
with normal cognitive function. In normal brains, activation of
the insulin receptor initiated a signaling cascade which led to the
production of many downstream insulin signaling proteins. The
blunted insulin response observed in the Alzheimer’s brain tissues
was similar to the insulin resistance observed in Type 2 diabetes
peripheral tissues (Talbot et al., 2012).
The formation of amyloid beta plaques has been implicated as
a possible impetus for the removal of insulin receptors in brain
cells. Studies of Alzheimer’s brains have demonstrated that the
binding of amyloid beta oligomers to hippocampal neurons triggers the removal of dendritic insulin receptor substrates from
the outer membrane of the cell (Xie et al., 2002). These studies
prove that elevated amyloid beta levels induce the removal of cell
surface insulin receptors, thereby furthering insulin resistance.
A molecular model has been proposed to explain how the amyloid beta plaques found in Alzheimer’s disease promote insulin
resistance (Dineley et al., 2014). This model is based on the inflammatory pathway observed in Type 2 Diabetes, where inflammatory cytokines play an important role in establishing insulin
resistance. Signaling from the inflammatory cytokine Tumor
Necrosis Factor (TNF) stimulates JNK (Hoeks et al., 2012).
Activation of the JNK pathway by TNF results in serine phosphorylation of the insulin receptor (Zhao et al., 2008). In order
to be activated, phosphorylation of the insulin receptor must
occur at a tyrosine residue. Addition of the phosphate group at
the serine amino acid in individuals with Type 2 Diabetes results
in inhibition of the insulin receptor (Bomfim et al., 2012).
In a similar fashion, inflammatory cytokines induced by the presence of amyloid beta in the brain can lead to insulin resistance in
Alzheimer’s. Recent work suggests that soluble misfolded amyloid beta can induce inflammatory cytokines through an inflammatory pathway known as NF-κB-inducing kinase (NIK). The
resulting inflammatory state induces insulin resistance through
feedback inhibition of the insulin receptor (Carrero et al., 2012).
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In this case the many signaling chemicals produced by the inflammatory pathway stop the activity of the insulin receptor
(Talbot et al., 2012).
Insulin resistance may promote Alzheimer pathology through
several mechanisms. Firstly, abnormal insulin signaling may
promote amyloid beta and hyperphosphorylated tau formation
through the kinase GSK-3. The activity of GSK-3 is normally
regulated through inhibition by the protein AKT, which is an important kinase in the insulin signaling cascade referred to as the
IRS-1 –AKT pathway (Yarchoan and Arnold, 2014). Therefore,
dysfunctional insulin signaling caused by disturbances in the
IRS-1 –AKT pathway leads to increased GSK-3 activity. Studies
of GSK-3 found that its activity increases tau protein phosphorylation (Li, X et al., 2006) and that it is involved in amyloid beta
production (Takashima, 2006).
Abnormal insulin signaling also interferes with memory and
learning pathways. Insulin is a direct regulator of the ERK/MAP
kinase pathway. This pathway is essential to the induction of
longer term potentiation (LTP) and memory consolidation in
the hippocampus (Winder 1999). LTP is responsible for the
maintenance of long term memory, which is the ability to recall
episodes which are not part of the immediate past (Kelleher et
al., 2004). Disruptions of LTP and memory consolidation contribute to the impaired cognitive function typified by Alzheimer’s
disease (Dineley et al., 2014).

Discussion: New Role for Diabetes Drugs as a
Treatment for Alzheimer’s
Given the role of insulin resistance and deficiency in the pathogenesis of Alzheimer’s disease, it is possible that a drug currently prescribed for Type 2 Diabetes may able also be useful for
Alzheimer’s. Various diabetes drugs are under study to test for
their potential activity in Alzheimer’s. This section provides an
overview of the various clinical studies which assess the potential prospects of using the diabetes drugs insulin and amylin,
as well as the weight loss hormone leptin, to treat Alzheimer’s.

Insulin
The administration of exogenous insulin has predictably become
a prime focus of the effort to treat insulin signaling dysfunction
in Alzheimer’s. Clinical trials have demonstrated that insulin administration acutely affects behavior and cognitive performance
in both healthy individuals and those suffering from Alzheimer’s.
A 2001 study assessed the effects of peripherally administered
insulin infusion in non-impaired individuals (Kern et al., 2001).
Two groups were infused with insulin for 6 hours, one at a high
rate and the other at a low rate. Any effects of the insulin administration on blood glucose concentrations were counteracted by constant glucose infusions. Comparison of the results
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of the high rate insulin and low rate insulin treatment groups
indicated an improvement in the cognitive function of the high
rate insulin group. Subjects exposed to higher insulin infusion
rates demonstrated changes in auditory-evoked potentials, had
enhanced memory as evidenced by improved word recall and
improved cognitive flexibility as measured by the Stroop test.
Similar benefits of peripheral insulin administration on cognitive function were observed in individuals with Alzheimer’s. In a
1999 study, Alzheimer’s patients showed improved story recall
and attention during insulin infusion relative to saline infusion
(Craft et al.,2012).
Despite the results of these clinical trials, there are two main
concerns that must be addressed with regards to utilizing peripheral insulin administration as a treatment for Alzheimer’s.
Firstly, peripherally administered insulin cannot bypass the blood
brain barrier in order to enter the central nervous system (CNS)
and is therefore unable to affect and improve brain function.
Secondly, peripheral insulin infusions can induce hypoglycemia.
Hypoglycemia is a condition characterized by abnormally low
blood glucose which can lead to a seizure or unconsciousness
if left untreated. Although hypoglycemia was mitigated by simultaneous glucose infusions in both studies involving peripheral
insulin administration, this solution is highly impractical outside of
a research setting (Yarchoan and Arnold, 2014).
In light of these concerns, intranasal insulin is considered to be
the best method for insulin delivery in Alzheimer clinical trials.
Insulin that is delivered nasally bypasses the blood brain barrier
and is rapidly delivered into the cerebrospinal fluid from where
it can easily enter the CNS (Mao et al., 2016). Additionally, because intranasal insulin is preferentially delivered to the CNS, it
is possible to achieve clinically relevant insulin concentrations
in the CNS without causing systemic hypoglycemia (Yarchoan
and Arnold, 2014).
Pilot clinical trials using intranasal insulin have had successful results.A 2008 clinical trial reported that delivery of intranasal insulin
for 21 days improved story recall, attention and caregiver-rated
functional status in cognitively impaired subjects or individuals with
Alzheimer’s (Reger et al., 2008). In another clinical trial subjects
given insulin spray over a placebo demonstrated improved delayed
memory and cognitive function (Craft et al., 2012).
One study sought to illustrate the underlying mechanisms
through which intranasal insulin ameliorates Alzheimer’s pathology (Mao et al., 2016). APP/PS1 mice possessing the pathological features of Alzheimer’s disease received intranasal insulin
treatments for a total of 6 weeks, while a control group received saline treatments. Tissue samples were harvested from
both groups upon the conclusion of the treatment period.

In order to determine whether intranasal insulin enhances brain
insulin signaling, the respective levels of key components of the
insulin signaling pathway, such as the insulin receptor beta-subunit (IRB) and protein B kinase (AKT), were measured through
Western Blot analysis. Tissue from healthy wild type mice was
also analyzed to serve as a reference marker of normal levels.
The total levels of IRB and AKT were significantly decreased
in the saline treated APP/PS1 mice compared with wild-type
controls. However, the levels of IRB and AKT in the mice which
received intranasal treatment were closer that of the wild-type
mice, indicating that intranasal insulin treatment can partially
protect APP/PS1 mice from brain insulin signaling deficits.
Intranasal insulin was also shown to reduce the activation of
JNK in APP/PS1 mice. Activation of the JNK pathway results
in serine phosphorylation of the insulin receptor and induces
apoptosis. The level of phosphorylation of JNK was significantly
increased in the hippocampus of saline-treated mice compared
with wild-type controls, signifying that intranasal insulin reduces
JNK activation.
Immunohistochemical analysis of the tissue samples measured
the amounts of amyloid beta plaque deposits in the brains of
the APP/PS1 mice. The number of amyloid plaques in the APP/
PS1 insulin-treated mice was significantly reduced in both the
hippocampus and cortex compared to the saline control group.
It was also discovered that the area of amyloid beta plaques
was significantly decreased in both the hippocampus and cortex
of the insulin treated mice. Additionally, quantitative analysis
revealed substantially reduced soluble amyloid beta oligomers
in insulin-treated APP/PS1 mice. This revelation is especially significant considering that soluble amyloid beta oligomers
are considered the most neurotoxic form of amyloid beta.
Enhanced neurogenesis was also observed in the insulin-treated
APP/PS1 mice. It was shown that intranasal insulin significantly
increased levels of DCX, a marker of neurogenesis. The overall
conclusions of the study were that intranasal insulin treatment
improves cognitive deficits, ameliorates defective brain insulin
signaling, strongly reduces amyloid beta plaque formation, inhibits JNK activation and promotes neurogenesis in APP/PS1 mice.
Despite the successful results observed in studies involving
intranasal insulin treatment, there is concern that chronic hyperinsulinemic conditions in the brain may actually promote
brain insulin resistance. Excessive exposure to insulin in mice
has been shown to lead to abnormal phosphorylation of key
components of the insulin signaling pathway, such as AKT and
GSK-3, in a manner consistent with insulin resistance (Kim et
al., 2011). It may therefore be beneficial to explore avenues
of diabetes treatments which restore the byproducts of insulin
signaling without directly affecting insulin levels.
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Amylin
Amylin is a metabolic hormone which is co-secreted with insulin by pancreatic beta cells (Adler et al., 2014). Amylin’s systemic
effects in diabetic patients include the lowering of blood glucose
levels through delayed gastric emptying, increased satiety, and
decreased secretion of glucagon, which is an antagonist of insulin (Yarchoan and Arnold, 2014).
Amylin’s signaling activity has the potential to alleviate the
detrimental effects of insulin resistance in Alzheimer’s disease. Amylin binds to independent receptors in the brain to
activate signaling pathways that converge with insulin signaling.
Amylin activates the production of the protein AKT, which is
needed for the proper regulation of GSK-3, a protein which
can lead to increased production of amyloid beta plaques and
hyper phosphorylated tau (Moon et al., 2011). Amylin is also
a known modulator of the ERK signaling cascade, a pathway
significant in the maintenance of long term memory and memory consolidation (Adler et al., 2014). An advantage of using
amylin as a medication is that it poses no risk of hyperinsulinemia, as it can activate the insulin pathway without interfering
with the concentration of insulin in the body (Yarchoan and
Arnold, 2014).
One study investigated the potential outcomes of using amylin
as a treatment for Alzheimer’s. The first part of the study compared plasma human amylin levels between individuals with
Alzheimer’s or mild cognitive impairment and individuals with no
cognitive impairments (Adler et al., 2014). The results showed
significantly lower amylin levels among subject with Alzheimer’s
and mild cognitive impairments compared to individuals with no
cognitive deficits. With this correlation between amylin levels
and cognitive function established, a follow-up study was conducted in order to investigate the effects of amylin administration on Alzheimer’s pathology. A senescence-accelerated prone
(SAMP8) mouse was selected as a model of Alzheimer’s related
dementia, because it displays multiple features known to occur
early in the pathogenesis of Alzheimer’s including cortical atrophy, amyloid beta alterations, tau phosphorylation and severe
deficits of learning and memory. The SAMP8 mice were treated
with either amylin or saline infusions for a total of 5 weeks. Due
to the tendency of amylin to aggregate into brain plaques in its
natural form, a soluble analog of amylin called pramlintide was
used in the study.
The object recognition test was performed on the mice during
the last week of the 5-week treatment period in order to assess
the effects of amylin on cognitive function. The object recognition test is a behavioral assay that is based upon the natural
tendency of mice to investigate a novel object instead of a familiar one, as well as their innate tendency to restart exploring
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when they are presented with a novel environment. The mice
were placed in an open field box filled with different objects of
various shapes and sizes. After a series of trials, during which
the mice habituated to the configuration and properties of
the different objects, some of the objects were replaced with
new ones to evaluate novel object recognition. The pramlintide-treated SAMP8 mice spent a greater proportion of time
exploring the novel objects as compared with the familiar objects, whereas the saline-treated SAMP8 mice did not differ in
time spent with the novel and familiar objects. The behavior of
the pramlintide-treated mice signified a marked improvement in
their cognitive function.
Hippocampal tissue samples were harvested from the SAMP8
mice in order to assess the effect of amylin on oxidative
stress, an important pathologic feature of Alzheimer’s. The
protein levels found in the pramlintide-treated SAMP8 mice
indicated a decrease in the molecular markers associated
with oxidative stress and neuro-inflammation. The pramlintide-treated SAMP8 mice had significantly decreased expression of the protein H0-1 in the hippocampus compared with
saline-treated mice. HO-1 is a cellular stress protein that is
activated during high oxidative stress and inflammatory states,
and is also known to be increased in the cerebral cortex of
Alzheimer’s brains. The pramlintide-treated SAMP8 mice also
had decreased levels of the lipid peroxidation adduct HNE
and the enzyme COX-2. HNE is a protein that is known to
be an early and abundant cellular stress marker in Alzheimer’s
brains, while C0X-2 is a classic marker of inflammation which
is increased in Alzheimer’s brains.
The pramlintide-treated SAMP8 mice expressed high amount of
proteins associated with synaptic activity and dendritic growth.
Amylin was found to increase expression of hippocampal synapsin I, a protein located in neuronal synaptic vesicles that is
involved in synapse formation, neurotransmitter release, and
learning and memory. A robust increase in CDK5 was also observed in the hippocampus of the pramlintide-treated SAMP8
mice. CDK5 is a kinase which plays an intimate role in synaptic
plasticity, learning and memory in adult brains.
The overall conclusions of the study were that chronic infusion
of amylin in SAMP8 mice was found to improve memory performance in object recognition tests, increase neural synaptic
activity and decrease inflammatory markers in the hippocampus. Amylin treatment improved both the cognitive status and
Alzheimer’s pathology features of the SAMP8 mice.
Another study also assessed the results of amyloid treatment
on behavioral impairment and brain amyloid pathology in
mouse models of Alzheimer’s disease (Zhu et al., 2015). The
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study utilized 5XFAD Alzheimer mice which exhibit significant
neuron loss. The 5XFAD mice were treated with intraperitoneal injections of either pramlintide or saline once daily for 10
weeks.
The 5XFAD mice were tested for improvements in cognitive
functions by going through a Morris water maze. The Morris
water maze test is used to determine hippocampal spatial
memory deficits. The test consisted of placing the rodent in a
circular tank filled with cloudy water, which is used to motivate
the animal to escape the water by swimming to a hidden platform located in one quadrant of the pool. Over several days the
rodent learnt to find the hidden platform by using spatial cues,
such as posters or taped objects strategically placed on the walls
outside of the water maze, in the testing room. The pramlintide
treatment improved the performance of the mice in the Morris
water maze test, reducing the time necessary for memory acquisition and retention during maze training as compared to
the saline-treated control group. The improved performance of
the pramlintide-treated groups over the saline-treated groups
in the Morris water maze test demonstrated that peripheral
treatments with pramlintide improves learning and memory in
the 5XFAD mice.
Pramlintide treatment was shown to have an effect on amyloid beta levels, one of the prime pathological hallmarks of
Alzheimer’s. Immunoassays of brain tissue from the 5XFAD
mice revealed that pramlintide-treated 5XFAD mice experience
a reduction in both size and intensity of amyloid beta plaques
in the cortex, hippocampus and thalamus and had decreased
numbers of amyloid beta plaques in all areas of the brain with
the exception of the hippocampus. Furthermore, comparison
of amyloid beta serum levels from before and after the intraperitoneal pramlintide infusion revealed a significant increase in
serum amyloid beta after the infusion. These results indicate
that pramlintide enhances the removal of amyloid beta from the
brain and its transfer into the blood.
The successful outcomes of these separate studies assessing the
effect of pramlintide treatment on different Alzheimer’s mouse
models indicate that amylin has potential to become a promising new avenue for the treatment of Alzheimer’s. Amylin was
shown to improve cognitive function, reduce oxidative stress
markers, increase synaptic activity and enhance clearance of amyloid beta from the brain.

Leptin
Leptin is a chemical produced by fat tissues which activates the
central nervous system to regulate food consumption and energy expenditure (Oomura et al., 2006). Although leptin has traditionally been studied in the context of obesity, recent studies

have examined its neurological effects. Leptin receptors are
highly expressed in areas of the brain that are involved in learning and memory, such as the hippocampus (Li, X-L et al., 2002).
A study was designed in order to assess leptin’s role in the
regulation of hippocampal functions and the control of learning and memory processes (Li, X-L et al., 2002). The study
focused on leptin receptor-deficient mice. The behavioral
and molecular data obtained from the leptin receptor-deficient mice was compared against a positive leptin receptor
control group. Both groups of mice were put through the
Morris water maze task. The leptin receptor-deficient mice
swam greater distance than their positive controls before
they found and climbed onto the hidden platform. When
the platform was removed, the leptin receptor-deficient mice
crossed the original platform location fewer times than the
positive control group. The hippocampus was removed from
the leptin receptor-deficient rodents and the control group.
Electrophysiological analysis of the hippocampal tissue of the
leptin receptor-deficient mice showed impairments of long
term potentiation (LTP) and long term depression (LTD). The
decreased cognitive behavior and impaired LTP and LTD processing observed in the leptin receptor-deficient mice support
the conclusion that leptin enhances LTP and regulates mechanism involved in both learning and memory
Leptin also appears to regulate a number of defining features
of Alzheimer’s disease. AMP- dependent kinase (AMPK) is
known to regulate glycogen synthase kinase-3B (GSK-3B), a
kinase which is crucial in the regulation of tau phosphorylation
(Nikolaos et al., 2009). It has been shown that leptin directly
activates AMPK and thereby possesses the ability to modulate
tau phosphorylation (Yu et al., 2004). Leptin also facilitates the
uptake of amyloid beta complexes via its regulation of the lipoprotein receptor-like protein (Fewlass et al., 2004). Thus, leptin’s
activity directly affects the regulation of amyloid beta uptake
and tau phosphorylation, two of the impaired pathophysiological
features of Alzheimer’s disease.
One study assessed the effects of leptin treatment on CRND8
Alzheimer’s mouse models (Greco et al., 2010). The CRND8
mice received daily treatments of leptin for a total of 8 weeks
with a control group receiving saline infusions. Leptin-treated
mice spent statistically more time with the novel object compared to the saline-treated control group during the object
recognition test, indicating an improvement in working memory
performance after leptin treatment. Analysis of brain tissue from
the CRND8 mice revealed that the leptin-treated group had
reduced amyloid beta levels in both brain and serum. Staining
of the brain tissue for amyloid fibers showed a significant decrease in amyloid burden in the hippocampus of the leptin
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treated CRND8 mice, which was associated with a decrease
in the average size of amyloid plaques. There was no significant
increase in the levels of the inflammatory molecule C-reactive
protein, tumor necrosis factor or cortisol in the plasma of the
leptin-treated group compared to the saline-treated group, indicating that leptin does not induce an inflammatory reaction.
The results of the study fully support the ability of leptin to
ameliorate Alzheimer’s like pathological pathways, strengthening
leptin’s potential of becoming a novel therapeutic treatment for
Alzheimer’s disease.

Synergistic Effects of Amylin and Leptin
Leptin and amylin activate overlapping signaling cascades and
ultimately converge on the insulin signaling pathway by activating AKT and increasing insulin sensitivity (Yarchoan and Arnold,
2014). Recent studies have indicated that leptin and amylin signaling appear to have synergistic properties.
One study profiled hypothalamic neurons in order to determine the effects of amylin and leptin on hypothalamic activity (Li,
Z et al., 2015). It was discovered that hypothalamic expression
of lapp, a precursor to amylin, was markedly decreased in mice
with mutations in the gene regulating the production of amylin,
but was normalized after infusions of leptin. The decrease of
amylin expression in mice that had mutated leptin genes showed
that hypothalamic amylin is a neuropeptide that is leptin regulated. Additionally, AC187, an amylin antagonist, was found to blunt
the activity of leptin and decreased its effects on neurons in the
hypothalamus. The presence of the amylin antagonist significantly inhibited the effects of leptin on both leptin depolarizing
and hyperpolarizing neurons. The ability of an amylin antagonist to blunt the response of leptin suggests that amylin can
modulate leptin’s effects. Leptin and amylin were also found to
have synergistic effects on hypothalamic neurons. Patch clamp
recordings demonstrated that the presence of either leptin or
amylin elicited similar excitatory and inhibitory effects on hypothalamic neurons. Leptin excited 65% and inhibited 35% of
the neurons, while amylin excited 62% and inhibited 38%. The
significant correlation between the effects of individual neurons
exposed to both treatments indicates that amylin depolarizes
the same neurons that are depolarized by leptin and hyperpolarizes the same neurons that are hyperpolarized by leptin. This
suggests that the response of the neuron would be amplified
upon simultaneous presentation of amylin and leptin.
The synergistic potential of these two treatments has been
explored with regards to treating obesity. Stand-alone obesity treatments have proven unsuccessful because diet-induced
obese (DIO) rats and obese humans are only minimally responsive to even high pharmacological doses. Nonetheless, amylin
possesses the ability to heighten leptin’s effects. For this reason,
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one study found that doses of exogenous leptin that was highly effective in lean rats had minimal effects on weight or food
intake in DIO rats. However, the results of the study showed
that administration of amylin together with leptin resulted in a
synergistic, fat-specific reduction in body weight in two independent experiments (Roth et al., 2008).
In light of this discovery, a clinical trial was designed in order to
evaluate the weight-lowering effect of combined amylin/leptin
(using pramlintide/mertreleptin) treatment in human obesity.
A 24-week, randomized, double-blind, study was conducted in
obese or overweight subjects. Subjects receiving pramlintide/
metreleptin lost almost 13% of their initial body weight over
24 weeks, compared with only ~8% in subjects receiving either pramlintide or metreleptin. Towards the end of the study,
weight loss plateaued in subjects treated with monotherapy,
but not in subjects treated with the combination. The overall
results of the study showed that weight loss caused by the
combination of leptin and amylin in humans was greater than
the additive weight loss of each drug used alone (Ravussin et
al., 2009).
Thus far, there have been no studies to examine the efficacy of
combination therapy of leptin and amylin to treat Alzheimer’s.
The successful results observed in weight loss clinical trials suggest that even greater improvements in memory in Alzheimer’s
patients may be possible by using amylin and leptin as a combined therapy.

Conclusion
The discovery of insulin resistance in Alzheimer’s has given
way to a growing interest in restoring insulin signaling in
Alzheimer’s with therapeutic agents originally developed for
the treatment of Type 2 Diabetes. Intranasal insulin, amylin
and leptin are examples of hormones typically associated with
obesity and diabetes which have shown promise for treating
Alzheimer’s disease. An advantage of using amylin and leptin
as medications for Alzheimer’s is that unlike with insulin, treatment using these hormones pose no risk of inducing hyperinsulinemia, as they activate the products of the insulin signaling
pathway without interfering with the concentration of insulin
in the body. Furthermore, weight loss studies have discovered
that amylin and leptin are synergistic substances which produce significantly enhanced results when used in combination.
This unique synergy suggests that achieving even greater improvements in memory may be possible by using amylin and
leptin as a combined therapy for Alzheimer’s. Further research
will need to take place before the proposed combined therapy
can be tested in a clinical trial and ultimately be distributed
pharmaceutically.
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Abstract
Obesity has emerged as one of the most preeminent concerns of the modern era. Thirty six percent of our country’s
citizens are classified as obese and six percent qualify as extremely obese. Developing obesity as an adult is fairly common, but countless studies have shown a direct correlation between childhood obesity and remaining severely overweight as an adult. Aside from the physical and aesthetic discomfort of maintaining superfluous girth, the health hazards
threatening the obese population are extremely discomfiting.The enormity of the issue requires extensive study so that
society can educate themselves of the dangers and how to prevent them. The purpose of this paper is to explore the
ramifications of childhood obesity on adult quality of life; given the probability that overweight youth will remain that
way, it is vital to determine the groups at risk for obesity and what diseases they’re likely to be at risk for. The studies
discussed support the theory that obese children will usually remain that way and that they are at even higher risk for
diseases like diabetes and heart disease than their obese peers who had not suffered from childhood obesity.
Part I-Introduction:

Physical Consequences of Childhood Obesity

The last three decades have witnessed an enormous increase
in childhood obesity in the United States. It is estimated that at
least 17% percent of children are currently overweight according to the Centers for Disease Control and Prevention (CDC),
and certain demographics like Hispanic and Black Americans
display more alarming percentages. As more children become
classified as overweight, those already at risk for extreme obesity are becoming even heavier. This becomes a grave concern
because an adolescent develops an acute probability of becoming an obese adult. Consequently, childhood obesity has evolved
into the most widespread predominant nutritional disorder affecting American children that pediatricians address (Childhood
Overwieght, 2014).

Adolescents who suffer from extreme overweight issues are
prone to a host of severe medical issues at every stage of life,
amongst them problems that normally afflict only the senior
population. A well-documented study indicates that the lifetime
risk of being diagnosed with type 2 diabetes (a disease brought
on by excess weight) is estimated at 30% for boys and 40%
for girls. Other publicized studies of the health issues directly
or indirectly caused by obesity include cardiovascular disease,
hypertension, high cholesterol, and in some rare but disturbing
incidents, heart attacks in children as young as 5 (Bagchi, 2011).

Contributors to Childhood Obesity
The factors that contribute to this serious health concern are
numerous. The most obvious ones are food choices consumed
in an individual’s diet, and average physical vs. sedentary activity. Less obvious but still pertinent are hereditary and genetic
factors. There are numerous genetic alterations, or single gene
mutations that are responsible for weight gain, although this is
rarer (Childhood Overwieght, 2014). Parental obesity is a very
significant indicator of a child’s potential for being overweight.
Specifically, parental BMI preceding and during pregnancy is a
dominant early‐life risk factor influencing BMI of offspring in
adulthood. BMI is an acronym for body mass index which is a
figure that relates weight to height and is obtained by dividing
a person’s weight in kilograms by his or her height in meters
squared (Definition of Body mass index, 2016).
In the Australian pregnancy cohort study, offspring of mothers
who had not received a college education, smoked and gained
excessive weight during pregnancy or had high BMIs preceding pregnancy, had a higher chance of being obese at age 22.
Paternal obesity, bottle fed babies and those who had a high
birth weight had an increased risk of childhood but not necessarily adult obesity (Rath et. al. 2016).

Children who suffer from these contributing factors to heart
disease may be suffering from Metabolic Syndrome (MS), which
refers to a group of risk factors that increases the danger of
developing heart disease and other health problems, such as
diabetes and stroke. (What Is Metabolic Syndrome?, 2016).
In a study to determine MS prevalence, 201 obese subjects aged 6
to 18 were studied.The subjects in the study were diagnosed with
MS if they had a BMI above the 97th percentile and met two or
more of the following conditions: triglyceride level ≥ 1.7 mmol/L,
HDL ≤ 1.03 mmol/L, fasting glucose ≥ 5.6 mmol/L, and arterial hypertension (systolic blood pressure ≥ 130 mmHg and/or diastolic
blood pressure ≥ 85 mmHg). Of the 201 children and adolescents,
110 (54.7%) subjects were moderately obese and 45.3% were categorized as severely obese. The frequency of MS was 24.5% in the
group of moderately obese and 37.4% in severely obese subjects.
The majority of children and adolescents in the study had one or
two components of MS.This discovery highlights the significance of
recognizing degrees of obesity in children and adolescents, which
could theoretically influence different rates of displaying cardiovascular risk factors (Šimunović et. al. 2016).
The obese pediatric population is also prone to developing
nonalcoholic fatty liver disease (NAFLD). In a Japanese study
conducted on NAFLD, researchers determined that more than
10% of all obese children had at least modest increases in serum
transaminases, which indicates liver damage, even if they hadn’t

31

Miriam Weinstock

developed full NAFLD. Other consequences of obesity include
cholelithiasis, pseudotumor cerebri, obstructive sleep apnea,
polycystic ovary syndrome, and orthopedic conditions such as
slipped capital femoral epiphysis (Allcock., 2009).

Psychological Impact
Aside from the many alarming medical conditions these children grapple with, the detrimental impact their circumstance
can have on their emotional wellbeing can be devastating. Obese
and overweight children often develop depressive symptoms
that can lead to negative body image and put them at risk for developing an eating disorder. Consequently, these children suffer
from low self-esteem, which can instigate behavior issues that
may develop into learning difficulties (Childhood Overwieght,
2014). A well detailed study on the psychological effects of
childhood obesity found that children aged 5 to adolescents
aged 18 shockingly compared their quality of life to individuals
undergoing chemotherapy treatment for cancer (Bagchi, 2011).
A study involving young school age girls was conducted to determine how much behavior is impacted by weight. The study
observed behavioral problems in 17%, 27%, and 2% of obese,
overweight, and normal weight children, respectively. Cultural
differences between varying countries didn’t impact the correlation between the two factors and similarities were observed
in most of the emotional-behavioral problems related to overweight and obesity. Internal emotional baggage, which includes
anxiety, depression and withdrawal were seen in 11%, 15%,
and 2% respectively, and external indicators of emotional disturbance, including aggression and delinquent behaviors, were
observed in 8%, 17%, and 2% in obese, overweight, and normal
weight children, respectively. (Seyedamini, et. al. 2012)

The data we have concerning childhood obesity and its correlation to significant impact on the physical and emotional health
of the child is concerning enough. But the consequences on
health later in life also requires study. Thus, the essential question in this field is: What effects will adolescent obesity have on
the health of the child when s/he becomes an adult?
This paper will examine the various health issues that can surface for individual who continue to suffer from extreme overweight into adulthood, in addition to proposing some solutions
for those who fall into that category.

Methods
Information was obtained online with access to online publications through the Touro college library. Additional references
were obtained through Pubmed.

Part 2- Results and Discussion:
Correlation Between Childhood Obesity and
Adult Obesity
Before determining what the medical impacts on adult health
are due to childhood obesity,we need to answer a fundamental
question: Do obese children become obese adults? According
to the response of test subjects, roughly twice as many individuals who reported that they were “considered a fat child” were
more than 155% larger than what their ideal body weight should
have been as young adult women, compared with women who
did not report that they were “considered a fat child” (Rimm,
1976). Corpulence in infants leads to a twofold increase for risk
of subsequent obesity. Another study concluded that the odds
ratio for the persistence of obesity rises with age among obese
children; endurance of obesity for overweight children hovered
at 50%. Considering that this study was conducted before the
enormous surge in childhood obesity in recent years, the current figure would be even higher (Allcock et. al., 2009).
A study was conducted where 1,355 participants from the
Australian Pregnancy Cohort were analysed. This represented
an Australian birth group born between 1989 and 1991. There
were 12 periodic intervals where mothers and children were
surveyed starting from early pregnancy: birth, 1, 2, 3, 5, 8, 10, 14,
17, 18, 20 and 22 years. The data collected provided researchers
with an opportunity to track BMI patterns from birth to maturity and to examine the significance of early-life contributing
factors to obesity.

Figure 1 A diagram of a child’s obese body with labels on the parts
of the body that can be affected by obesity (Williams, 2010).
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Factors that were investigated as possible causes of being extremely overweight were: sex, most advanced level of education
of the mother (paternal education level not available), maternal and paternal pre‐pregnancy BMI (based on recalled weight
recorded at 18 weeks of pregnancy), maternal smoking during
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pregnancy, maternal anemia and diabetes during pregnancy
(pre-existing or gestational), and excessive pregnancy weight
gain (change in weight from pre-pregnancy to 18 weeks and
34 weeks’ gestation). These factors all represent pre-birth conditions. Post-partum, other factors of influence were observed
to be cesarean delivery, early birth, birth-weight, first-year
growth and extent of breast-feeding.
BMI of the participants was recorded; to eliminate any gender
discrepancy the BMI was standardized using z scores and standard deviations. A BMI higher than the 85th percentile was considered overweight and obesity was declared above the 95th
percentile. In adulthood, these would correlate to BMIs of 25
and 30 respectively.
The results indicated that maternal and paternal BMI produced
the strongest effect on offspring BMI, particularly in adolescence
and early adulthood. Compared to children whose parents were
not overweight, children at ages 14 and 22 with overweight
mothers had more than 4 times the risk of developing obesity.
This paled in comparison to children of obese mothers which
predicted a 7to10-fold increase of risk. Paternal overweight almost tripled obesity risk at age 14 although it was determined
to be non-impacting at age 22. But paternal obesity resulted in
an almost fourfold increased risk of offspring obesity at both
ages (Rath, 2016).
In an attempt to clarify the correlation between childhood and
adult obesity, statistics were assembled from four longitudinal
studies conducted between 1929 and 1960. The studies compared the BMI at the target adult age of 35 to the BMI between
1 and 18 years. BMI at age 13 usually predicted the BMI at 35 and
the BMI at 18 was usually extremely accurate in predicting adult
size. One study tracked the BMI of infants until the age of 21. At
the study’s completion, 41% of the individuals that were lean at
one year remained in the lean category and 41% of the fat infants
remained in the fat category. Further studies have projected that
up to 81% of overweight (BMI greater than 85th percentile) adolescents will become obese young adults. (Whitaker, 1997)
Researchers have also had to determine which BMI should be
the cutoff point that ascertains obesity. They established that
the likelihood that obesity will continue in 50% of adolescents
identified by a BMI ≥95th percentile, or by a weight-for-height
of 130%, which is slightly larger than a BMI ≥95th percentile,
suggests that a BMI ≥95th for children of the same age and
sex signifies a realistic cutoff point to identify lasting obesity.
After establishing these percentage guidelines, researchers then
had to establish the number adolescents that fall into these
categories. The CDC has determined contemporary data that
demonstrates that 31.9% of youth aged 2-19 are at or above the

85th percentile, 16.3% are at or above the 95th percentile and a
shocking 11.3% are at or above the 97th percentile of the 2000
BMI-for-age growth charts. This indicates that approximately
one in three individuals between the age of 2 and 19 years is
either overweight or obese (Allcock., 2009).

Health Implications for Obese Adults
Now that we have determined the immense likelihood that
obese children will morph into obese adults, we need to examine
the health consequences this correlation presents. Individuals
who suffer from childhood obesity are at risk for higher rates of
developing disease as an adult as well as dying earlier. This can
be referred to as the impacts on adult morbidity and mortality,
which is defined in the following way: Morbidity describes the
unhealthy state of an individual while mortality occurrence of
death in a population (Morbidity vs. Mortality, n.d.).
A 1988 follow up on the Third Harvard Growth Study of the
early 1930s that tracked school-age youth into adulthood provided some insight into the effects on adult health and quality
of life. Overweight participants were determined to be adolescents who had more than two measurements of their body
mass index (BMI) above the 75th percentile during high school.
Subjects with a BMI between the 25th and 50th percentile
throughout high school were classified as slim. The follow-up
data was collected when the subjects were 55 years of age,
and the results were modified to represent smoking status and
reported weight. There was an extremely high correlation between disease and their excess childhood weight. Both males
and females had increased rates of the classic diseases that
afflict the obese population: diabetes, coronary heart disease,
atherosclerosis, hip fracture and gout.The risk of these diseases
was only slightly diminished after adjustment for smoking and
adult weight. Only the risk of diabetes became insignificant after
adjustment for lower adult weight; type 2 diabetes is known to
be directly correlated to high weight (Dietz, 1998).
A Dutch study similarly sought to observe the impact of a higher BMI at age 18 on premature adult mortality from all causes. A
group of over 78,000 Dutch men at the age of 18 were studied
and tracked over a 32-year period. They found a higher incidence of all-cause deaths in those individuals with a BMI >25
(classified as overweight) compared to individuals with a BMI
between 18 and 25 (Hoffmans, 1988).

Cardiovascular Disease and Risk Factors
Of all the diseases mentioned, the most severe are arguably
cardiovascular. How does childhood obesity impact adult heart
health, or lack thereof? With rising evidence to help conclude
that childhood obesity is linked to adult obesity, the medical
world has been grappling with the question as to whether obese
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adults’ risk of cardiovascular disease (CVD) is increased by their
pediatric obesity or just similar to weight-matched peers.
The precise connection between obesity in youth and adult
development of cardiovascular disease was researched in the
Princeton Follow-up Study. As expected, the group that presented symptoms of MS in childhood due to obesity had a dramatically increased risk of developing cardiovascular disease 25
years down the road, compared with the group that didn’t suffer
as children. In fact, MS in childhood was a stronger determinant
of future cardiovascular disease in adulthood than was gender
or even genetic history of cardiovascular disease. The youth in
their initial study exhibited an adolescent incidence of MS of 4%.
In the follow-up study, this had risen to 27.2% for adults. This
study also demonstrated that risk of CVD increased by more
than 24% for each 10 % increase of BMI (Allcock, 2009).

youth who grew to be obese adults had a particularly high risk
of MS. Incredibly, the risk was lower in obese adults who had
not been that way as children. This reinforces the theory that
obesity determined prior to adulthood is more detrimental
than late onset obesity. The probable explanation for this is that
unceasing obesity serves as a “generator” for protracted insulin
resistance, which is directly correlated to and causes hypertension and metabolic irregularities. The study results indicate that
prevention of adult obesity and consequent MS and CVD risk
is dependent on the earliest possible intervention for obese
children to ensure they lose the weight (Vanhala, 1998).

Researchers also wanted to establish the connection between
weight change or maintenance from youth to adulthood and the
subsequent development of MS.

One of the indicators of CV. is carotid artery intima-media
thickness (IMT) and is recognized as an important predictive
measure of clinical coronary atherosclerosis health issues in
middle-aged and elderly populations. Carotid artery IMT measures the thickness of the inner two layers of the carotid artery,
the intima and media. A thickening of both is a measure used to
diagnose the extent of carotid atherosclerotic vascular disease
(Carotid Intima-Media Thickness Test, n.d.).

From 1993-4, a population study examining participants born
between 1947-57 was implemented in Finland. Records of the
7-year-old height and weight were obtained for 439 subjects.
Obesity was delineated as the top third BMI measure and MS was
diagnosed based on observations in the following areas: a systolic blood pressure ≥140 mm Hg and a diastolic blood pressure
≥90 mm Hg. If a patient was receiving treatment of antihypertensive drugs they were considered to have high blood pressure as
well. Other factors were: dyslipidaemia (hypertriglyceridaemia
≥1.70 mmol/l, low HDL cholesterol levels <1.00 mmol/l (<1.20
mmol/l in women), insulin resistance (abnormal glucose metabolism according to the World Health Organization’s criteria or
hyperinsulinaemia (≥78 pmol/l), or both).

From September 1973 to December 1996, a study that investigated the effect of childhood adiposity on adult heart health
examined a cohort of 486 participants from a community in
Bogalusa, Louisiana. Surveys were conducted approximately
every 3 to 4 years; 7 surveys examined children from the ages
of 4 to 17 years while 5 surveys followed up with young adults
aged 18 to 38 years, who had participated as children and remained available. The premise of the study (observing children
into adulthood over a 20-year span) enabled the researchers
to measure the collective and snowballing effect of risk factors
since childhood. The purpose of the study was to observe the
link between carotid IMT in young adults and traditional cardiovascular risk factors measured since childhood.

The number breakdown amongst the 439 subjects was as
follows: 75 were obese as both adults and children, while 219
weren’t obese for either age. Of these, 71 were obese adults
who hadn’t been fat as children, and another 74 were overweight in their youth but not as adults. Eight per cent of men
and 5% of women displayed symptoms of MS, which amounted
to 30 individuals in total. Of those people, 21% were obese
adults and 21 had also suffered from childhood obesity. The
study found that risk of MS was 2.9% for adults who had been
obese as children but this figure increased to 26.7% for people
who continued to obesity into adulthood. Interestingly there
was a zero incidence of MS in the 74 people who had formerly
been overweight but had since slimmed down.

Participants experienced the following procedure for each examination: Height and weight were obtained within a .1% range
of error after the subject fasted for half a day. These measures
were used to calculate BMI. Next, duplicate blood pressure
measurements were taken. Systolic and diastolic blood pressure
levels were evaluated 6 times and these levels were averaged for
the final observation.

The study concluded that ultimately childhood obesity augmented the dangers for developing MS as an adult and that obese
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The results found strong correlation coefficients between CVD
risk factors measured since childhood and the carotid IMT in
young adults: Overweight adolescents with high levels of LDL
cholesterol (“bad” cholesterol) in childhood, high BMI and systolic blood pressure were interrelated with carotid IMT in young
adults, with LDL-C level showing the highest correlation.As mentioned previously, this is concerning as high carotid IMT levels are
strong indicators of developing cardiovascular disease. (Li S 2003)
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Prostate Cancer and Obesity
Prostate cancer has also been linked to obesity. When the prolonged nature of this disease is considered, it can be assumed
that adolescent health may be an early life contributor. A number of studies of the correlation between prostate cancer and
early life obesity. It is important to note that the results of the
studies provided conflicting data: some observed a direct link
between childhood BMI and prostate cancer risk, while others
actually determined that increased BMI served as a protective
measure against the disease.
A contemporary study that tracked 950,000 men for a 20-year
span was conducted in Norway. The study determined that a
BMI larger than 30 amplified the risk of prostate cancer by only
9%. Conversely, the 50 to 59 age group of obese men had a 58%
increased risk of prostate cancer but no younger age group presented a substantial risk. Another study that incorporated data
from the Health Professionals Follow-up Study by Giovannucci
and colleagues, discovered that an increased BMI was actually
correlated to a decreased risk of prostate cancer among men
younger than 60 years or those with a family history of the
disease (Freedland and Aronson, 2004).

Psychological Ramifications of Childhood
Obesity into Adulthood
Aside from the obvious physical implications obesity presents,
the Harvard Growth study also determined that additional
psychological repercussions resulted when adult morbidity was
linked to childhood obesity. In a large sample studied during the
National Longitudinal Survey of Youth, surveyors revealed that
obesity present in adolescent females had grave social consequences several years later as an adult. Amongst them were: low
marriage rates, decreased years of education, inferior net incomes and compounded poverty levels.The prevalence of these
results, (after adjustment for the income and educational levels
of the individual’s family as well as self-esteem) indicated that
female obesity actually triggered these socioeconomic links, as
opposed to being a result of these socioeconomic associations.
This further demonstrates the detrimental impacts of adolescent obesity on adult quality of life. (Dietz, 1998)

Part 3: Future- Preventions and Treatment
Youth Intervention Studies
Looking forward, it is incumbent on us as a society to prevent
and treat obesity given all the severe and often fatal maladies
obesity causes. So far, exploration of obesity prevention was
conducted in only a limited number of studies. This may be for
a host of reasons including a dearth of funding for public health
and obesity investigation; insufficient prevention tactics, and
overall inadequate training in medical education programs. The
prevention tactics targeting obesity on a small community-wide

scale that have been used are the following: Targeting a community wide population with the goal of reducing the average
BMI collectively, which is known as an intervention strategy. If a
strategy narrows the scope to target only individuals already at
high risk (offspring of obese parents) it is a selective prevention.
This kind of program seeks to educate and imbue these people
with the necessary skills to avoid weight gain. Finally, a targeted
prevention tactic assists those who are already overweight or
obese in their attempt to lose weight. One example of how this
was implemented was in the North Carelia Project which incorporated media education, as well as programs specifically designed for schools and work places. The program saw the most
success in a ten year follow up when children were treated in
conjunction with their parents. Weight changes and decreased
incidence of obesity proved the efficacy of the family based and
lifestyle mediations.
Researchers on the subject believe that primary intervention
for youth is better than attempting to treat already obese adults.
There are established periods that have been identified as crucial to preserving healthy body weight: the prenatal stage, the
period between 5 and 7 years of age (which is referred to as
the adiposity rebound) and the teenage years. Although a large
percentage of individuals may only experience weight gain as
adults, there is a substantial correlation between childhood and
adult BMI. Childhood obesity persevering into adulthood appears to rise linearly as a child get older. Precursors of adult
diseases such as hypertension are increasingly affecting obese
children. As demonstrated earlier, childhood obesity is a strong
predictor of adult morbidity and it has therefore been suggested that an effective treatment of adult obesity may be youth
intervention. Based on this assumption, researchers developed
the KOPS (Kiel Obesity Prevention Study) which inaugurated
in 1996. A cohort of 5 to 7 year old children was gathered in
a the city of Kiel, Germany and the study was supervised with
cooperation from school physicians and teachers, in addition to
the formation of a new sports program for heavy children. Basic
information gathered at the beginning of the study included:
evaluation of the nutritional state and dietary habits of the child,
review of lifestyle (active vs. sedentary) social status, physical
fitness compared to a subgroup of children, muscle strength,
and preexisting health factors that increased risk, such as blood
pressure, glucose levels and cholesterol. The cohort (which
amounted to 25,338 children in total) had their BMIs recorded in comparison to the norms of the total group of 5-7 year
olds born in 1998. Overweight and obese BMIs were designated
based on the following criterion: triceps skinfold thickness (TSF)
as a parameter of fat mass. The 90th TSF percentile was used
as the value to determine obesity. The study was designed to
conduct a follow up session with the participants every 4 and 8
years. The study was implemented by introducing a nutritional
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awareness and health promotion program for children and their
parents in three intervention schools every year. Corresponding
data from demographically similar schools were designated as
the control groups. This reversed every alternate year. Family
assistance and a structured sports program were offered to
families with overweight or obese children, as well as families
with normal-weight children with obese parents.
The premise of the study was that preventing obesity is dependent on healthy lifestyle. Lifestyle changes can only be implemented by augmenting knowledge and self-awareness as well as
harnessing self-esteem and personal independence. The rigorous
intervention methods included a panoply of directives, amongst
them: eat fruit and vegetables daily, reduce the intake of high fat
foods, keep active at least 1 hour a day, and decrease TV consumption to less than 1 hour a day. These messages were delivered to
pre-school age children within their first year. Teachers working
in conjunction with skilled nutritionists offered 8 hour courses
on nutrition for the students as well as parents, who were asked
to attend school meetings to address the issue. Aside from the
programs offered in school, families with obese children or parents were provided with counseling and support programs for
the family as a whole. This consisted of home visits arranged by
a nutritionist who visited on between 3 to 5 times in a span of 3
months to assist with shopping, cooking and ‘resetting the family
table’.The counseling instructed parents to screen food ingestion
and physical activity. A half year program of structured sports biweekly was also offered to overweight youth. Assessment of the
results were collected with the intention of determining the following outcomes: primarily, a change in BMI and second, change in
health-related comorbidity, or the presence of diseases caused by
obesity. The differences were examined in both the intervention
and the control schools.
In the first 4 years of the study, school interventions were directed
at 414 children, their parents and teachers. 92 out of 368 eligible
families partook in the family intervention program and 25% of the
families finished the program.The short-term effects were studied
for all children within 3 months after the end of the interventions.
Due to the interventions, 60% of the children exhibited adequate
nutrition recognition (as opposed to the original 48%), 65% of children related that their physical activity had increased (while time
spent in TV watching had diminished) and 28% of them had joined a
sports group. Families as whole had a 50% increase in their produce
consumption and low fat food was also consumed more frequently, increasing from 20% to 50%. The nutritional state of children
in the intervention schools was reevaluated after 1 years’ time.
Compared to the nutritional states of children in control school,
the intervention school group showed drastically improved results:
the control groups had higher increases in TSF as well as percentage of fat mass. (Müller et al. 2001)
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Another study was conducted to evaluate various methods of
intervention for adolescents ranging from behavioral, which
consisted of introducing simple intervention methods, to pharmacological treatments which consisted of a drug regimen, and
finally, surgical interventions for the morbidly obese sector.
Behavioral interventions were incorporated in schools or specialty health care settings to target youth aged 5 to 18 years and
introduced behavioral modifications similar to the Kiel Obesity
Prevention study: education about healthy dietary habits and
augmented physical activity. The data collected from the school
interventions described a 0.4 to 2.07 difference in mean BMI
change between those that were treated and the controls at 6 to
12 months, with a collective estimate of .82 lower BMI in those
treated. This would mean a loss of 3 pounds for an 8-year-old
boy or girl, (assuming growth of 2 inches or less), and a 4-pound
loss for a 12-year old boy or girl. For a 16-year-old adolescent,
this would mean a weight loss of 4.5-6 pounds, depending on
gender. Specialty health care setting proved to be much more effective, displaying a 1.9 to 3.3 BMI difference, compared to control
groups, for 6–12 months post-treatment. This would mean a 1213-pound weight loss for an 8 year old (again, assuming 2 inches
of growth), and a 16.6 to 17.75 pound weight loss for a 12 year
old. 16 year olds enrolled in the program could experience up to
a 23-pound weight loss (Whitlock EP et al. 2008).
It is important to acknowledge that the trial results would not
necessarily translate well to helping individuals in a real world
setting. The studies utilized media advertisements for enrollment; it follows that those participants may have been more
inspired to lose weight, and had a surplus of free time. Parental
alarm, multiple failed attempts at weight loss or other such factors may have produced skewed results.
Pharmacological aides in addition to behavioral interventions
have been investigated only in obese youth aged 12 to 18 years
that meet adult criteria for class II obesity, which is a mean BMI
of 35 to 40 the beginning of the trial. Drugs incorporated into
the weight loss regimen such as sibutramine and orlistat were
administered in conjunction with behavioral interventions for
a 6-12 month span. Unfortunately, longer term impacts after
treatment termination are not presented for any of the pharmacological trials (Whitlock EP et al. 2008).
A sizable trial consisting of 498 people tested 12 months of
sibutramine in combination with a behavioral intervention
plan. The control group received the same behavior modification plans but a placebo pill. Sibutramine is a medication that
supports weight-loss by altering neurotransmitters within the
brain. Nerves need to correspond with other nerves and neurotransmitters are what nerves produce to accomplish the
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process. When neurotransmitters are sent out, they either attach to other nerves or they may experience reuptake, which
is when the same nerve reabsorbs it. Sibutramine obstructs the
reuptake of the neurotransmitters dopamine, norepinephrine,
and serotonin. Preventing reuptake of neurotransmitters modifies the balance of neurotransmitters within the nerve cells and
thus affects nerve function and interaction.

Definition of Body mass index. (2016, May 13). Retrieved from
MedicineNet.com: http://www.medicinenet.com/script/main/
art.asp?articlekey=16125

After 12 months, the subjects who took the 10-15 mg dosage of subatramine lowered their BMI by almost 3 units, which corresponds
to a 14-pound weight loss. Astonishingly, the participants of the
control group experienced a 4.2-pound weight gain. Interestingly, it
seems the decrease in weight that occurs over a year with intense
and successful behavior intervention rivals the achievements of the
pharmacological interventions in the same time span, but more
direct comparison would be necessary to substantiate the claim.
(Whitlock, et al. 2008) Although this drug proved to be successful,
it’s important to note that it’s no longer available in the U.S. for fear
of heart attack or stroke (Eni Williams, 2015).

Freedland, S. J. (2004). Examining the Relationship Between
Obesity and Prostate Cancer. . Reviews in Urology, 73-81.

Conclusion
Childhood obesity is increasing with alarming frequency and
can be attributed to a number of factors including diet, health
education, and parental BMI. The impacts can be devastating;
obese children battle with deadly diseases that can severely
compromise their quality of life. This issue only gets amplified if
obesity persists into adulthood. Numerous studies have demonstrated the adult health ramifications caused by childhood obesity, including diabetes, metabolic syndrome and cardiovascular
disease. Overall mortality for adults also increases when they
have a BMI above 25 (overweight range). Although the present
seems bleak, various studies have investigated prevention and
treatment for obesity, amongst them community wide behavior
interventions that have been very successful. If obesity is effectively conquered in childhood, the individual’s adult health and
quality of life can be immeasurably improved.
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Abstract
Due to numerous drawbacks with current modes of treatment for various ocular diseases, researchers are synthesizing
drug dispensing contact lenses. The lenses will contribute to greater bioavailability of the drug, the minimization of negative side effects, and increased patient compliance. As treatment for glaucoma, in vivo studies have been conducted with
latanoprost, timolol maleate, and brimonidine tartrate-eluting lenses, and have succeeded in reducing intraocular pressure
to desired values (Ciolino et al., 2016), (Schultz and Mint, 2002). As treatment for fungal keratitis, in vitro studies prove
that econazole and natamycin-eluting contact lenses have been successful in killing 100% of fungi for sustained periods of
time (Ciolino et al., 2011), (Phan et al., 2013). Finally, for allergic conjunctivitis, contact lenses containing nanoparticles of
prednisolone have been synthesized and demonstrate effective drug-releasing capabilities (ElShaer et al., 2016).
Introduction

Glaucoma

Current methods of treatment for various ocular ailments include both oral medications and topical eye drops. There are
significant downsides to both. Orals are often not the first line of
treatment both because, they take a circuitous route to the eye
and cause many more negative systemic side effects (Kim, et al.,
2014). Next, in the case of eye drops, there are multiple barriers
to overcome. First, much of the dispensed eye drop is inhibited
by pre-corneal factors which include nasolacrimal drainage, tearing, and blinking.These factors significantly lower the bioavailability of the medication. Research indicates that only a fraction of
the precious medication, a mere one percent to seven percent,
reaches its required destination, thereby reducing the drug’s effectiveness (Schultz and Mint, 2002). Furthermore, the drops are
often administered by the patient, and sometimes are required
multiple times a day. This commonly leasds to low patient compliance, and doses are frequently forgotten or skipped purposely
(Ciolino et al., 2011). Given the above, there exists an impetus to
develop alternate methods of delivering ocular medications, thus
enabling effective treatment. Researchers are currently working
on developing a contact lens that will also dispense nanoparticles
of medication directly into the eye while correcting refractive
error. In patients who don’t have refractive error, the contact
lenses can simply be worn for the purpose of delivering the
needed medication into their eyes. The use of contact lenses for
ocular drug delivery can solve many of the issues associated with
eye drops. First, the space created by the lens with the cornea
has limited tear mixing, and potentially a greater amount of contact time between the drug and the cornea.

Glaucoma, a group of conditions that damages the eye’s
optic nerve, usually results from increased intraocular pressure (IOP) which can result in vision loss and blindness. The
two main forms are open-angle glaucoma and angle-closure
glaucoma. Both forms, involve clogging of the eye’s drainage
canals, leading to elevated ocular pressures and subsequent
nerve damage. In open-angle glaucoma this leads to a gradual
increase in IOP because, the angle between the iris and cornea
is wide and open. In angle-closure glaucoma there is a sudden

This causes greater bioavailability. Additionally, there is an
added benefit of eliminating the need for multiple doses a day,
which will increase the amount of patient compliance. Under
ideal kinetics, the drug will release in a time dependent manner, extending the therapeutic effects of one dose (Phan et al.,
2014). Research with a drug dispensing contact lens (DDCL), is
currently underway for a number of ocular conditions. In this
work specifically, a DDCL for the diseases of glaucoma, fungal
keratitis, and hay fever are discussed.
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increase in IOP because, the angle between the iris and cornea
is either very narrow or closed. Current methods of treatment
include surgery, oral medications, and eye drops, depending on
the classification and extent of the disease. When surgery is
warranted however, it usually does not resolve the increased
IOP completely and generally a regimen of eye drops are prescribed as well post operatively. Additionally, surgery can cause
negative side effects including, cataract formation, inflammation, ocular infections, corneal issues, and low IOP. Negative
side effects caused by oral medications can include irritation,
stinging, redness, blurred vision, itchiness, low blood pressure,
fatigue, shortness of breath, headaches, dry mouth, frequent
urination, upset stomach, and memory problems, depending
on the class of drug prescribed. In general, topical eye drops
are the first line of treatment. However, due to the issues
posited above, a contact lens that can dispense anti-glaucoma
drugs is currently being developed.

Are Contact Lenses an Effective Vehicle for Ocular-Disease Drug Delivery?

Research for Anti-Glaucoma Drug Dispensing
Contact Lens
Joseph B. Ciolino, MD, at the Massachusetts Eye and Ear, conducted an in vivo study on the effectiveness of a Latanoprostdispensing contact lens for female monkeys with induced
glaucoma. Latanoprost is currently on the market as a topical
anti-glaucoma eye drop. It belongs to a class of anti-glaucoma
medications knows as prostaglandin analogues, which work to
lower the IOP by increasing uveoscleral flow (although more recently research suggests that it may occur through a trabecular
pathway) and it is prescribed for cases of open-angle glaucoma
(Lindén and Alm, 1999, Winkler and Fautsch, 2013). In Ciolino’s
research, a thin latanoprost-polymer film was introduced into
a methafilcon hydrogel contact lens. Both a low-dose contact
lens (CL), and a high-dose CL were synthesized. The intraocular
pressure of the glaucomatous monkeys was monitored after a
period of the following cases:
1.

Treatment with Latanoprost eye drops

2.

Treatment with CL-low

3.

Treatment with CL-high

4.

No treatment

The results demonstrated that the latanoprost eye drops succeeded in reducing IOP approximately 5 mmHg, the CL-lo by
about 6.5 mmHg, and CL-hi by about 11 mmHg.
Evidently, “Sustained delivery of latanoprost by contact lenses is
at least as effective as delivery with daily latanoprost ophthalmic solution. More research is needed to determine the optimal continuous-release dose that would be well tolerated and
maximally effective. Contact lens drug delivery may become an
option for the treatment of glaucoma and a platform for ocular
drug delivery (Ciolino et al., 2016)”
Additional anti-glaucoma contact lenses that are currently being
researched, synthesized, and patented are those that contain
timolol maleate or brimonidine tartrate within a polymeric hydrogel.Timolol maleate belongs to a class of anti-glaucoma drugs
known as beta-adrenergic blockers and brimonidine tartrate is
an alpha agonist. Both are prescribed for cases of open-angle
glaucoma. Specifically, in the case of beta blockers, systemic side
effects can be pretty severe such as, cardiac arrhythmias, bronchospasm, and stroke and is therefore prescribed based on a
patient’s complete medical history. The aim of the study was
to develop contact lenses that maintain normal hydration and
comfort, and will dispense lower doses of drug for extended
periods of time. This will lead to increased patient compliance,

decreased negative side effects, and efficacious treatment
(Schultz and Mint, 2002).
Etafilcon contact lenses (hydrogels) were washed in a saline
solution and briefly dried. Then they were immersed in either a
dilute solution of brimonidine tartrate (0.02%), or a dilute solution of timolol maleate (0.05%). (Topical ophthalmic solutions of
the above drugs are commercially available as 0.2% solutions for
brimonidine, 0.25% for timolol, and 0.5% for timolol ophthalmic
gel forming solution). The lenses were subsequently tested on
multiple patients as a replacement for their current regimens of
eye drops. Instead of the patient administering their daily eye
drop, he wore the contact lens for 30 minutes each day. In all
cases, this method allowed for IOP to remain below the necessary value of 20 mmHg, with no evidence of ocular toxicity.
An additional study was conducted on glaucomatous beagle
dogs. NIGHT & DAY™ silicone hydrogel contact lenses were
immersed in timolol and phosphate buffered saline solution.
Then, one lens was inserted into one of the dog’s eyes, while
the other eye served as the control, and no lens was inserted.
The lenses with similar dosing to timolol eye drops led to an
IOP reduction of about 5 mmHg (which is slightly greater than
the IOP reduction resulting from timolol eye drops). However,
lenses with a third drug loading as the eye drops led to a similar
reduction in intraocular pressure, suggesting increased bioavailability. Finally, the eye without the contact lens remained unaffected by its proximal lens, which suggests reduction in systemic
absorption of the drug released by the lens (Peng et al., 2012).

Fungal Keratitis
Fungal keratitis is an infection of the cornea (the clear, round
dome covering the eye’s iris and pupil) which causes pain, reduced vision, light sensitivity, and tearing or discharge from the
eye. Resulting from infection from contact lens use, or from
injury to the eye, fungal keratitis usually develops very quickly,
and if left untreated, can cause blindness (Boyd, 2015). Fungal
keratitis is also prevalent in tropical and subtropical climates
(Ciolino et al., 2011).
Current treatment options for fungal keratitis vary depending
on the severity of the condition. Topical eye drops are often
the first line of treatment (Ciolino et al., 2011). Once again the
above drawbacks to eye drops are present:
“The failures of topical antimycotic treatments may be
related to the limitations of eye drops as a form of drug
delivery. Eye drops generate a transiently high concentration on application followed by a short period of effective therapeutic concentration and then a prolonged
period of underdose. Furthermore, each drop is diluted
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and washed away by reflex tearing and dispersed by
blinking. As a consequence, only 1% to 7% of drug in a
drop is absorbed in the eye. The cornea absorbs only
a fraction of this dose, in part due to the tissue’s short
contact time with the topical drops (Ciolino et al.,
2011).”
Currently there is only one drug available on the market, natamycin, as a topical ophthalmic antifungal. However, this drug
specifically is shown to have poor corneal penetration and is
mainly effective with superficial corneal infections caused by
Fusarium species (Singh, 2015). Depending on the severity and
identity of the disease, often subconjunctival injections of an
antifungal agent are prescribed and the dosage times are not
infrequent, (twice every hour for the first 24 hours, then once
every hour for the next 24 hours etc). “Successful antifungal
therapy for fungal keratitis requires frequent drug administration for prolonged periods (ie, at least 12 weeks) (Singh, 2015).”
Sometimes antifungals in an oral form are prescribed. However,
15 to 27 percent of patients with fungal keratitis require surgical
intervention (Boyd, 2015). Even after surgery, a course of topical
drops is often prescribed as well. Finally, surgery is not effective
in all cases, and a patient may be rendered significantly visually
impaired (Singh, 2015).

Research for an Anti-Fungal Contact Lens
The ineffectiveness of the topical regiment arises from low
penetrance of the drug to the corneal epithelium as well as
inadequate contact time between drug and tissue. Additionally,
low patient compliance is common due to the frequency with
which the drug needs to be administered. A contact lens that
dispenses antifungal particles could resolve all these issues. A
prototype antifungal contact lens (Ciolino et al., 2011) was synthesized using the following method:

The lenses were also tested for their drug-releasing capabilities.
The testing was conducted by immersing the lenses in a yeast
nitrogen base medium and incubated.Then they were immersed
in fresh medium every 24 hours. The yeast nitrogen base drug
release medium was collected at different intervals, and diluted
with new medium containing C. albicans. Once again after a period of dilution and incubation, the suspension was plated and
counted for viable colonies.
The results showed that both methods were capable of killing
100% of fungi for extended intervals.The release medium which
contained contact lenses with 16 mg of econazole (PLGA-16)
killed 100% of fungi for 21 days! The mediums from contact
lenses, containing lower concentrations of econazole, killed fungus for shorter amounts of time. In the cases where the contact
lenses came directly in contact with the fungal suspension, 100%
of fungi were killed for 8 to 10 days (with PLGA-16). Studies
show that C. albicans is more difficult to kill than Fusarium
species. Therefore if Candida was killed by econazole, Fusarium
should be as well (Ciolino et al., 2011). (Currently econazole is
not FDA approved for ophthalmic use, although many ophthalmologists would prefer to treat fungal infections with something other than Natamycin, currently the only available drug).
Contact lenses that could elute the drug natamycin have also
been synthesized (Phan et al., 2013). The study focused specifically on manipulating various contact lens materials. Hydrogels
were composed of:
1. 100 % pHEMA,
2. 85% pHEMA and 15% [Tris(trimethylsiloxy)silyl]-propyl
methacrylate (TRIS)
3. 75% pHEMA and 25% TRIS

Econazole, an antifungal drug, was added to a film of poly (lactic-co-glycolic) acid (PLGA). PLGA is desirable because of its
biocompatibility and biodegradability, and its effectiveness at
controlling drug release kinetics. Various film sizes were synthesized and all were encapsulated into polyhydroxymethacrylate (pHEMA), a common contact lens material. Contact lenses
were synthesized with different concentrations of econazole.
A control lens was created as well which contained the PLGA
film inside the pHEMA hydrogel without the econazole. The
contact lenses were tested against the fungus C. albicans, a
common agent of fungal keratitis. First the lenses were placed
directly onto a rich medium, a culture plate containing 1 mL of
the Candida suspension. After a number of cycles of incubation
and refreshing the medium, the culture was diluted, incubated,
and counted for viable colonies. This was done to determine
the effect of the contact lenses in direct contact with the fungi.
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4. N,N-dimethylacrylamide (DMAA),
5. 85% DMAA and 15% TRIS
6. 75% DMAA and 25% TRIS
The lenses were monitored by their uptake and release of two
forms of natamycin. The first form was Natamycin dissolved in
deionized water, and the second form was Natamycin encapsulated within poly(D,L-lactide)-dextran nanoparticles. Results
indicated that the optimal materials to use were those containing DMAA. Furthermore, all gels had a greater uptake with the
nanoparticles of natamycin versus natamycin alone. Finally, the
release of natamycin within nanoparticles was greater than the
natamycin alone. Also, the first hour of release was noteworthy.
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The lenses with regular natamycin released 28-82% within the
first hour. In the nanoparticle lenses this was reduced to 21-54%
(Phan et al., 2013).

MAA (methacrylic acid) and a small amount of EGDMA (ethylene glycol dimethacrylate) were mixed together along with
the PNPs.These four hydrogel materials were allowed to polymerize thermally for 4 hours at 80°C in molds of polypropylene.

Hay Fever and Allergic Conjunctivitis
“Spring allergies are triggered as trees start blooming and billions of pollen grains are released into the air, causing susceptible individuals to develop allergic rhinitis… In these patients,
the pollen causes degranulation of mast cells, which contain
inflammatory mediators, ie, histamine and other allergy-causing
chemicals.This process is clinically represented by sneezing; red,
tearing eyes; postnasal drip; sinus headaches; feelings of sinus
fullness; and itchy, scratchy throat (Medscape, 2016).”
As the conjunctiva of the eye is a mucosal membrane, it too is
subjected to the inflammatory responses of allergic rhinitis. Per
the CDC (Center for Disease Control and Prevention), approximately 19 million adults and another 6 million children suffer
from hay fever in the U.S. alone. For the ocular symptoms of rhinitis, also known as allergic conjunctivitis, eye drops containing
anti-histamines and/or mast cell stabilizers can be prescribed or
recommended. Another class of treatments are corticosteroids
and glucocorticoids, which also work to reduce the allergic
reactions which affect the eye and relieve the negative symptoms. These can be prescribed as an ophthalmic suspension for
topical use. Once again due to inhibitive pre-corneal factors, an
alternate drug delivery mechanism is currently being researched
in the form of a drug dispensing contact lens.

Research for DDCLs for Allergic Conjunctivitis
The Kingston University London conducted an in vitro experiment to synthesize a contact lens that could dispense nanoparticles of a synthetic glucocorticoid, prednisolone, into the eyes
of patients with allergic conjunctivitis. (Currently prednisolone
is on the market as prednisolone acetate ophthalmic suspension
for topical use.) The main purpose of the experiment was to
consider the effects of the encapsulated drug on the contact
lenses’ functionality and safety as well as the drug’s bioavailability (ElShaer et al., 2016).
Prednisolone nanoparticles (PNP) were synthesized using an
emulsion-solvent evaporation method. The experiment was designed to maximize three key nanoparticle features: small particle size (increased surface area/bioavailability), highest encapsulation efficiency, and maximum surface charge (no coagulation
of particles; increases stability). To obtain the smallest particle
size, four variables were manipulated: PLGA (poly-lactic-co-glycolic acid), PVA (polyvinyl alcohol), API (amount of prednisolone
used), and homogenization time. Through optimization of these
components a particle size of about 295 nm was obtained. To
form the contact lens molds, HEMA (2-hydroxymethacrylate),

The in vitro drug release pattern of the contact lens with 0.4
grams of PNP was observed to be a two-phase process: an initial burst, followed by a period of slower release. The lens was
placed in a release medium of phosphate buffered saline for 24
hours. 10.8% of drug was released in that time.The slow release
of the drug can be due to the need for the drug to get past its
nanoparticle barrier and through the contact lens as well. One
of the issues with eye drops is that all of the drugs are released
within a few hours. Nanoparticles of medication embedded in
contact lenses can provide a longer lasting therapeutic regimen
(ElShaer et al., 2016).

Method of Drug Release from Contact Lens
Although some studies for drug-eluting contact lenses pre-soak
the contact lenses in drug, to allow for eventual diffusion into
the eye, to achieve a more controlled method of release, other
methods are being researched. The human tear film contains an
enzyme called lysozyme. In a study on anti-glaucoma contact
lenses, timolol maleate was encapsulated in nanodiamond (ND)
particles. The NDs were coated in both polyethyleneimine (PEI)
and chitosan. Chitosan is an enzyme-cleavable polysaccharide
and PEI enables a more effective cleavage. The drug release of
these impregnated lenses was monitored in vitro. In the absence
of lysozyme, no release of timolol maleate was detected. In the
presence of lysozyme the lens released 9.41 micrograms in 24
hours (Kim et al., 2014).

Addition of Drug to Contact Lens Material and
Subsequent Hydration and Oxygen Permeability
This feature was monitored in the prednisolone study cited
above. Contact lenses lacking the PNPs had an average hydration of about 36%. Lenses containing a smaller volume
of drug nanoparticles (0.2 g) had a decreased hydration
by about 31%, whereas the lenses with a higher volume of
PNPs (0.4 g) had a further reduction in hydration to about
30.5%.
Surface wettability determines comfort of the lens, and was
measured as well. A good surface wettability is identified by a
contact angle less than 90 °C. Unmodified lenses have a contact angle of 85 °C. The prednisolone encapsulated lenses had
further reduced angles which should increase ocular comfort
(ElShaer et al., 2016). Similarly, contact lenses containing nanodiamond particles of timolol maleate demonstrated acceptable
hydration values (Kim et al., 2014).
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Transparency/light Transmission Capability of
Drug-Impregnated Lens
Ideally a contact lens should have a light transmittance of
above 90%, so vision is unobstructed. The control contact
lenses (lacking PNP) in the prednisolone study had a high
transparency of 94.5%. The lenses containing 0.2 grams and
0.4 grams of PNP had a reduced transparency of 86.23% and
83.1% respectively. However, this amount contributes to low
or no opacity, and as long as the correct amount of nanoparticle is added to the lens, vision should not be compromised
(ElShaer et al., 2016). Similarly, addition of nanodiamond particles of timolol maleate to a pHEMA lens did not cause any
discernable changes to the lens’ optical clarity. The lens with
a higher concentration of NDs maintained a transmittance of
84.5% (Kim et al., 2014).

Dimensions/measurements of Drug-Eluting
Contact Lenses Compared to Commercially
Available Lenses
In the study done on antifungal contact lenses, when synthesizing the econazole-laden lenses, parameters of an 8.05
base curve and a 15.5 mm diameter were measured, which
are consistent with commercially available lenses (Ciolino et
al., 2011).

Preservation of Contact Lens through
Lyophilization (to prevent drug elution/
degradation) Effect on Lens Capability
Depending on the method used to impregnate the lenses with
drug, there exists a risk of the drug eluting out of the lens during
storage. In order to combat this, anti-fungal contact lenses were
lyophilized, a preservation process involving the freeze drying of
a substance and subsequent removal of water by a vacuum causing the water to go from an ice state directly to a gaseous one.
The fungicidal activity of the lyophilized lens was then assessed
and found to be intact, although the duration of its effectiveness
was reduced by 1 to 2 days (Ciolino et al., 2011).

Risk Factors and Drawbacks Associated with a DDCL
Although there is a lot of potential is this innovative drug delivery system, several potential downsides should be noted. There
are many consumers who do not wear contact lenses because
they find them uncomfortable or haven’t found the proper fit.
Others do not wear contact lenses because they have no refractive error and would thus need a special fitting session just
to wear a short-term lens. Additionally, glaucoma often affects
the geriatric population. Individuals of this population could also
have difficulty inserting and removing the lenses, however this
issue could be aided by an eye-care professional. These factors
could potentially minimize the market for such lenses. Another
problematic feature involves the drug-eluting property of the
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lenses. Once removed by the patient any remaining drug may
continue to diffuse out. In the case of anti-fungal drugs, this
could have an effect on the development of resistant strains
while in the case of other drugs this may simply pose as a hazard
for children. (It should be noted though that with lenses controlled by lysozyme presence this undesired drug-elution may
be minimized).

Conclusion and Further Applications
Contact lenses for the treatment of glaucoma, fungal keratitis,
and allergic conjunctivitis have been synthesized and demonstrate much potential in effective treatment. However, the lenses are far from having a clinical relevance. Much more animal
and human testing is required prior to the necessary FDA-type
approvals. Although in this paper glaucoma, fungal keratitis, and
allergic conjunctivitis were discussed, research is also underway for additional ocular conditions such as, chronic dry eye
and bacterial infections (Legett, 2009), (ElShaer et al., 2016).
Additionally, the studies are working on embedding various drug
nanoparticles into lenses without obstructing optical transparency. Potentially, instead of drugs, various ocular-necessary vitamins and supplements can serve as the embedded nanoparticle.
As salt is iodized to promote proper thyroid function, perhaps
macular degeneration could be prevented by infusing contact
lenses with nanoparticles of lutein and zeaxanthin, two nutrients
vital to a healthy macula.
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Abstract
For years, the genetic element of heart morphogenesis has been studied.This review focuses on a relatively new area of
study, namely, mechanical factors influencing heart morphogenesis. To understand the context of the role of mechanical
factors in heart development, an extensive review of the stages of heart morphogenesis is provided.
It is found that shear stress, surface tension, fluid forces, and contractions of certain cells play a role in various stages
of heart development. Numerous studies have shown that in cases where these mechanical forces were modified,
abnormal heart defects were produced. These studies prove that the mechanical forces are essential for normal heart
morphogenesis.
Although attempts have been made to define the mechanisms involved in these pathways, most of the research done so
far has been inconclusive.While it has been proven that the mechanical forces play a role in heart development, it is still
unclear exactly how the forces are involved in the developmental pathways, and what initiates them to proceed. As of
current studies, it is also still unclear if there is any correlation between the genes and the mechanical factors involved
in heart morphogenesis.
Introduction
One of the most widely studied biological topics is the field
of morphology. Specifically focusing on embryonic morphology,
much research has been done to link genetics with the various
formations and stages of embryonic development. Throughout
the years, genetics has been used to explain and account for
countless aspects of development patterns and pathways found
in embryonic development. Many genes and signaling molecules
have been identified and used to formulate blueprints of morphogenic pathways in a developing embryo.
In recent years, there has been a shift in the study of embryonic
development. New studies are beginning to focus on the possible role of mechanical and physical forces in morphogenesis.
There are numerous physical forces found within the embryo
during the stages of development. This review focuses on contractions of cells, fluid forces, shear stress, and surface tension,
and their impact on cardiac morphogenesis. Breakthroughs and
new technology in mechanical biology allowed for advanced
studies of these forces.
Finally, the data will be analyzed to determine if these physical
forces that are involved in cardiac development can potentially be linked to genetic factors. Recent studies have begun to
attempt to relate the mechanical factors affecting heart morphology with the genetic factors which have been studied for
many years. By bridging the gap between genetic and mechanical
forces, we will have a better understanding of the control of the
development of cardiac tissue and the heart within an embryo.

Methods
Critical analysis of peer reviewed journal articles and original
clinical research papers was used to write this review. The articles and papers from which the research was gathered were
obtained by using the PubMed search engine found on the government’s National Center for Biotechnology Information website. Additional references were obtained from those sources.
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Heart Fields and the Heart Tube
Before analyzing mechanical factors involved in embryonic cardiac morphology, it is essential to have a solid understanding
of the stages of heart development in an embryo. The current
accepted model of cardiogenesis was first discovered during the
last decade. Heart morphogenesis begins with cells with myocardial potential that are located in a specific region, known as a
heart field (Buckingham et al., 2005). This was the first research
done which classified two individual heart fields, both of which
participate in cardiac development. Before this, there were
others who identified a second heart field (Kelly et al., 2001).
However, Buckingham was the first to explain the process by
which the two different fields give rise to distinct portions of
the human heart.
Much of this research was done with chick embryos and mouse
embryos. Comparisons of gestation timelines of chicks or mice
to humans can be made using the formulas outlined by Srivastava
(Srivastava, 2006). The anterior lateral plate mesoderm gives
rise to cells in the first heart field. A crescent shape is formed
by the first heart field. This occurs at approximately the second
week during human gestation. By the third week the ends of
the crescent merge with each other, forming a basic heart tube.
This heart tube is considered basic because it is simply made up
of two layers: an interior endothelial cell layer, and an exterior
myocardial cell layer (Srivastava, 2006).
Simultaneously, the second heart field is expanding in a formation which appears to encircle the first heart field. The first
heart field in the basic heart tube acts as a platform upon which
the second heart field is able to settle and begin the process of
becoming the various chambers found in the heart (Buckingham
et al., 2005). Figure 1 labels the heart fields and shows how each
field ultimately gives rise to a different portion of the heart.
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It also gives a clearer understanding to the anterior/posterior positioning of the first heart field (labeled “FHF”) and the
second heart field (labeled “SHF”) at two and three weeks of
human gestation. It depicts how the second heart field (shown
in yellow) uses the first heart field (shown in red/pink) as a support in the initial stages of morphogenesis. Figure 1 also clearly
illustrates how the second heart field completely surrounds the
first heart field by three weeks of human gestation.

elongation, interventricular grooves are formed. These grooves
ultimately become the bending points upon which the bottom
curve of the “c” looping is established. Upon the completion of
c-looping, three bended bands are easily noticeable: the truncus
arteriosus (which will later develop into the aorta, its branching
arteries, and the pulmonary trunk), the primitive atria region, and
the primitive ventricular region (Manner, 2000). Figure 2 gives detailed pictures of the process of dextral looping.
It can be seen clearly in Figure 2 that throughout the process
of dextral looping, the heart loses the symmetry and linearity it
possessed during the previous stages of the heart tube (Manner,

Figure 1. Mammalian Heart Development (Srivastava, 2006).
It is unclear what exactly causes the crescent shaped first heart
field to bend into a heart tube. It is theorized that contraction
of the crescent, caused by microfilaments in the apical regions
of the epithelial cells results in the production of the tube. The
contractions force the cells to assume a wedge-shape, causing the
plane of the cell sheet to begin to bend into a tube-like formation (Taber, 1998). Unrelated research supported this theory by
reporting that administering pharmacological agents that inhibited actin filament function prevented the heart tube formation
and resulted in the persistence of the crescent shape (Ettensohn,
1985). Because no experimental work has definitively linked contractions of the actin microfilament with the crescent bending
and heart tube formation, it would be inappropriate to say that
this is definitely the mechanism which forms the heart tube.
Nonetheless, the research provided is enough to strongly suggest
that this is the correct method of heart tube formation.

Dextral Looping
Before the heart can fully develop into its various components
and chambers, it must go through an event known as looping.
Looping produces the c-shaped structure present in the third segment of Figure 1.There are various stages of this looping process,
also known as “dextral looping.” To analyze this process research
was performed using chick embryos. Before looping begins, in a
stage referred to as the prelooping stage, the heart tube is essentially bilaterally symmetrical. As the heart tube undergoes rapid

Figure 2. Stages of Dextral-Looping. Slides A and B represent the
prelooping stage. In Slide B, “1” and “2” represent the interventricular
grooves. Slides C – G show the incremental changes in the heart tube
as it proceeds through the process of dextral looping. In Slide H, upon
completion of dextral-looping, “c” represents the conus, “v” represents
the primitive ventricular region, and “a” represents the primitive atria
region (Manner, 2000).
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2000).The conus will ultimately give rise to the aorta, the left and
right subclavian arteries, the left and right carotid arteries, and the
pulmonary trunk. The primitive ventricular region will ultimately
give rise to the left and right ventricles.The primitive atria region
will ultimately give rise to the left and right atria (Srivastava, 2006).
While the slides in Figure 2 show actual images of the stages
of dextral looping, the third segment in Figure 1 diagrams how
the developing heart appears after dextral looping of the heart
tube is completed. Upon completion of looping, the aorta and
its various branching arteries are not fully developed. The aorta
appears as a simple structure known as the aortic sac (labeled AS
in Figure 1). At this stage of development, the branching arteries
of the aorta (left and right subclavian arteries and left and right
carotid arteries) are bilaterally symmetric branches (labeled “III”
and “IV” in Figure 1) stemming off of the aortic sac. As Figure 1
illustrates, following dextral looping, the aortic sac and its branches are not yet positioned between the atria (Srivastava, 2006).

Transformation of C-Shape to S-Shape
Following dextral looping, the heart goes through another morphogenic process, converting the c-shaped heart loop (created
by dextral looping) into an s-shaped heart loop, resulting in the
placement of the ultimate locations of the chambers and modifying the position of the craniocaudal axis. This process pushes
the right atrium to be positioned superior to the right ventricle,
and drags the left atrium towards the right atrium, aligning the
left atrium almost directly above the left ventricle. This process
causes the aortic sac and its branches to become positioned
between the atria. Because the ultimate location of the aorta
will be parallel to what will eventually be the interatrial septum,

Figure 3. S-Shaped Heart Loop.The left and right atria are
represented by “la” and “ra”, respectively, the ventricles are
represented by “v”, and the aortic sac is represented by “c” and “t”
(Manner, 2000).
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this positioning of the aortic sac and its branches between the
atria is essential for the process of heart morphogenesis to
proceed (Manner, 2000). Figure 3 shows the resulting s-shaped
heart loop with the aortic sac positioned between the atria,
which have become aligned superiorly to the segment destined
to be split into the left and right ventricles.

Blood Flow during Heart Formation
By the time that looping is completed, there is already blood
flow present in the developing heart. At this point, septation of
the atria into right and left components has not yet occurred.
The blood flows from the portion of the primitive atria region
destined to be the left atrium down into the primitive ventricular region. It flows through an area known as the AV canal,
the walls of which will ultimately give rise to the region of the
atrioventricular valve. Because septation of the ventricles has
also not yet occurred, the blood must flow through the primitive ventricular region with enough force to navigate the entire
ventricular loop. The blood enters the primitive ventricular
region via the inlet tract, ultimately destined to become the
left ventricle, and exits the ventricular loop via the outlet tract,
ultimately destined to become the right ventricle. The inlet and
outlet tracts are delineated by the interventricular foramen,
which is an opening separating what will ultimately be the left
and right ventricles. As will be described later, septation of the
ventricles occurs by the closing of the interventricular foramen
(Moorman et al., 2003).

Development of the Cardiac Chambers
(Septation)
Changes in the atria and ventricles occur over the same period
of time. As the developing lung forms, a network of vessels surrounds the lung buds. This network of vessels connects with the
primary atrium (the unseptated atria) and attaches at a point on
the left portion, in its inferior region. (This network of vessels,
ultimately destined to become the pulmonary veins, does not
expand and become fixated on the roof of the left atrium until
after septation is completed.) In the right portion of the primary
atrium, the sinus venous, the small cavity where the superior and
inferior vena cava drain, attaches to the right atrium.
As this group of vessels attach to the primary atrium, the left
and right atrial appendages begin to grow out of the walls of
the primary atrium. The appendages are sacs which form in the
muscular walls of the left and right atria. While the right atrial
appendage is quite large and expands distally in a continuous
path parallel with the right atrium, the left atrial appendage is
narrower, and positioned in the superior portion of the left atrial wall. This is because the formation of the left atrium consists
of a much larger portion of the primary atrium.The appendages
are notably the first appearance of morphological differentiation
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between the left and right atria. Known as morphological sidedness, this development is controlled by a pathway governed by
the Pitx2 gene (Moorman et al., 2003).
As all of this is occurring, septation of the atria is also progressing. Cardiac jelly found in the edges of the region of the septum
begin to fuse into ridges, eventually giving rise to an almost
complete atrial septum dividing the primary atrium into the left
and right atria. Blood resists entering into pulmonary circulation
because the lungs do not become inflated until the baby is born.
The foramen ovale is an opening found in the atrial septum. The
foramen ovale allows for the blood in the right atrium to shunt
into the left atrium, avoiding pulmonary circulation. It is formed
by the overlapping of the two bands of the septa, resulting in a
unidirectional valve (Bressler, 1990). At birth, the foramen ovale
closes, and is represented in the adult heart as the fossa ovalis.
Figure 4 shows a drawing of the embryonic heart with the foramen ovale. It is clear from the diagram how the foramen ovale is
formed by the overlapping of the two bands of the septa.

Right Atrium

Left Atrium

Foramen
Ovale

Right Ventricle

Left Ventricle

Figure 4. Diagram of Foramen Ovale Shunting Blood from the Right
Atrium to the Left Atrium
Simultaneously, development of the interventricular septum is
occurring. By the time that heart tube looping finished, the primary interventricular foramen (which connects the left and right
ventricles before the interventricular septum develops) becomes
noticeable (Moorman et al., 2003). The dextral loop is made up of
an inner curve and an outer curve. The outer curve balloons out,
extending the ventricular wall and increasing the size of the lumen
(Davis, 1927).
Numerous studies have attributed ventricular development to
consolidation of myocardial trabeculae found in the primitive
ventricular region. Myocardial trabeculae are spongy jagged folds
of endocardium running along the circumference of the primary
heart tube (Icardo, Fernandez-Teran, 1987). As these jagged edges

become more compact and consolidated, the ventricular walls are
formed (Moorman et al., 2003). Unfortunately, due to the geometric randomness and inconsistencies of the folding and compacting
of ventricular trabeculae, so far no one has been able to successfully
produce an accurate and definitive model of the methods involved
in ventricular trabeculation (Taber, Perucchio, 2000).

Valvulogenesis
As the heart chambers undergo morphological pathways to
attain their final shape, sizes, and orientations, the atrioventricular valves are forming. In the right side of the heart, the
atrioventricular canal expands in order for the right atrium to
become continuous with the right ventricle. During this process, the muscle tissue found in the right half of the atrioventricular canal becomes integrated with the right atrium, forming
the region where the tricuspid valve will develop. In the left
side of the heart, the left atrium is already continuous with the
left ventricle due to a mechanism which occurs during looping.
Similar to the right side, the muscle tissue found in a portion
of the atrioventricular canal becomes integrated with the left
atrium, forming the region where the mitral valve will develop
(Moorman et al., 2003).
The function of the heart valves is to prevent backflow of blood
from the ventricles into the atria.The valves are often described
as multileaflet structures (Bartman, Hove, 2005). There is an
abundance of a gelatinous substance known as cardiac jelly
found in between the endocardium and the myocardium. It
is believed that as the cardiac jelly in specific regions of the
heart begins to swell, endocardial bulges are formed. These
cushions are further enhanced by migrating cardiac endothelial
cells, changing the cardiac jelly into cardiac mesenchymal cells,
causing the endocardial bulges to begin to grow. Once their
growth is completed, they are referred to as endocardial cushions (Markwald et al. 1977). These endocardial cushions then
proceed through another stage of growth, ultimately forming
heart valves made of fibrous tissue. The fibrous tissue found in
the heart valves allows for them to open and close as the heart
pumps blood throughout its chambers (Bartman, Hove, 2005).
The pulmonary valve and aortic valve have similar functions to
the atrioventricular valves. They prevent backflow into the right
ventricle and left ventricle, respectively.The mechanism for their
morphogenesis is very similar to the growths of endocardial
cushions described above in the formation of the atrioventricular valves (Bartman, Hove, 2005).

Development of the Arterial Trunks
Throughout heart development, the aortic sac undergoes
changes to become the outflow tracts of the heart. As the distal outflow portion of the original ventricular loop begins to
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extend out of the pericardial cavity, it is divided into two, forming the ascending aorta and the pulmonary trunk. The ascending
aorta and the pulmonary trunk are two separate tubes, divided
by the aorticopulmonary septum. Figure 5 shows a scanning
electron micrograph image of the bend formed in the tube. The
edge of the distal outflow portion of the original ventricular
loop completely extends to the edge of the pericardial cavity.
The distal outlet portion of the aortic sac develops into the distal portions of the aorta and its branching arteries, completing
the systemic circulation path. The pulmonary trunk extends and
attaches to the lungs to complete the pulmonary circulation
path (Moorman et al., 2003).

Figure 5. Bending of the distal outflow portion of the ventricular
loop (Moorman et al., 2003).
As can be seen in this image, the dog-leg bend produced by the
outflow tract helps align the aorta with aortic arches III and IV,
and the pulmonary trunk with arch VI (Moorman et al., 2003).

Mechanical Forces Involved in Heart Morphogenesis
When analyzing mechanical factors affecting heart morphogenesis, the initial, and probably most striking piece of data, is that
the heart begins to function before it is completely developed.
Blood begins to flow through the primitive heart chambers by
the time that initial stages of heart looping are completed. This
suggests that the actual pumping of the heart, along with other
forces produced by blood flowing through the heart chambers,
might actually be the cause of later steps of heart morphogenesis (Bartman, Hove, 2005).
One of the accepted mechanisms of heart tube formation involves forces caused by contracting actin microfilaments. The
forces caused by the contractions mold and bend the crescent
into a tube shape, forming the heart tube (Taber, 1998).
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Many theories have been produced to try to link biomechanics
with heart looping. As early as 1970, a theory was suggested
that looping is caused by differential growth of portions of
the heart tube. Differential growth is when cells of the same
structure grow at different rates, causing the structure to undergo a physical change of shape and other physical properties
(Stalsberg, 1970). Others suggested that heart looping is caused
by pressures placed on the heart tube due to the expanding
cardiac jelly (Manasek et al., 1984). Later scientists proposed
that looping is caused by residual stress which causes the dorsal
mesocardium to shorten and bend (Taber, 1995).Although these
theories give possible mechanisms for the cause of heart looping, they do not provide a clear explanation for what causes the
heart tube to bend in a specific orientation.
Additionally, all of these theories are based on the assumption
that the forces controlling heart looping are forces from within
the heart tube (Bartman, Hove, 2005). In 2002, an experiment
was run to attempt to prove that heart looping is caused by
forces placed on the heart tube from external adjacent tissues
pressing on the embryo. The splanchnopleure is an extraembryonic membrane which presses against the heart tube on its
ventral side. Because heart looping involves ventral bending and
rightward rotation, the forces applied by the splanchnopleure
assist the heart in rotating in the rightward direction. In an
experiment, the splanchnopleure was removed from 24 chick
embryos. In all 24 cases, abnormal heart looping was reported,
proving that forces applied by the splanchnopleure have a direct
effect on heart looping. In most of the cases, slightly skewed
ventral bending was reported, along with reports of minimal
rightward rotation of the heart tube.
In most ex vivo experiments that analyze heart development,
such as this one, conditions required to analyze the growth
are dependent on factors which cause surface tension. Under
normal in vivo conditions, surface tension forces have not been
found to affect heart looping. It is interesting to note that in
a parallel experiment, it was found that by placing the chick
embryos in a liquid medium and thereby eliminating standard
ex vivo surface tension forces, some abnormalities were found
with respect to heart looping.This suggests that there are in fact
surface tension forces present in vivo which play a role in heart
looping (Voronov, Taber, 2002).
Another pathway regulating heart looping begins with secreted
proteins flowing through the heart tube. Although very little is
known about this pathway and the forces involved, it is known
that it in some manner provides the forces required to initiate
rightward rotation of the heart tube. This pathway is controlled
by the Pitx2 gene, the nodal gene, and the lefty gene (Moorman
et al., 2003).
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Myocardial trabeculae are known to have many effects on
the developing heart. While they are mainly known for their
assistance in helping blood flow in the appropriate direction
prior to formation of the atrial and ventricular septa, myocardial trabeculae also produce peristaltic contractions within
the myocardium. These contractions help the trabeculae to
become more compact and to fold along each other, thereby producing the ventricular walls (Thompson et al., 2000).
A result of producing and solidifying the ventricular walls is
that the intramyocardial blood flow increases. This increase in
blood flow will cause an increase in the fluid forces affecting
heart morphogenesis, and will also cause these stresses to be
more evenly distributed within the portions of the heart upon
which they are working (Taber, 1998).
The role of hemodynamics in septation has been debated for many
years. The “flow molding” hypothesis suggests that cardiac septa
form due to opposite pressure gradients formed by two antiparallel
streams of blood flowing through the heart simultaneously (Jaffee,
1963). Scientists who support the flow molding hypothesis believe
that the cells lining the heart tube are able to detect changes in
pressure caused by different flow velocities and directions. When
such changes are detected, morphological changes are induced,
causing the septa to form. Using this biomechanical mechanism as
a springboard, they also suggested that these fluid forces assist in
shaping and molding the cardiac jelly into firm structures in order
to form the walls of the heart chambers (Dewey et al., 1981).
Furthermore, experiments proved that modifying the fluid velocities in developing chick hearts can result in many heart malformations, including deformed ventricular septum formation (Clark et al.,
1989). Challengers of the flow molding theory argue that the whole
foundation of the theory is incorrect.They have used advancements
in imaging technologies to show that the initial blood flow through
the heart chambers does not appear as two antiparallel streams.
This data suggests that perhaps septa formation is not at all affected
by fluid forces. Possibly, it is the formation of the septa which may
actually create and direct the streams of fluid; the heart septa might
be the initial cause of formation of certain fluid forces found in the
heart (Yoshida et al., 1983).
The frictional force caused by fluid flowing along the surface of
a cell is known as shear stress. In the developing heart, shear
stress is caused by the blood which is being pumped throughout
the developing chambers. Shear stress is known to play a very
major role in valve formation. In a study done with zebrafish,
reduced fluid forces resulted in complete prevention of valve
formation (Hove et. al., 2003).
In a recent study, a positive displacement pump was used to
simulate the fluid forces and shear stress produced in the developing heart. Because the experiment focused on valvulogenesis,

embryonic chick hearts with endocardial cushions were isolated. They were placed inside a tubular collagen scaffold, and
remained there untouched for 72 hours. The purpose of this 72
hour period was to guarantee that the cells adhered to the inside of the tube (Tan et al., 2012). It is known that hemodynamic
forces increase as heart development progresses (Biechler et al.,
2010). Therefore, the forces applied by the pump were divided
into two periods, one of a low force, followed by one of a higher
force. Obviously, the actual level of fluid forces and shear stress
found in vivo could not be completely replicated, for had these
forces been applied, the cushions would have been pushed out
of the tubular scaffold. The forces used in the experiment were
based on formulas used to determine the highest magnitude
of force that the cushions would be able to withstand without
being dislodged from the tube. Initially, through the use of a positive displacement pump, a force with a frequency of 5.38 x 10-2
Hz with an average velocity of 0.07mm/s was applied in the tube
for a period of three days. The shear stress calculated based on
these numbers is 7.6 x 10-4 Pa and a positive pressure of 4.3 x
10-3 Pa. After this three day period, the flow rate was raised to
a force with a frequency of 0.29 Hz with an average velocity of
0.86mm/s, and was applied for an additional four days.The shear
stress calculated based on these numbers is 9.4 x 10-3 Pa and

Figure 6. Comparison of flow and no-flow cushions (Tan et al., 2012).
a positive pressure of 0.053 Pa. The shear stress in the second
flow phase is equivalent to a 92% increase. Control groups were
set up in tubes where no pump was attached.The control tubes
were attached to bioreactors to ensure a closed loop would
exist, thereby maintaining comparable oxygen levels and other
conditions with the flow tubes.
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Following the first (days 1-3) and second (days 4-7) phases of
pumping forces, the “flow” cushions and the “no-flow” cushions
were analyzed. After the first phase, no significant differences
were found between the flow and no-flow cushions. However,
analysis after the second phase revealed amazing results. The
no-flow cushions formed a scattered network of cells in the
lumen of the tube. This network was very loose, and did not
exhibit signs of the rigidness or compactness normally found
in heart valves. In contrast, the flow cushions formed a very
compact mass of cells. The mass was wedge-shaped, and had
leaflet-like structures extending off of it (Tan et al., 2012).
Figure 6 shows confocal laser scanning microscope images
comparing the cushions.
A signaling molecule, rhoA was also studied in this experiment. rhoA regulates the stiffening of the AV cushions, a
prominent characteristic. The flow cushions were found
to be much stiffer than the no-flow cushions. It was found
that rhoA message levels were increased by flow forces.
In addition to that, it was also reported that inhibiting a
downstream effector of rhoA, rhoA coiled-coil containing
kinase (ROCK), caused a decrease in stiffness of the fibers
in the AV cushions. Figure 7 shows a graph comparing the
expression of rhoA in flow and no-flow cushions (Tan et
al., 2012).

Figure 7. rhoA expression in flow and no-flow cushions (Tan et al., 2012).
This study was a major breakthrough in relating biomechanical forces to heart development. Even though the shear
stress and fluid forces applied in this study were significantly below values found in vivo, the cushions and proteins
still responded appropriately. The flow cushions still developed into wedge-shaped stiff masses, and rhoA was clearly
upregulated.

Discussions
Formation and development of the human heart involve many
precise and intricate steps. New studies have analyzed how
many of these steps are initiated by mechanical factors. A
major element of this hypothesis is that the heart begins to
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pump blood before it is completely developed. The fluid rushing through the developing heart causes shear stress, flow
pressure, and surface tension. With experiments, these forces
have been proven to play a role in propagating various stages
of heart development, with specific focuses on heart looping
and valvulogenesis.
Other mechanical factors, such as contractions and expansion
of cardiac jelly, have also been linked to heart development.
With regard to all of these forces, studies have been done to
show abnormal heart development in experiments where the
forces have been eliminated. This provides a strong basis for
theories suggesting that these mechanical forces play a major
role in heart development.
Because the study of mechanical factors affecting heart
development is relatively new, much of the research is still
inconclusive. While in many cases it has been proven that
mechanical factors play a role in specific stages of heart development, much of the research has not been able to specify exactly which mechanical factors affect which steps of
heart development. Additionally, the research done to date
has not been able to prove, in many cases, if the mechanical factors involved are causes or effects of certain stages.
Specifically with regard to septation, it has been debated for
years whether the blood flow paths cause the septation to
occur, or is a result of septation. Nonetheless, it has been
documented that mechanical factors are definitely present in
heart development, and regardless of whether they are the
cause or effect of one step, they definitely affect propagation
of further steps of heart development.
An interesting facet of studying the role mechanical forces
play in heart development is to attempt to link these forces
to the genes and genetic pathways which have already been
discovered. Due to the relative novelty of studying mechanical forces in heart development, minimal breakthroughs have
been made with respect to linking these forces to genetics.
Although a few genes have been recognized as working simultaneously with mechanical factors, it is unclear whether
these genes are influencing the mechanical factors, or are
merely present at the same time and only affecting other,
non-mechanical, elements of heart morphogenesis. Future
studies need to be performed in order to determine whether or not these mechanical force are linked to genetic factors. If they are proven to be linked, future studies will be
necessary to determine to what extent they are linked and
to determine the exact mechanisms relating the genes to the
mechanical forces. Relating mechanical factors to genetics
could lead to major breakthroughs in diagnosing and preventing heart developmental abnormalities.

Mechanical Factors Affecting Heart Morphogenesis
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Abstract
With a push towards a more active lifestyle, the sports drink industry has grown substantially in recent years. However,
despite their popularity, sports drinks contain acid, giving them extremely low pHs, which can cause erosion.There have
been many studies, including self-administered surveys, studies in vitro, and studies in situ that have shown sports energy
drinks cause dental erosion, leading to permanent loss of tooth volume and a softening of the outer layer of the tooth.
Introduction
Sports drinks were initially created for the purpose of rehydration and electrolyte replacement for athletes during intense
physical activity. (Mathew et. al. 2002) The drinks have proven
to increase concentration, stimulate metabolism, and eliminate
harmful substances from the body (Pinto et. al. 2013). However,
sports drinks have become popular today among amateur athletes and ordinary exercisers looking for a drink after a workout. With the push for a healthier lifestyle, more people have
begun to exercise and many drink sports drinks on a regular
basis. In 2000, the sports drink market was estimated at 1.2
billion dollars and has been growing since (Hooper et. al. 2005).
Current research has demonstrated that these drinks have negative effects on teeth and can eventually lead to teeth rotting.
With the growth in the sports drinks industry, it is critical to
understand the effects sports drinks have on the body. This
paper attempts to examine sports drinks from the perspective
of oral health and review the current knowledge on the effects
of sports drinks on teeth.

Tooth structure
Teeth are composed of three different types of tissues: enamel,
cementum, and dentin. The enamel is the most superficial of
all three and is the hardest substance in the entire body. The
enamel is composed of 96% minerals with the rest being water
and organic content. The hardness and density of enamel both
decrease further from the surface (Lussi et. al. 2011). Because
the enamel comes into contact with the outside, it is the most
affected by acid producing bacteria, which can cause dental caries. The cementum, which is avascular, is the part of the tooth
that covers the root of the tooth. Collagen fibers project out
of the cementum, forming most of the periodontal ligament,
which keeps the tooth attached to in its socket. Deep to both
the enamel and cementum is the dentin (Ross et. al. 2003).
The dentin makes up most of the tooth and is in contact with
the dental pulp. The dentine is made up of 47% minerals and
33% organic content (Lussi et al. 2002). This dental pulp is both
highly vascularized and very innervated (figure 1).

Effects of Acid on Teeth
Dental erosion is the dissolution of tooth mineral caused by
external sources and not from bacteria, like plaque (Arnauteanu
et. al. 2015). It is characterized by initial softening of the enamel
surface. This leads to further dissolution of the enamel crystals,
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Figure 1.The anatomy of a tooth.The enamel being most superficial
and moving deep, the cementum, dentine, and pulp. (https://
medlineplus.gov/ency/images/ency/fullsize/1121.jpg)
which will cause permanent loss of tooth volume and a softened
surface layer (Lussi et. al. 2002). Erosion, as opposed to tooth
decay, leads to a widespread thinning of the tooth surface without causing dental caries (Milosevic 2004.) Erosion occurs when
the pH of the solution around the enamel is lower than 5.5.
At this low pH, the hydrogen ions dissolve the minerals which
allows the calcium and phosphate ions to diffuse out of the
teeth (Adhani et. al. 2015). In dentine only the mineral portion
dissolves in acid while the organic component remains (Lussi et.
al. 2011)(figure 2).

Figure 2. The different stages of dental erosion. On the left the
softening of the enamel without tooth material loss. In the middle
there is partial tooth material loss and softening of the underlying
surface. On the right is significant tooth material loss. (Lussi et. al.
2011)
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A study was done in which tooth samples were incubated in
two different solutions, one at pH of 7 and the other at a pH of
4. Both showed a decrease in the minerals of calcium, zinc, and
phosphate, with the solution at pH of 4 showing a greater decrease. This demineralization is characteristic of teeth in acidic
conditions (Adhani et. al. 2015).
While erosion affects all teeth, the extent of erosion will differ
for each type of tooth. A study was conducted using different
types of teeth to compare the effects of acid and also to examine how the buccal/labial and lingual/palatal sides are affected
(figure 3). The results showed that the lingual/palatal surface of
the teeth showed greater loss due to acid dissolution than the
buccal/labial side of the corresponding tooth. The palatal side
of all maxillary teeth showed greater susceptibility than the lingual surface of the mandibular teeth. The teeth in the mandible
showed great variation among teeth and based on surface, while
the maxillary teeth showed similar dissolution for the palatal
side and little variation among the buccal/labial sides. The difference can be due to the fact that the lingual/palatal sides of
the teeth generally are observed have more wear due to being
exposed to food for longer periods of time than the buccual/
labial sides (Tucker et. al. 1998).

Acidity of Sports Drinks
The acidity of many sports drinks is much lower than the critical
pH of 5.5, which has been shown to cause dental erosion.
Product
pH
Monster Assault
3.49
Red Bull
3.37
Gatorade Fruit Punch
3.27
Propel Mango
3.23
Gatorade Lemon-Lime
3.07
Full Throttle Energy Drink
2.94
Gatorade Cool Blue
2.92
5-Hour Energy
2.81
Powerade Red
2.77
Rockstar
2.53
Figure 3.The pH of many common sports drinks. (http://www.
sheltondentistry.com/patient-information/ph-values-common-drinks/)

Erosion Caused by Sports Drinks
A study was performed to determine if there is an association
between drinking sports drinks and dental erosion. Seven hundred and ninety-five patients filled out a self-administered questionnaire, which included their background, dietary habits, and
frequency of tooth brushing. The patients then were checked
for dental erosion, checking twenty surfaces in total among
fourteen different teeth for each patient. A patient with three or
more surfaces exhibiting erosion was considered to be affected.

Of the people who had a low consumption of sports drinks,
less than 0.24 liters/day, 26 percent were affected. Of those with
moderate consumption, 0.25-0.75 liters/day, 41 percent were
affected and of those with high consumption, more than 0.75
liters/day, 77 percent were affected. An athlete during training
will drink at least 1.5 liters/day, which is much higher than those
considered in the high consumption group for this study, and
would therefore be highly susceptible to dental erosion due to
these sports drinks. This study showed that there is an association between drinking sports drinks and dental erosion (Sovik
et. al. 2015).
In a two-part experiment the erosive potential of 5 sports
drinks was first checked in vitro for erosive potential and then
the most erosive drink was tested to determine how it affected teeth in situ. The in vitro part took Gatorade, powder and
liquid, Isotar, powder and liquid, and Isotar liquid and immersed
six enamel samples for each solution for a total of four hours,
checking the erosion every hour. The Gatorade liquid was the
most erosive and therefore was used for the in situ part. In this
experiment ten adults wore intraoral appliances that contained
two teeth. The adults were then put on a drinking regimen of
the Gatorade for ten days. Upon completion the samples were
checked for erosion. The results showed marked erosion in
three, mild erosion in two, and slight erosion for the remaining five. This showed how there is variability among individual
susceptibility to enamel erosion. This variation can be due to
many components including drinking habits, amount of saliva,
and biological variation in tooth specimens. It also showed that
individuals that are susceptible can have major erosion due to
sports drinks (Hooper et. al. 2005).
In another experiment, Sting, a sports drink with citric acid
with a pH between 2-3, was investigated for its effects on tooth
enamel. Anterior teeth were submerged in Sting for five minutes every six hours for fifteen days. The results showed surface
irregularities, pitting and structural loss of enamel. This experiment confirmed previous studies that beverages with “higher
concentrations of citric acid have an aggressive effect on the
enamel surface leading to its dissolution” (Kazmi et. al. 2016).
In another study, three sports drinks were tested for their erosive potential. The three drinks were Gatorade Citron, 5-Hour
energy, and Powerade Cherry. Fourteen premolars were chosen
for the study and were divided into groups for each drink. The
teeth were exposed to the specified drink for four times for
two minutes each over a one hour span every day for fourteen
days. Compared to the control group held in artificial saliva, the
Gatorade was the most erosive with an average loss of 10% of
calcium ions and 8% of phosphorous ions. The Gatorade was followed by Powerade in erosive potential, having an average loss of
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9% of calcium ions and 6% of phosphorous ions.The least erosive
of the three drinks was 5-hour Energy, which showed an average loss of 5% of calcium ions and 3% of phosphorous ions. The
results showed that each of the drinks caused erosion of the
enamel and loss of calcium and phosphorous ions, with Gatorade
showing the most erosive potential (Arnauteanu et. al. 2015).
In a study, three beverages and medicated cough syrup (Johnson
and Johnson) were tested on teeth with and without restorations. The drinks were a carbonated drink (The Coca-Cola
Complany), a non-carbonated drink (Parle Agro), high-energy
sports drink (Red Bull). The sports drink had a pH of 3.26 but
also compared to the other drinks had the highest neutralizable
acidity. The specimens were in the high-energy sport drink for
350 hours over fourteen days, equaling fourteen years of normal
beverage consumption. The teeth without restorations showed
erosion and the restored teeth showed microleakage, due to the
erosive effects of the sports drink.The drink contained citric acid
which can “bind to calcium and phosphorous thereby promoting increased titratable acidity levels.” The citric acid added to
the drinks for flavoring agents leads to an increase in the sports
drinks erosive potential. The microleakage caused by long term
use of the sports drinks can eventually lead to restoration failure
or secondary caries (Trivedi et. al. 2015).
Another problem for people who drink sports drinks is the hyposalvation that occurs during exercise. Due to the strenuous
activity, an athlete can lose up to 1.5 liters of liquid from perspiration. This leads to a decrease in saliva resulting in xerostomia,
dryness of the mouth. Saliva normally acts as a buffer and can
neutralize the acidity of consumed liquids or foods.The saliva will
also clear the liquids and foods quicker from the mouth thereby lessening the harmful effects of the acid. Even as acids cause
ions to release from the teeth, the saliva can provide calcium and
phosphorous to replenish the teeth. However, when there is less
saliva in the mouth during an exercise the sports drinks’ acidity
will have an even greater effect than normal and cause more erosion than during rest. Also, because of this dryness in the mouth
a person will usually drink more and therefore will have more
acidic drink with less buffer (Noble et. al. 2011).
In the future drink companies are looking for ways to combat
the erosive potential of sports drinks. By adding calcium, companies can see a pH adjustment which will reduce the erosive
potential of the sports drinks, as it has been done for soft beverages (Arnauteanu et. al. 2015). This concept of adding calcium
has also been tried with Ribena ToothKind. Compared to regular Ribena, the Ribena Toothkind showed significantly less enamel loss. (Milosevic 2004). If these results can be duplicated with
sports drinks then their erosive potential will be decreased and
be healthier for athletes.
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Conclusion
Originally developed for professional athletes, sports drinks
have become increasingly popular among the general population as well. However, studies indicate that the acidity levels
found in sports drinks can cause dental erosion. Sports drinks
have a pH well below the critical pH of 5.5 and therefore have
harmful effects on teeth. The low pH of the drinks causes the
minerals to diffuse out of the tooth and cause a loss in tooth
volume. The acid also causes a loss in hardness, which can lead
to further tooth damage. New ways of making these drinks may
help mitigate the adverse negative effects of sports drinks on
dental health.
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Abstract
There is no other foreign tissue transplant that has such a strongly parasitic relationship with its human host as the
fetus. Although the fetus contains paternal genes, is completely tolerized by its maternal host in almost all pregnancies.
This presents an immunological paradox and has generated a lot of attention from leading researchers in the reproductive and immunology fields. This paper reviews the leading explanations for this paradox; that it is attributed to a
detailed mechanism of the maternal and fetal immune system in which tryptophan suppresses T-cells from attacking
specific paternal cells, while maintaining a strong immune response against other foreign antigens during pregnancy.
Other opinions contribute fetal tolerization to the maternal immune systems strong bias of Th2 cells and a decrease
of Th1 cells. Researchers suspect that women suffering from recurrent miscarriages are unable to tolerize their fetus,
and consequently, their immune system attacks the fetus several weeks after implantation and aborts the pregnancy.
Other medical implications include preeclampsia, which is attributed to immunological issues. Doctors are now trying
to understand how these mechanisms work to provide treatment for women who cannot naturally tolerize their fetus,
and for patients suffering from preeclampsia.
Introduction
MHC as being nonself and will therefore attack it. A fetus has
The immune system is incredibly complex in its means of maintaining health and protecting the body against foreign invasion.
It is a network of cells, tissues, and organs that work together
to defend the body against “invaders” known as antigens. If the
body recognizes a cell as being “non-self”, it triggers an immune
response against the antigen. The immune response includes
different cells that the body stores in preparation for attack
(Storey, Jordan, 2008).
All immune cells begin as immature stem cells in the bone marrow. They respond to cytokines (which are proteins involved
with immune system cell communication) and other signals to
develop into B cells, T cells, and phagocytes. B cells’ main role is
to secrete antibodies. When B-cells encounter an antigen, they
create plasma cells for that antigen, which then secretes hundreds of identical antibodies that are specific to that antigen.
Antibodies, also known as IG- immunoglobin, are highly specific
proteins found in body fluids that identify antigens and connect
to them with its specific shape and mark them for destruction.
They neutralize the antigen and prevent it from attacking a host
cell. Phagocytic cells then destroy the antigen (Storey, Jordan,
2008).
Another type of immune cell is called a T-cell. There are two
different types of T cells; Helper T cells (CD4’s) contribute by
directing immune responses, and Killer T cells (CD8’s) attack
infected cells. The Major Histocompatibility Complex (MHC)
are proteins on cell surfaces and code for the specific unique
proteins that the cell contains. MHC protein bind to the surfaces of antigenic cells and help T-cells distinguish other cells as
being self or nonself (Adar, et. al. 2015).
This leads to the concept of transplantation. If foreign tissue
is implanted in the body, the T-cells will recognize the tissue’s
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the distinction of being a tissue alloantigen in the mother’s body.
This is because it is impossible for a mother and child to be
genetically identical since the fetus inherits a set of genes from
each parent so the paternal genes are going to be considered
foreign to the maternal immune system (Mellor, Munn, 2007).
Furthermore, if the fetus is a boy, then they are certainly genetically different due to the presence of the Y chromosome in all
males (Simpson, et. al. 1997). Consequently, one would assume
that the maternal immune system would identify the fetus as
being a foreign tissue and reject it. However, nature proves that
this is not the case. Additionally, pregnant women do not seem
to be more susceptible to infection. This proves that the maternal immune system is functioning and carrying out all other
appropriate immune responses (Sacks, et. al. 1999).The purpose
of this review is to explore this unusual relationship, and by surveying the recent literature, gain insight into the complexities
of the immune system and explain this seemingly paradoxical
relationship. The first to have raised the question of the maternal-fetal immunological paradox was Peter Medawar. His initial
1953 lecture and essay on this topic led to extensive research
till this day. Retrospectively, scientists give him the distinction as
the father of reproductive immunology. Upon doing pioneering
research on skin graft rejection, Medawar wondered why a fetus
is different than any other foreign transplant if the body clearly
tolerizes its presence. He proposed three possible explanations;
the mother and fetus have a physical anatomical separation, the
antigenic immaturity of the fetus, and the immunological inertness of the mother (Billington, 2003).

Methods
Research was compiled from original journal articles, accessed
through Touro’s online library (www.tourolib.org) which has a
subscription to the EBSCO and ProQuest databases. Key phrases such as maternal fetal immunology, rejection of fetus, and
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tolerization of fetal allograft were searched to find relevant information. These were the basis for this comprehensive review
of the topic.

Discussion
The first to have raised the question of the maternal-fetal immunological paradox was Peter Medawar. His initial 1953 lecture and essay on this topic led to extensive research till this
day. Retrospectively, scientists give him the distinction as the
father of reproductive immunology. Upon doing pioneering research on skin graft rejection, Medawar wondered why a fetus
is different than any other foreign transplant if the body clearly
tolerizes its presence. He proposed three possible explanations;
the mother and fetus have a physical anatomical separation, the
antigenic immaturity of the fetus, and the immunological inertness of the mother (Billington, 2003).

T cell Awareness of Fetal Presence
In response to Medawar’s first hypothesis, research was done
to test if the maternal immune system is aware of the fetus’s
presence. The trophoblast is a tissue layer that surrounds the
embryonic cells. It supplies that embryo with nutrients, and its
outer layer separates the fetal and maternal circulatory system
throughout the entire pregnancy (Bonney, Matzinger, 1997).
Researchers performed an experiment to discover if there are
fetal MHC molecules at the extraembryonic tissues and if so,
if the paternal genes are present in equal proportion to the
maternally inherited genes. They implanted an embryo with paternal (foreign) and maternal (identical) MHC class 1 genes in a
mouse and tracked them. On day 13 of gestation, fetal cells had
low levels of MHC class 1 genes, yet equivocally high levels of
both paternally and maternally derived genes were present at
the interface of the extraembryonic and uterine tissues . Since
the paternally derived genes are present in high numbers at the
interface, it is unlikely that the paternal antigens are not accessible to the maternal immune cells. This study proves that the
maternal tolerance cannot be contributed to a lack of paternal
gene expression or to a lack of contact between the mother’s
immune system and fetal cells (Philpott, et. al. 1988).
Another study which strengthens this point was done on mice
in which H-2K females were mated with H-2B males. For comparison purposes, they also mated these females to H-2K synergic mice and a third party, H-2s bearing mice. When tested
mid-pregnancy, mice bearing H-2B conceptuses had reduced
numbers of T cells with high expression of the clonotype and
6-9 times more clonotype positive cells that were missing CD4
and CD8 than the control mice. This reaction proves that the
maternal T cells are exposed to and recognize the paternal alloantigen (Tafuri, et al. 1995).

They tested the mice further to determine if the T cell changes
were still present after delivery of the fetus and found that the
T cells were restored to the same levels as the control mice.
However, that could just indicate that there is only tolerization
when the paternal alloantigen is present in the body.To test this,
after delivery, they introduced grafts of the H-2KB gene and
the mice rejected it. They have also tried transplanting paternal
grafts and have found that the mother’s immune system only
accepted it if the MHC peptide complexes on the graft were
identical to that of the fetus. After the pregnancy, however, the
maternal immune system did reject the graft. This study proved
that pregnancy induces a transient state of tolerance for the
paternally derived genes of the fetus (Tafuri, et. al. 1995).
These studies indicate that Medawar’s first two hypotheses
were wrong.The maternal tolerance is clearly not due to lack of
exposure, and must be contributed to some mechanism which
occurs during pregnancy that protects the fetus from rejection.
As for his argument that the fetal antigenic cells are immature,
we do see that fetal cells may lack high levels of MHC expression during gestation. However, he was assuming that the only
exposure the maternal immune system has is from the fetal
cellsf. As the above experiments proved, the trophoblast, which
is definitely in contact with the mother’s immune cells, had
MHC genes at high levels from the beginning of gestation. Thus,
it cannot be that the tolerization is due to antigenic immaturity.
Another study was done to test Medawar’s third hypothesis
which is that the mother is in an immunological tolerant state.
They found that the T cells in the spleen and lymph node displayed characteristics that were typical of functionally unresponsive T cells and are not typical for antigen-experienced T
cells (Zhou, Mellor, 1998). Researchers conclude from this data
that maternal T cells are exposed to the paternal alloantigen’s
and this exposure somehow induces a tolerant state. Scientists
are now focused on trying to figure out what exactly causes this
tolerant state. However, it is clear that the mother’s immune
system is not suppressed, because it is responsive to all other
antigens. Therefore, it would be inaccurate to describe the maternal immune system as being inert.

Indoleamine 2,3-dioxygenase (IDO) Mechanism
There is a mechanism discovered by Drs. Mellor and Munn
which is currently the most well accepted explanation for this
immunological contradiction. They attribute this tolerance to
the fetus shutting off the mother’s natural defenses. Their hypothesis is that the embryotic cells in the placenta, known as
syncytiotrophoblasts, produce an enzyme called indoleamine
2,3-dioxygenase (IDO) which destroys an amino acid, tryptophan, that is necessary for the maternal T cells to protect the
maternal body effectively (Munn, et. al. 1998).

57

Adina Ziemba-Goldfarb

In order to test this hypothesis, an experiment was done in which
they had four groups of female mice. Two groups (A and B) were
mated to mice that were genetically identical to them and two
groups were mated to mice that were genetically different (C and
D). Levels of IDO were first assessed in all groups. IDO transcription were present in all mice from 7.5 to 9.5 dpc (days post coitus). At later gestation times, such as on days 10.5 and 13.5, IDO
was present in the placenta but not in the uterus or embryonic
tissue. This data proves that IDO is only found in synctytiotrophoblasts and not in other tissue (Munn, et. al. 1998).

to obvious ethical considerations, it is impossible to do complete experiments on humans, because of the rejection results
that will likely occur. However, another research group tested
for presence of the IDO enzyme in the human placenta. They
first detected IDO at around week 14 and then levels increased
rapidly and remained high throughout the pregnancy. When
studying pregnancies with retarded intrauterine development,
the IDO levels were significantly lower. This suggests that IDO
enzyme is protecting the fetus from the maternal immune system (Sedlmayr, et. al. 2002).

1-methyl-tryptophan, a pharmacologic agent that inhibits IDO
enzyme activity was then inserted under the skin of mice from
groups A and C. Groups B and D were used as a control. On
6.5 dpc, mice from all groups were carrying normal numbers of
concepti and development was normal as well. However, from
7.5 to 8.5 dpc, the number of concepti in mice from group C
(mice that were mated with allogenic males and treated with
the IDO inhibitor) decreased significantly and there was hemorrhaging around the concepti that were left. At 8.5 and 9.5
dpc, all concepti showed signs of inflammation and deterioration. After 9.5 dpc, no concepti that were treated with the IDO
inhibitor remained. To contrast, the concepti from groups A and
B, fetuses whose parents were genetically identical, all survived
and showed signs of normal development. This is despite group
A having received treatment of the IDO inhibitor. Group D,
which included the mice mated with synergetic partners, were
not given IDO inhibitor and the pregnancy progressed normally
and all concepti survived (Munn, et. al. 1998).

Because tryptophan is an amino acid and cannot be synthesized
by the body, the body’s only source of it is from dietary intake.
When placing golden hamsters on a high tryptophan diet, experimenters found that there was reduced embryonic survival and
it influenced pregnancies adversely.This seems to link tryptophan
levels with maternal rejection of the fetus (Meier, Wilson, 1983).

To test if a single paternal MHC class 1 difference will also lead
to rejection, the scientists altered one gene and mated the mice.
They found that the mice treated with IDO inhibitor all lost
their concepti. The results of this experiments clearly indicate
that IDO is an important factor in preventing the maternal immune system from rejecting the fetus (Munn, et. al. 1998).
A closer look at this data sheds some light on the mechanism
that is likely to be responsible for protecting the fetus from rejection. Data showed that fetal rejection happened very early on
in gestation, which does not give enough time for B cells to have
produced the appropriate antibodies. This leaves it to T cells to
have taken the active role in rejecting the fetus. Furthermore, it
would be impossible to attribute the fetal loss to toxic effects
of 1-methal-tryptophan, because the synergetic mice that did
receive the inhibitor displayed no symptoms, indicating that it
must have been an immunological effect of the inhibitor. This
groundbreaking study indicates that it is the fetal allograft that
protects itself from being rejected (Munn, et. al. 1998).
Many studies have since been done to test this hypothesis. Due
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Another finding which seems to give credence to Mellor and
Munns findings is the progressive decrease of tryptophan levels in
serum from the beginning of human pregnancy until delivery.This
shows a distinct inverse relationship between tryptophan levels
and successful pregnancy in humans (Schröcksnadel, et. al. 1996).
In addition to the discovery of the role of IDO enzyme, further
experiments indicate that there is another enzyme, Tryptophan
2,3-dioxygenase (TDO), which also contributes to tryptophan degrading activities.While establishing a time course, they have found
that on days 9.5 to 12.5, IDO enzyme was at its peak expression.
This phase coincides with the days of placental appearance and
growth. In this experiment, IDO levels did decrease after this small
phase, but tolerization lasted throughout the pregnancy which can
indicate that once tolerance is established, it lasts despite continued tryptophan activity. However, on days 5.5 to 10.5, at the early
stages of gestation,TDO enzyme was found at high levels. It is clear
that during this early stage, IDO enzyme is not there, as 1-methal-tryptophan (an IDO inhibitor) was administered and did not
inhibit the tryptophan degrading activities.This study suggests that
early tryptophan inhibiting activities is due to TDO enzyme and
during placental formation, IDO enzyme is responsible for inhibiting the T cell proliferation (Suzuki, et. al. 2001).

Th-2 Bias Mechanism
Many researchers contribute the tolerization to mechanisms
other than the IDO enzyme.
Another mechanism that is now being researched is based on
the link between successful pregnancy and a bias of Th2 cells.
There are two types of helper T cells, Th1 and Th2. Th1 cell
secretes pro inflammatory cytokines such as IFN-y and TNFa. Th2 cells secrete anti-inflammatory cytokines such as IL-4,
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IL-10, and IL-13. IL-4, which is produced by Th2 inhibits the
growth of Th1 cells. IFN-y, which is produced by Th1 inhibits the
growth of Th2 cells. Dr. Wegmann, hypothesized that in successful pregnancies, there is a strong bias of Th2 cells circulating at
the maternal-fetal interphase. Because Th2 is anti-inflammatory,
a significantly strong presence of Th2 cells will protect the fetus
from th1 cells that cause inflammation and will allow fetal tolerization. In order to test this hypothesis, he injected pregnant
mice with IFN-y and found that it resulted in pregnancy loss.
This indicates that Th2 cells may promote maternal tolerance
(Wegmann, et. al. 1993) .
Similar experiments done on both humans and mice have indicated this mechanism. Several studies showed that in normal
human pregnancies there were increased levels of Th2 cell ration
bias and at fetal loss there was a Th1 cell ratio bias (Ng, 2002).
Furthermore, after examining samples from pregnant women,
they found increased expression of IL-4 mRNA and decreased
expression of IFN-y mRNA (Tranchot-Diallo, et. al. 1997).
A study of the th1/th2 cell levels in peripheral blood of women
showed further links. Researchers examined the blood of
women who have a history of recurrent miscarriages which is
assumed to have been caused by maternal rejection.Within that
group, they had a subgroup of women who were currently in
middle of a healthy pregnancy and a subgroup of women who
just had a miscarriage.They found that the women in the middle
of a normal pregnancy had a strong bias of th2 compared to the
women who just had a miscarriage and that the women who
just miscarried had a strong bias of th1 cells (Makhseed, et. al.
2001). This implicates that th1/th2 cell ratio may play a significant role in the maternal tolerization of paternal alloantigens.

Nonconcurrent Theory
There have been suggestions that the fetal cells migrate to the
maternal circulatory system: the lymph node, spleen, and thymus,
where they will proliferate and then inactivate the potentially
reactive T-cells. Several studies prove this to be the case with
tolerized organ transplants. However, later research proved that
it is highly unlikely that fetal cell migration can account for maternal tolerization. They found that, in fact, this scenario of fetal
cell migration occurred in 1 out of 5 pregnant mice and at a
level of 1-5 fetal cells per every 100,000 maternal cells. Because
this event occurs so rarely, it doesn’t seem rational to list fetal
cell migration as a likely mechanism that protects the fetus from
being rejected (Bonney, Matzinger, 1997).

Clinical Implications
Recurrent Spontaneous Abortions
As the experiments on mice indicated, fetal rejection resulted
in the death of concepti. The death was caused by the maternal

immune system’s rejection of the placenta, which led to severe inflammation and hemorrhaging of the embryo, causing it to choke
and die. This scenario can present in human pregnancy as well.
Clinicians now wonder if the underlying explanation behind a lot of
the miscarriages that occur is really the maternal immune system’s
rejection of the foreign paternal alloantigen (Mellor, Munn, 2000).
Furthermore, if it is indeed the cause of recurrent miscarriages,
then discovering the mechanism that induces maternal tolerance
has clinical relevance as it is essential for proper treatment.
In order to test the IDO enzyme explanation for fetal tolerization,
and to uncover if failure or dysfunction of this mechanism can lead
to a miscarriage, researchers tested the cervical mucous, placental
villi and decidua tissue. They surgically removed the tissue samples
and mucus from women with recurrent miscarriages and divided
the group into those that exhibited normal chromosomal groupings and those that did not. They compared the level of IDO enzyme presence to samples from women who had normal pregnancies and delivery. In samples of cervical mucous and decidua tissue
they did not find a significant difference among levels of IDO in any
group. However, when comparing villi from miscarried pregnancies of normal chromosome analysis and abnormal chromosome
analysis, they found that the tissue from the normal chromosome
group had significantly higher levels of IDO enzyme than tissue of
the abnormal chromosome group. These results suggest that IDO
enzyme dysfunction is linked to women suffering from recurrent
miscarriages. Further research is necessary to test if IDO enzyme
treatment can prevent women from miscarrying by preventing the
maternal immune rejection that likely takes place (Obayashi, et. al.
2016).
Similarly, researchers who believe that a Th2 cell bias is responsible for maternal tolerance have studied the connection between helper T cells and recurrent miscarriages. In one experiment, they mated female mice who were deficient in IL-4 and
IL-10 with male mice who were genetically different.They found
that these mice experienced fetal loss. They treated some of
these mice with an intraperitoneal injection of IL-10 and found
that it protected the fetuses from resorption. (Sykes, et. al. 2012)
Women who are suffering from recurrent spontaneous miscarriages are assumed to have a dysfunction in the immunological
response to their fetus.This study implicates that by intervening
and manipulating the levels of Th2 cells at the beginning of a
pregnancy can protect these women from future miscarriages.
Further research is being done on specific treatment methods.

Preeclampsia
Preeclampsia is a pregnancy complication characterized by high
blood pressure. The high blood pressure seems to result from
abnormal formation of blood vessels in the placenta. ET-1 is the
peptide which causes vasoconstriction. Studies have found that
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increased level of ET-1 in the plasma correlated with a bias of
th1 cells. Upon further examination, this observation can indicate that if maternal tolerance mechanisms do not function
normally, preeclampsia can occur.

Bonney E, Matzinger P. The maternal immune system’s interaction with circulating fetal cells. Journal Of
Immunology (Baltimore, Md.: 1950) [serial online]. January
1, 1997;158(1):40-47. Available from: MEDLINE, Ipswich, MA.
Accessed January 3, 2017

When comparing women in middle of normal pregnancies to
women with preeclampsia, they found that the ratio of th1/th2
was 7.6 in normal pregnancies and 11.6 in preeclampsia pregnancies. This shows that significant increases in levels of th1 are
associated with preeclampsia (Kuwajima, et. al. 2001).

Kuwajima T, Suzuki S,Yoneyama Y, Sawa R, Asakura H, Araki
T. Relation between plasma endothelin 1 levels and T helper
1: T helper 2 cell immunity in women with preeclampsia.
Gynecologic And Obstetric Investigation [serial online].
2001;52(4):260-263. Available from: MEDLINE, Ipswich, MA.
Accessed January 4, 2017.

The th1/th2 cytokine imbalance that is found in preeclampsia
can be explained since th1 cell is a proinflammatory cell and the
vasoconstriction can be a result of inflammation of the placenta
and umbilical cord (Vargas-Rojas, et. al. 2016).

Conclusion
The mystery of why a mother does not reject her fetus, as she
would reject any other foreign object, is the focus of much research and academic debate. There is clear evidence to prove
that the maternal immune system is in contact with the fetus
and aware of its presence. The fetus is surely expressing paternal genes that are considered foreign to the immune system.
Furthermore, the maternal immune system seems to otherwise
function completely as normal, indicating that there is a specific
mechanism which must protect the fetus. One suggested mechanism is that the fetus secretes IDO enzyme which inhibits a
maternal amino acid, tryptophan, which supports the T cells of
the immune system. This forces the maternal immune system
to tolerize the fetus. Another explanation is that tolerization
is due to th2 bias in t cell1/2 ratio. Th2 is an anti-inflammatory
cell and can protect the embryotic tissue from a strong immune
response. Details of these possible mechanisms has medical relevance for recurrent spontaneous abortions and preeclampsia
because both conditions seem to be caused by immunological
dysfunctions of the tolerization mechanism. Further research is
being done to uncover other details of the mechanism and learn
the entire explanation for this immunological paradox.
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Abstract
The field of cosmetic dentistry emerged when people began to realize the importance of a good smile. Stains on teeth
were no longer deemed acceptable with the advent of cheap and safe procedures like tooth bleaching. This new procedure replaced the older, more costly and invasive method of laminated veneers and crowns. The chemistry behind
this bleaching occurs via unstable hydroxyl radicals and thus the question arose as to how safe this accepted procedure
really is. The purpose of this paper is to analyze the negative ramifications of tooth bleaching and to determine if it’s
truly safe.The null hypothesis is that the procedure is innocuous and the status quo of cosmetic dentistry is appropriate.
Data for this report was obtained from EBSCOhost, Google scholar and PubMed. Tooth sensitivity, oral mucosal and
gingival irritation are among the most common side effects observed. More serious side effects like weakening of bond
strength, leakage of restorations, cervical root resorption, bleachorexia and degradation of enamel matrix are all observed and are concluded to be serious issues. Though they are reported in the literature, carcinogenicity, mutagenicity
and depletion of oral microbes are all determined to not be of any true concern. With a plethora of reasons to avoid
tooth whitening, it’s imperative that users be properly informed before commencing whitening. This will ensure that
all possible measures to avoid these negative effects are indeed taken. Needless to say, the use of such toxic materials
shouldn’t be available OTC (over-the-counter) as they currently are. If a new and cheaper system is developed on
the heels of the successful Pearl Brilliant White Ionic Teeth Whitening System, then bleaching will finally be a safe and
universal procedure.
Introduction
In many social circles a good smile is considered indicative of a
healthy lifestyle and a wholesome person. Anthropologists have
shown that people with striking smiles are more successful and
confident than their peers (Townsville Bulletin, 2005). It has
been noted that the biggest indicator to a smile’s importance
is the recent surge in purchase of whitening products and the
reading of articles pertaining to such goods (Kihn, 2007). By nature, most people have a low self-esteem and will do anything to
gain confidence in themselves or others. This is the root cause
for the recent popularity of whitening procedures being used by
adults to restore their original white tooth shade.
Most people are born with the potential for untainted white
teeth, yet when they reach their adult years this doesn’t become the reality. What happened along the way to change this
potential? The answer is that their teeth became stained in one
of two manners, intrinsically or extrinsically. Extrinsic staining
occurs when the enamel of the teeth is discolored by intensely
colored pigments termed chromogens that possess ability to
bind to its white, outer portion. Coffee, red wine, cola, and tea
all have these chromogens and contribute to extrinsic staining.
Smoking is another lead cause as the tobacco is composed of
two different key components. Tar is naturally dark and promotes staining, while nicotine is colorless. However, when the
nicotine is mixed with oxygen it becomes a yellowish surface
staining material.
Intrinsic staining is an entirely different subject and is the result of a discoloration of the internal structure of the teeth,
known as the dentin. Dentinogenesis imperfecta is a genetical
disorder of tooth development which causes improper dentin
formation and results in teeth that may take on a blue-gray or
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yellow-brown hue. Both deciduous and adult teeth are subject
to this malady which may weaken teeth more than normal, making them prone to erode, break, and even become permanently
lost. Although fluoride is necessary to help prevent decay, if
taken too far and ingested in excessive quantities it can lead to
fluorosis. Fluorosis will result in white streaks that appear on
the teeth and can only be removed with dental measures like
bleaching.Trauma to the teeth can either cause internal bleeding
discoloration or alternatively lay down more dentin under the
enamel layer. As a result of dentin being a darker shade than the
enamel layer, the darkness shows through and gives off a darker
appearance. Another source for internal staining is tetracycline
staining.The minocycline binds to plasma proteins and becomes
deposited into the collagen-rich connective tissues of the bone,
teeth and pulp. It starts with a light yellow tinge and develops
into stronger colors when it oxidizes upon exposure to light
(Good, Hussey, 2003). Finally, the most prominent cause for the
odd tone of teeth is the indefatigable age factor. As people age,
their enamel wears thin and reveals the yellower dentin beneath
it. All of these causes can lead people to seek change and investigate the subject of tooth whitening.
The tooth whitening that will be dealt with in this thesis is far
more effective in removing extrinsic stains than intrinsic ones.
Tooth whitening by definition means the reestablishment of
the initial and natural color of the tooth, while tooth bleaching
is going beyond that which is natural. However, being that the
terms are used interchangeably in varying circumstances and
throughout the literature, the same pattern will be followed
here. Both whitening and bleaching will thus always be referring to the general color change, without discussing its earlier
appearance. Furthermore, it must be pointed out by way of introduction that prior to bleaching, the way to change the color
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of teeth was via laminated veneers or crowns. The invention of
tooth bleaching was designed to be a more cost-effective and
less invasive procedure.
The mechanism of the bleaching isn’t fully understood but the
principle concept is almost universally accepted. The active ingredient is either HP (hydrogen peroxide), or CP (carbamide
peroxide) which breaks down into 33% HP and is thus a weaker
version of the former.An oxygen species which can vary between
perhydroxyl anion (H02-), hydroxyl radical (HO-) and various
other radicals subsequently forms from the HP. The structure of
the radical depends on the reaction conditions such as presence
of transition metals, light, temperature and pH (Joiner, 2006). This
radical reacts with the extracellular matrix portion, specifically the chromophores and pigments it contains, to degrade the
stains formed on the surface of the teeth (Goldberg, et. al. 2010).
The chromophores are the part of the molecule of a dye that is
responsible for its color, while the chromogens are those substances that can be converted into a pigment or dye. In a broader sense, it can be said that HP or CP break stains into smaller
pieces, making the color less concentrated and consequently the
teeth brighter. In a more technical chemistry sense, it can be said
that the reaction with HP or CP leads to the oxidation of carbon
double bonds in organic chromogens. This in turn fragments the
chromogens so that the power of their color is subdued or even
eliminated (Carey, 2014).
A study aimed at determining the relative effectiveness of CP
or HP tested six people, having three of them perform bleaching with 3.5% HP and the other three by using 10% CP. These
two concentrations are equivalent, as the more complex CP
molecule breaks down into 33% HP and 67% other materials.
Comparing results by using the Vitapan Classical shade guide to
test the percentage of color change, the two substances were
deemed to be statistically similar. Canines and incisors both decreased a few shades despite the fact that the concentration
of peroxide was on the lower side of the bleaching spectrum
in both cases (Berga-Cabarello et. al. 2005). Although the sample size was small, it is sufficient as it is merely confirming that
which was previously understood as common knowledge. It can
be seen from this study that pure HP is a more potent whitener than CP, as CP requires three times the concentration for
equal results. However, it has been postulated although not yet
proven, that CP does have its own advantage over HP. Equivalent
amounts of oxygen species are released in both HP and CP,
but not in equivalent amounts of time. CP releases the oxygen
species slower and is consequently more stable, yielding better
long-term results. Due to a lack of experiments on this theory,
further testing should be performed to substantiate this claim
about the long-term results.

There are three methods of bleaching that effectively remove
most extrinsic stains and some intrinsic ones as well. Whitening
toothpaste isn’t among these three as it is only effective for
light surface stains. The first is the power bleaching method
performed chairside by a dentist. It requires usage of a high
concentration of bleach (usually between 30% and 38% HP) and
is applied for a duration of 30 minutes to an hour. During such a
procedure, the dentist creates a seal around the bleaching area
to ensure that the highly-concentrated bleach doesn’t end up
being ingested or in contact with the gums and thus irritating
them. A second method is the supervised take-home method
that is also monitored by a dentist. First, the patient visits the
office to create molds for the teeth that will be used for the
treatment. Then the peroxide is given in a gel form to be placed
in the trays and applied at the dentist’s recommended concentration. This is usually between 10% and 20% CP (equivalent to
3.5% and 7% HP respectively) and involves duration of a few
hours daily for a couple of weeks. Periodic complementary
appointments at the dentist’s office are recommended to ensure the success of the operation. A third method is the OTC
(over-the-counter) bleaching method. The user can find these
whitening strips or gels at their local pharmacy or even on the
internet. The concentration of peroxide in OTC products is in
the 5% to 7% HP range.
The advantage of the chairside power bleaching is that it can
be done at a rapid speed, with high concentrations, expediting
the bleaching process. Its higher price tag, requirement to visit
an office for treatment and use of dangerous concentrations of
powerful chemicals makes some people wary of its usage. OTC
products are far cheaper and can be done at the user’s convenience, however the lack of professional regulation makes some
people hesitant to employ it. Furthermore, it can get messy and
is less effective for strong stains, making some people question
if it’s worth the bother. The take-home method is moderately priced and is the intermediate between the fully regulated
power bleaching and the more controversial OTC products.
A study was performed to compare the color change and rebound effect of power bleaching in comparison to take-home
bleaching. Rebound effect is a measure of how quickly the results
of the whitening fade and the initial discoloration returns. A split
mouth design was used where twenty patients were randomly
assigned chairside bleaching to either their mandibular or maxillary anterior teeth and then followed by take-home bleaching
to the other. Excluded from this study as well as all other studies
listed in this thesis were those with active caries, periodontal
diseases, previous bleaching procedures and orthodontic treatments. Additionally, those with tetracycline-staining, fluorosis
and those who habitually smoke were omitted. This ensured
that the results would be a direct indicator to the effectiveness
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of bleaching to standard patients with regular extrinsic stains,
and not tainted by outside factors during the treatment time.
Patients were evaluated by a single examiner, blinded to each
patient’s bleaching regimen, immediately after treatment and
2 weeks, 1 month, 3 months and 6 months later. The testing
was done to measure for bleaching effect, rebound effect and
color difference between post-treatment and unbleached teeth.
The results showed that there was no significant difference
between power bleaching and take-home whitening on any of
the matters being evaluated except for rebound effect at the
6 month follow-up. While take-home whitening didn’t have a
distinguishable rebound effect at 6 months, the power bleaching
did. This can be explained by the dehydration effect that power
bleaching has on the teeth, which will interfere temporarily with
the evaluation of color differences. It can be said that a lot of
the color improvement associated with power bleaching is an
illusion caused by this dehydration effect rather that an actual
improvement in the tooth shade. Another explanation is the
longevity of treatment. Take-home bleaching is continuous for
two weeks which allows for bleaching demineralization to work
together with natural remineralization and results in longer
lasting effects. However, power bleaching is a one-time treatment and thus remineralization begins right away, resulting in
faster regression of the whitening effect. Although regression
occurs faster in the power bleaching, there is no overall statistical difference in the color comparison of post-treatment teeth
and those untreated (Moghadam, et. al. 2013).
More recently, it has been suggested that the use of laser heating
can enhance the effects of tooth whitening. Regular whitening
without heating works because the peroxide releases hydroxyl
radicals that diffuse into the outer enamel and break down the
stains in a matter of hours. Lasers can heat the HP and expedite
the chemical reaction that leads to radical formation, reducing
bleaching time. However, despite the popularity of such heating
devices, it really has no effect on the quality, durability or speed
of the bleaching (Carey 2014). Although there are those who
argue and that it does work faster, it is still more costly and
has reportedly increased the subsequent tooth sensitivity. It can
be concluded that the results of light-activated procedures are
equal to those lacking such treatment and there is no real benefit to using such methods (Kihn, 2007).
A study was performed using third molars to test the effect of
various concentrations of bleaching substances on the degree
of whitening. Hydrogen peroxide of 5, 10, 15, 25 and 35% concentration was applied to test the degree of whitening each one
would do in the same 3 x 10 minute sessions. Unsurprisingly
the 35% HP was the most effective, while the 5% was the least
effective in changing tooth shade. Furthermore, the 35% HP
reached the maximum degree of whitening in just one session,
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showing that it’s the fastest method. However, the 5% HP took
a staggering 12 sessions to reach the same maximum shade.The
expectation was that the relationship would be linear and that
5% HP would require only 7 sessions to equal its 35% HP counterpart. Instead, results showed that the number of sessions
increase exponentially with lower concentration and that the
relationship isn’t merely linear. An explanation for this phenomenon is that tooth whitening is far more complex and involves
numerous factors to attain the same results. Thus, the diffusion
and reaction of the degraded components of the peroxide with
chromogens may not work under expected patterns. Despite
this strange peculiarity, once the maximum shade is reached,
there is no difference between the higher and lower dosages of
HP with regard to its longevity (Sulieman, et. al. 2004).
As is the case with most medications and procedures, tooth
bleaching has its fair share of side effects. Is tooth bleaching
really as safe as advertised? Are potential by-products transient
or are their effects felt over the long haul? The null hypothesis
prior to investigation of the subject is that there are no serious
negative results to tooth bleaching, regardless of technique. The
procedures are ADA approved and it’s unlikely they would sanction the use of unsafe methods. Furthermore, the technique has
been in use for many years and if it was really harmful, would
undoubtedly have been banned by now.

Methods
Data was found using a variety of different internet sources.
PubMed and EBSCOhost were very helpful in providing data.
Additionally, Google Scholar was used as a powerful search engine.

Discussion
Dentin hypersensitivity (mostly thermal) is the cause for the
aches and pains associated with tooth whitening. Increased sensitivity is the most common by-product and some degree has been
reported in over 50% of patients (Jorgensen, Carroll, 2002). A
survey reported that 78% of tooth bleachers experienced pains
of some sort ensuing their bleaching regimen. The chemical process for whitening releases the dentinal plug that is thought to be
protecting the region. With the plugs removed, the core of the
tooth becomes exposed to things from which it is usually safe. A
dentinal fluid flow occurs internally, as a result, and leads to the
excitement of pulpal tissue and the consequent sensitivity.
There are two ways to counteract the sensitivity created by
removal of the dentinal plug that accompanies tooth whitening.
One method is to replace the dentinal plug by using dental sealants to cover the exposed root. Varnishes, bonding agents, and
restorative materials are all viable ways to physically close the
gap. Another related way is to commence the usage of fluorides
which will decrease the permeability of the teeth. A different
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approach is to cause depolarization of the nerve. Application of
5% potassium nitrate can cause a soothing effect on the nerve.
It acts as a tranquilizer and slows the repolarization, which in
turn eases the pain that is associated with the irritated nerve.
An experiment was conducted to compare the tooth sensitivity
experienced in at-home bleaching with 10 and 20% CP vs. in-office power bleaching with 35 and 38% HP.Twenty-five patients for
each of the four categories were gathered for this experiment.
The at-home treatments were accompanied by the antidotes of
potassium nitrate and fluoride to see if they would help. Tooth
sensitivity was measured qualitatively, as each week the patients
were asked if pain was absent, mild, moderate or severe.Thirteen
percent withdrew with pain they deemed intolerable, showing
that not all pain involved was so temporary and bearable. The
results dictated that 43.2% of patients experienced pain, which
fits well with Jorgensen and Carroll’s results in 2003. The puzzling
statistic was that a high volume of 71.4% of users of 20% CP
experienced pain. This phenomenon was astonishing considering
that only 15% of those power bleached with 38% HP experienced the uncomfortable sensation. As a whole, 9.5% from the
take-home treatments in comparison with 4.3% of the in-office
whiteners felt the sensation (Basting, et. al. 2012).This experiment
indicates that there are other factors besides concentration that
play a role in causing tooth sensitivity. Had it been solely based on
concentration, then the chairside whiteners would have endured
more sensitivity than their counterparts at home. Perhaps it can
be concluded that the duration of the take-home bleaching made
up for its lack in concentration. Another disappointing conclusion
was the minimal effect that remedies like fluoride and potassium
nitrate had on quelling the pain.
The split mouth design experiment also tested for tooth sensitivity and is important in regards to comparing sensitivity of at-home
treatments vs. in-office power bleaching. At all the time intervals
that color change was measured, tooth sensitivity was assessed
by use of a visual analog scale. The results showed no significant
difference between the two types of whitening treatments as
each reported sensitivity in the 40-60% range. Using standard
deviation this is deemed statistically insignificant and thus both
were considered to be equally irritating (Moghadam, et. al. 2013).
Another adverse by-product of bleaching is the oral mucosa
irritation that will occur if not applied properly. Oral mucosa
is the mucous membrane that covers the entire inside of the
mouth with the exclusion of the teeth. This protective membrane helps maintain oral health and is composed of strong
keratin fibers which makes it resistant to injury. At a concentration in excess of 10%, HP is deemed to be corrosive to the
mucous membrane and can cause burns and tissue damage.
When power bleaching is performed it’s imperative that there

be something that holds back the highly potent peroxide from
entering the oral cavity. Furthermore, patients shouldn’t be
numbed during such procedures, as they must be able to alert
the practitioner in the event they feel a burning sensation (Li,
2011). However, a patient’s perception of pain can’t be relied
upon and the dentist must constantly check the adequacy of the
barrier that was constructed. It would be prudent to use some
form of dyed substance to test how the barrier really is. If no die
leaks through, it can then be considered safe enough to proceed
with the whitening procedure.
A related issue is the gingival irritation that often occurs
post-bleaching. Gums are a soft pinkish tissue that is composed of oral mucosa, and is vital in supporting, surrounding,
and protecting the teeth. Issues with gums have been linked to
cardiovascular and respiratory disease by some health professionals. Therefore, it is highly alarming that patients who have
undergone whitening treatment have in certain cases developed
gingivitis. This inflammation of the gums will lead to red and
swollen gums that tend to bleed easily.The onset of gingivitis occurs because gums, like all oral mucosa, are subject to damage at
concentrations exceeding 10% HP. The cause for gingivitis is an
ill-fitting tray or a leaky and failing barrier during office whitening treatments. Although mucosal irritation is often temporary,
gingivitis is a dangerous disease that must be taken into account
when balancing the merits and dangers of whitening. With such
dangers lurking, it’s quite clear that such substances shouldn’t be
placed in the hands of minors or irresponsible people.
An interesting study of an innovative OTC bleaching tray system
helps shed some light on the mucosal and gingival irritation that
often accompanies whitening.Thirty-eight subjects were provided with the Pearl Brilliant White Ionic Teeth Whitening System
which contains 9% HP and uses electrodes in the wall of trays to
deliver an electrical current.The 4-15 milliamperes current activates the gel, causing it to diffuse through the enamel, and leads
to the oxidation of pigments and chromophores that is standard
in all whitening methods. The purpose of the electrical power is
to speed up the formation of radicals and thus reduce application time of trays. The 38 patients applied the trays twice daily
for five minutes and a mere five days. This contrasts with standard OTC strips which must be worn for excess of an hour per
application and multiple weeks per cycle. Patients were checked
after the first treatment and after five days for irritations, sensitivity and for effectiveness of the bleaching protocol. Results
after the first treatment reported a mean improvement of 2.3
shades and only 20% discomfort, with two patients reporting
slight burns of oral mucosa. After five days, only 15% of patients
reported any discomfort and nobody had to stop treatment
early. The average gingival score didn’t have a significant change
and there was no additional inflammation after application of

65

Yehoshua Krasnow

the gel. Only seven of 38 patients had any blanching of oral mucosa during any point of the treatment, and such side effects
lasted just a few minutes and didn’t require intervention. The
results showed a sharp contrast between the electric powered
tray system’s 20% discomfort level and standard OTC whitening
strips 50% sensitivity incidence (Ghalili, et. al. 2014)
The cause for the lower sensitivity and irritation prevalence
may have been a result of the addition of potassium nitrate to
the HP gel which slows repolarization of the nerve and lessens
the pain. However, it was shown in an earlier experiment that
such treatment doesn’t necessarily work (Basting, et. al. 2012). A
more likely explanation is the decrease in wearing time of trays
and contact time of the peroxide gel. These results and accompanying explanation would fit well with the conclusion that was
made earlier regarding that experiment, where it was stated
that increase in duration of bleaching can lead to increased sensitivity. The usage of this novel OTC treatment is slowed by its
heavy price tag of $200 per tray, but its prowess is important to
note. If time can be reduced significantly in an affordable manner,
then many of the main side effects of bleaching will disappear.
The most harmful effect that any substance can have is carcinogenicity, the ability to cause cancer, primarily by genotoxicity.
Genotoxicity is the negative effect that harmful substances can
have on the genome by causing mutations to the cell’s DNA.The
method for testing for genotoxicity is via a micronucleus test
that quantitatively measures chromosomal damage by counting
all cells that have inducted micronuclei into their cytoplasm after
exposure to genotoxic agents. These micronuclei form when all
or part of a chromosome isn’t incorporated into a daughter cell
during cell division. A high micronucleus count is indicative of
severe chromosomal instability and genotoxic effects that pose
a health risk. The DNA fragments will occur only in those cells
that have completed one round of cell division after exposure
to the genotoxic agent. The lack of incorporation of the micronuclei is due to a lack of centromeres that prevents the fragments from migrating to the spindle poles during late anaphase.
The end result is that fragments are left behind and they form a
secondary nucleus that is kept in the cell cytoplasm.
When compiling a list of the drawbacks to tooth bleaching, the
potential correlation to genotoxicity and carcinogenicity must
be thoroughly investigated. The theory had been proposed that
HP may raise the carcinogenic effect, much like it does in experimental animals. However, it has also been argued that those
artificial conditions are of no relevance to tooth bleaching, as
they have much higher levels of HP than tooth bleaching does. A
study was performed to find the genotoxic effect of 10 and 16%
CP on bleached patients. Particularly concerning is the presence
of reactive oxygen species in the peroxides that could damage
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proteins and cell nucleus. Thirty-seven patients were randomly
divided into two concentration groups and given customized
trays to wear for two hours daily for a duration of three weeks.
Collections of gingival margin cells were taken at baseline, 15
days and 45 days by abrasion and then properly affixed to slides.
One thousand cells were counted per slide and underwent a
micronucleus assay. Comparing the results of the 10 and 16%
CP there was no statistical difference between the rates of micronuclei formation at all three time periods. Most importantly,
the rates were in fact on the lower end of the 0.3 to 1.7% range
given in previous experiments (Bona
ssi, et. al. 2011). These results showed that when not applied for
long periods of time or improperly consumed, the use of peroxides alone isn’t cytotoxic. Hence it can be concluded that teeth
bleaching doesn’t pose a threat to human gingival epithelial cells
(Almeida, et. al. 2015).
Another study corroborated the results of the previous experiment. Thirty smokers and thirty non-smokers were given
10% CP to be used three hours daily for three weeks. The goal
of this single-blind trial was to compare the genotoxicity and
efficacy of at-home whitening between smokers and non-smokers. The usage of a micronucleus assay is a good indication of
cancer risk associated with genotoxicity, as most tumors in
humans originate in the epithelium. The results indicated that
bleaching didn’t increase the frequency of micronuclei in the
cytoplasm. The number of micronuclei was higher in smokers
than non-smokers, but that was the case prior to baseline (the
starting point used for comparisons).This is merely indicative of
the genotoxic effect of habitually smoking, and is unrelated to its
effect on bleaching. Smokers and non-smokers alike didn’t have
a significant increase in micronucleus formation after performing bleaching. Ten percent CP was thus proven to be safe when
used at low concentrations for the three-week period that was
required. The study did have limitations as it wasn’t truly a blind
examiner that was testing for genotoxicity. The smokers had
a stench on their clothing and in their breath, giving away the
identity of the group to which they belonged. Furthermore, the
timing of the post-bleaching micronucleus assay wasn’t optimal
as it was given shortly after the whitening treatment. In contrast,
the regeneration of the cells from gingival tissue takes approximately ten to twelve days. Thus, had the assay been performed
two weeks later it’s possible the results would have changed (de
Geus, et. al. 2015). However, the limitations can be overlooked
as the results are backed by other studies (Almeida, et. al. 2015).
A consensus opinion on the matter of genotoxicity and carcinogenicity is given in a recent review article. Direct contact with
peroxide can cause genotoxicity in cultured cells and bacteria.
However, when in the presence of catalase and other biological
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enzymes, the effect is mitigated. The free radicals of the reactive
oxygen species need to reach the DNA to inflict damage and the
presence of metabolizing agents inhibits their ability to reach the
target in vivo.Thus, while it is a threat to bacteria in a lab, in humans
it isn’t deemed a real threat. HP has a weak local carcinogenic potential and nothing more.The International Agency for Research of
Cancer put HP in group three as unclassifiable in its carcinogenicity
in humans. Most certainly, the mild dose of 10% CP found in many
at-home trays is of no threat to those not already predisposed to
oral cancer (Perchyonok and Grobler, 2015).
There was one case trial that did experience a higher rate
of mutagenicity as a result of using tooth whitening in vivo
on humans. Two different groups received different types of
in-office bleaching. The first group used ZOOM2, a 25% HP
that also features light activation. The second group received
Opalescence BOOST, a 38% HP which had no light treatment.
Cell samples were collected from both the upper lip lining and
the gingival area, via swab technique. Each sample was collected
before bleach application, immediately after and then 72 hours
post-whitening. The collection immediately after bleaching was
a control group, as there wasn’t enough time for mutant cells
to reproduce and appear in the results. The collection 72 hours
after treatment was the experimental group, as that is ample
time for reproduction of cells. Although there were only eleven
members in each group, the design was to capture large effects
and for this purpose Cohen’s size conventions test determined
that eleven was large enough.
Results showed slightly higher indicators of genotoxicity in
BOOST, but both forms of bleaching caused a large increase
in these markers. When comparing the control and experimental groups, BOOST saw a 157% increase in micronucleus
presence while ZOOM2 experienced a 142% hike. These results contradict those of other studies, however, there are numerous explanations to reconcile the differing conclusions. The
aforementioned experiments headed by both Almedia (2015)
and de Geus (2015) used low concentrations of CP, while this
experiment used high concentrations of the stronger HP. This
may have led to the genotoxicity increase and wouldn’t be indicative of issues in at-home bleaching. Furthermore, even power
bleaching isn’t necessarily problematic as there were flaws in
this experiment. Five out of 22 patients had minor restorations
which is usually grounds for exclusion, as they have a negative
effect and increase the micronucleus count. Also, patient’s lifestyles can’t be controlled and while in other experiments they
may have refrained from negative behaviors, this experiment
may have been an exception. Alcohol usage and improper diet
have been linked to an increase in micronucleus count. All of
these explanations make this case seem as more of an aberration than a rule (Klaric, et. al 2013).

Tooth whitening can cause permanent damage to the enamel structure. In addition to the free radicals, CP produces urea
which subsequently decomposes into CO2 and ammonia. This
is key in the bleaching process as the urea degrades the organic matrix in the enamel. Hydrogen bonds in matrix proteins are
dissociated by the urea and ammonium ions.These empty spaces
caused by the degrading of matrix proteins make possible for
penetration of the free radicals to enamel and even dentine layers.
However, whatever breakdown the urea creates is in fact real and
permanent damage to the enamel and is one of the more serious
issues of tooth whitening (Elfallah and Swain, 2013).
While enamel erosion is a serious issue, it has become well
publicized that remineralization agents are a viable method for
restoring tooth structure. An experiment was conducted to test
enamel erosion generated by two different high concentration
HP whiteners. Opalescence BOOST was used as a substance
that is chemically active, while Mirawhite is a 30% HP substance
that is activated by a diode laser.The experiment also tested four
different remineralization agents to see which would be most effective in restoring initial tooth structure. Twenty-five molars for
each whitening type were each subdivided into five groups, which
featured one control group and four different remineralization
experimental groups. The exact statistical measures for erosion
and remineralization are unimportant, but the generalizations
were quite startling. SEM/3D-SEM-micrographs revealed that
both types of bleaching caused emphasized perikymata, which
are the pits surrounding the long prisms of tooth enamel. These
emphasized perikymata as well as the loss of interprizmatic substance both clearly indicated enamel erosion.These negative signs
were even exacerbated in the teeth that were activated by the
diode laser. Remineralization occurred in all four experimental
groups, with calcium phosphate proving to be the best at covering the surface of the enamel. SEM/EDX-semiquantitative analysis
showed that certain crucial elements were reduced from the
tooth structure as a result of the bleaching procedure. Sodium
and magnesium were most prolifically lost in the non-laser
bleaching, while calcium and phosphorus were the hardest hit by
the laser bleaching (Coceska, et. al. 2016).
Although remineralization agents can help repair the erosive
effects of bleaching, this only works if patients are properly informed to commence application upon the onset of whitening
treatment. However, users of OTC products are generally not
properly informed and also further their plight by not reading
the instructions. Thus, even when side effects are indicated in
the user’s manual, most consumers remain oblivious to the need
for these remineralization agents. The loss of enamel causes a
decrease in insulation from potential painful temperature and
dangerous chemicals and can also lead to decay. Furthermore,
enamel erosion makes the tooth more prone to chipping. Once
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the enamel is lost it has no living cells to repair itself. All damage
is permanent and costly alternative treatments such as bonding
are now required.
The leakage of restorative materials ensuing tooth whitening
is another major by-product of the procedure. Restorative
materials have been used for many years to fill caries, repair
damage due to trauma and much more. Originally amalgam was
the primary restorative material, until a recent surge in the use
of composite resin material. Issues arise when there is a leakage
of mercury ions from amalgam upon the initiation of bleaching.
Mercury ions can be toxic and lead to numerous diseases when
the threshold concentration is reached.
The amalgam’s natural release is a redox (oxidation-reduction)
reaction in which the mercury metal reacts with non-metallic
elements to produce chemical compounds (von Fraunhofer and
Staheli, 1972). This same reaction would take place in vitro, as
the redox reaction takes place at the amalgam/bleach interface
resulting in the deposits. An experiment was thus conducted to
investigate how much of a role both concentration and time of
treatment have on the release of mercury. Tytin amalgam contains 42.5% mercury and is a typical dental restorative material.
Sixty-five discs of tytin amalgam were prepared and divided into
thirteen groups of five for the experiment. Four groups of discs
were each treated with 0%, 3.6% and 6% HP. The various groups
had varying times of exposure to HP of 1, 8, 48 and 156 hours
respectively. The 0% HP groups were the control groups and
contained saliva and other biological enzymes in place of the
peroxide.The 3.6% HP groups represented the classical at-home
concentration and the 6% HP represented a stronger version of
these groups. The various times made this into a double experiment that charted both concentration and time of exposure
against amount of mercury ion leakage. The thirteenth group
was treated with 30% HP for one hour and was an imitation of
in-office power bleaching. Each disc was measured five times for
amount of mercury ion release and each group had five discs to
ensure the accuracy of the measurements.
The results showed a greater release of mercury ions as the
concentration of bleach was increased. Time caused increased
release until the eight hour mark, at which point its effect plateaued. This showed that concentration was of greater effect
than time and thus power bleachers should be cautious before
starting whitening. However, the small amounts of mercury released don’t produce effects on humans, as the quantities are
well below the acceptable daily intake of forty micrograms. The
maximum sum released by any of the discs was 1.125 micrograms and thus would require 36 teeth with restorations to
pose any threat. Despite its relative safety, it’s still not healthy
to have any amount of harmful chemicals in the body and thus
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the release of amalgam is a side effect that must be taken into
consideration when considering bleaching. In fact, this danger
has caused Norway to ban amalgam restorations now that safer
alternatives are available (Al-Salehi, 2009).
Scientists hypothesized that upon the onset of bleaching, an additional consequence would result from the redox reaction that
occurs at the dentin. They feared bond strength at the dentin/
resin interface would be adversely affected. To confirm this suspicion, they performed an experiment to test all facets of bond
strength after application of varying concentrations of bleach to
teeth. For the shear bond strength test, forty slabs of intracoronary dentin were obtained and split into four groups. One was a
control group that was treated with artificial saliva that had no
HP concentration. The second group was 20% HP and also had
sodium perborate (a bleaching agent), a third group was comprised of 37% CP and a fourth group of 38% HP. Manufacturer
protocol was performed for all bleaching regimens and a seven
day waiting period ensued as a means to offer appropriate time
for the residual bleach to leave the dentin. These teeth then
received a shear bond strength test in a universal testing machine. Failure modes for the test were observed via microscope.
Next, a flexural/fracture strength of dentin test was done on
forty dentin bars from the cervical area of the buccal portion of
roots. These forty bars were divided into the same four groups,
underwent the same treatments and then received a three point
test carried out by a universal testing machine. Finally, an SEM
analysis of dentin surface and adhesive interface was prepared
with five hemi-sections of lingual surface of crowns, for both the
dentin surface and adhesive interface.
The results showed that shear bond strength of the control
group was nearly double to that of the experimental groups.The
unbleached teeth had mixed failure modes of both cohesive and
adhesive failures, while the bleached groups had predominantly
adhesive failures. Flexural strength was statistically significantly
higher for the unbleached group than the experimental groups.
The 38% HP was the weakest of all groups, although it was statistically similar to the 20% HP coupled with sodium perborate.
Lastly, unbleached teeth had SEM analysis that showed dentin
surface covered with its smear layer, the two middle groups had
some areas with fissures and the 38% HP sample had cracks
all over the specimens. Analyzing dentin/material interface there
was a continuous interface in the unbleached group, and progressively more discontinuity areas with the higher concentration bleached groups.
The explanation for the weaker shear bond strength in bleached
groups, is that hydroxyl radicals penetrate into dentin and break
down connective tissue, such as collagen and hyaluronic acid.
This in turn increases dentin permeability, reduces hardness and
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leads to the decrease in shear bond strength. The oxygen inhibits the entrance of the resin/material into dentinal tubules and
prevents their polymerization. Even after seven days, residual
oxygen remains and causes adhesive failure. Hence, the analysis
of failure modes indicated more adhesive failure for bleached
teeth, while unbleached teeth had less adhesion failure modes
and instead more cohesion failure modes. This furthers the notion that hydroxyl radicals formed from bleaching products interferes with the bonding of restorative materials. This may also
be a secondary reason for leakage of amalgam restorations, as
the failure to properly bind at adhesive interface causes the subsequent leakage. The SEM results were consistent with those
of the shear bond strength test, as those with the highest HP
concentration had more cracks in the dentin surface than those
with lower HP. Finally, the flexural strength test confirmed the
scientist’s fears, as those with higher HP had less strength and
would thus fracture faster in-vivo. All of these test results can be
explained with the common theme, that the hydroxyl radicals
ruin the structure of teeth while also reducing the ability of the
resin to properly bond to the dentin (Vieira, et. al. 2012).
There have been numerous mechanisms proposed as ways
to reduce and prevent the microleakage of composite resin
restorations. This microleakage is particularly common when
bleaching is done just prior to or soon after installation of the
restoration. The bleach leaves behind residual peroxide that
doesn’t allow for proper polymerization of the resin to the remaining portion of the natural tooth. A test was done to compare various suggested means of mitigating the microleakage
effect. Sixty intact premolars were split into six groups for the
purpose of this trial. Group one was the control group, as the
teeth were merely treated with saliva instead of the 10% CP
applied to other groups. There has been a theory that allowing
a three week time delay between bleaching and bonding would
be ample time to allow residual peroxide to dissipate out of the
teeth (Bittencourt, et. al 2010). Thus, group three was treated
with 10% CP followed by a three week delay before installation
of fillings. Group two provided the proper contrast to group
three, as it was treated with 10% CP and didn’t have the deferral of restorations found in group three. Group four had sodium ascorbate applied in between bleaching and the filling of
caries. This chemical is an antioxidant and was seen as a faster
alternative to the potentially equally effective but highly time
consuming delay period. A recent study suggested that addition
of surfactant (0.2% Tween 80) would enhance sodium ascorbate’s ability to prevent microleakage (Moosavi, et. al 2010).
Thus, group five presented sodium ascorbate coupled with surfactant treatment between bleaching and restorations. Finally,
group six was treated with catalase instead of the antioxidant
and surfactant, following a report that catalase removes residual
HP from the surrounding area after bleaching (Rotstein, 1993).

Microleakage was measured semi-quantitatively by the accepted
criteria of the depth of dye penetration at the interface between
restoration and cavity wall.
Data from the trial indicated a significant difference in amount of
microleakage between the unbleached group one and bleached
groups two through six. Furthermore, group two had the greatest microleakage as it had no preventive measures implemented
preceding addition of composite resin. Groups five and six, although significantly greater in microleakage than group one, was
significantly less than group two. It is thus evident that sodium
ascorbate in conjunction with surfactant and catalase by itself
are a sufficient method of reducing (but not completely terminating) composite resin microleakage. Groups three and four
were statistically similar to group two, showing they were relatively ineffective at preventing microleakage (Han, et. al. 2014).
Extending the theory that explained the results found in this
microleakage experiment, one can opine that application of catalase can also help cure the woes of the weakening of bond
strength caused by whitening. This in fact concurs with a previously performed experiment which also concluded that pretreatment of bleached surfaces with catalase prior to bonding
improves composite-enamel bond strength (Kum, et. al. 2004).
On the surface this seems very reasonable, as one of the causes
for both microleakage of restorations and weakening of bond
strength, is the oxidative materials left behind after bleaching
which prevents polymerization of installed materials to the
natural tooth. If catalase can serve as a deterrent to microleakage it should then follow that it should relieve the stress on
bond strength that the same residual harmful materials cause.
However, catalase wouldn’t be of any help for other side effects
mentioned earlier in this report, as those aren’t a result of the
residual oxidative materials that the bleach leaves behind.
Cervical root resorption (reabsorption) is a naturally occurring
process in primary teeth, as the deciduous teeth are uprooted
to make way for the permanent teeth. This process is caused by
the osteoclast differentiation that results from the pressure applied by the newly emerging teeth. However, as a result of trauma or excessive pressure of various orthodontic treatments, it’s
possible for a pathogenic resorption/breakdown of permanent
teeth to occur. Such a condition can ruin a tooth if not properly
treated. The problem is that this phenomenon is painless and
unless detected via x-ray will go undiscovered until after carious
lesions have taken hold in the external tooth. Bleaching is one of
the orthodontic treatments that is a root cause for resorption
due to the pressure associated with it.The disease is more commonly observed in those using HP bleaching than those using
sodium perborate alone (Fearon, 2007). Sodium perborate is a
milder procedure with less side effects, but shorter sustained
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results. Thus, the intensity of the bleaching regimen clearly has
a direct effect on likelihood of cervical root resorption. Use
of heating devices is another catalyst for this malady. This is a
logical consequence, as the heat generates hydroxyl radicals
from the HP which are highly reactive and subsequently break
down connective tissue found in teeth. Together, high concentration HP and heat can be a lethal combination for those trying to preserve their teeth. Another explanation why bleaching
causes root resorption, is that the acidic environment that the
bleaching procedure supplies enhances the disease (Dhillon, et.
al. 2011). The diffusion of hydrogen ions from the bleach makes
the region more acidic and creates an environment that is ripe
for bone resorption and osteoclastic activity. The proof to this
theory is that osteoclastic activity is strongest in 35% HP (3.7
pH), intermediate in 35% CP (6.5 pH), and weakest in sodium
perborate (pH 9.9), a basic substance (Dhillon, et. al. 2007)
Additionally, it has been suggested that the acidic environment
that bleaching creates can adversely affect the beneficial microbes that regularly grow in the oral cavity. It’s important to
have these essential microorganisms so that when adverse, exogenous viruses invade they are outnumbered and combatted
by the symbiotic microbes. The harsh, acidic conditions could
prove to be too much for the microbes to handle and thus diminish these protective organisms. Such a chain of events would
leave whitening users with a greater risk for microbial disease.
Four groups of eight were generated to test the effect various
treatments and combinations of treatments would have on the
overall concentration of microbes in saliva.The results would be
a direct indication of the overall concentration in the oral cavity.
The first group was treated with in-office CP 37% and at-home
CP 10%. The second group received the in-office CP 37% and
an at-home placebo, the third group an at-home 10% CP and an
in-office placebo, and the final group a double placebo. All patients were given uniform brushes and dentifrices and inasmuch
as possible were left under similar conditions. The in-office
bleach was conducted in three sessions of one hour and the athome whitening was three weeks in duration. Saliva was taken
at baseline, right after application of bleach, twelve hours later
and repeated each week during treatment. The results were
placed on various culture media, but all results showed no significant difference between microbial levels at various periods.
Thus, it was concluded that the bleaching of teeth has no effect
as an antimicrobial agent (Franz-Montan, et. al. 2009).
The final major side effect of bleaching teeth is the potential
to develop an addiction to the bleach. Such a disease is known
as bleachorexia and those afflicted are dubbed bleachorexics.
Much like anorexics who are convinced they aren’t skinny
enough, bleachorexics are convinced that their teeth aren’t
white enough. Instead of accomplishing a nice hue, these fanatics

70

whiten to the point where teeth reach a translucent blue or
grey appearance.This looks unnatural, especially when contrasted by a person who may have a darker skin tone. Bleachorexia
can lead patients to turn an eight week regimen into a full-year
program.These tooth whitening junkies present an added health
risk with gum, tooth or even throat problems from repeated
exposure (Bee, 2006). The relatively recent increase of bleachorexics is due to the prevalence of OTC methods which allows
patients to take whitening into their own hands. The enamel
becomes permanently damaged, root canal problems arise and
free radicals damage cells and pulp in teeth due to the over-indulgence of bleach. Gums may recede, teeth become weaker
and all other aforementioned side effects become amplified by
the excessive use. Psychological intervention may be required
to relieve patients of their plight.
Prior to drawing any conclusions, it’s important to examine the
long-term effectiveness of tooth whitening. A study was conducted to test for any difference in rebound effect at the twoyear mark vs. baseline and the one-week mark vs. baseline. This
was done for both at-home bleaching and in-office bleaching,
to test which one has more sustainable results over the long
haul. The general perception among clinicians has been that
the at-home bleaching lasts longer than the in-office bleaching.
Results in the split-mouth design experiment corroborated this
general view (Moghadam, et. al. 2013). For this experiment thirty patients were given power bleaching for two sessions of 45
minutes during a one-week span. Another thirty patients were
given at-home bleaching kits of 16% CP, to be applied for six
hours per night for four weeks. Color change was detected
using the Vita Lumina shade guide and was measured at baseline, one week later and two years subsequently. Results for
at-home whitening showed a mean increase of six shade guide
units for both one week and two years successive to bleaching.
Rebound effect was 0.25 shade guide units over two years and
this was deemed statistically insignificant. The in-office bleaching indicated a 5.5 shade guide unit improvement for both one
week and two years after whitening. Rebound effect was 0.30
shade guide units and this too is considered statistically insignificant. Contrary to the common perception, the longevity of
results for in-office bleaching was up to par with the take-home
bleaching’s durability (Tay, et. al. 2012).
The difference between the results of the in-office bleaching’s six-month instability in Moghadam’s experiment and
the two-year durability in Tay’s experiment is a simple distinction. In Moghadam’s experiment only one session of 45
minutes was given to chairside bleaching patients. In Tay’s
experiment two such sessions were administered on each
patient. According to some experts, it is only after the second bleaching of in-office treatments that tooth color does
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change significantly (Al-Shethri, et. al, 2003). Thus, to equal
the long-term stability of at-home bleaching, two sessions of
chairside bleaching are required.

Conclusion
Although tooth whitening doesn’t create a higher probability of
carcinogenicity or genotoxicity, it is far from innocuous. Almost
50% of patients experience some form of tooth sensitivity for
the first month of treatment. Oral mucosal and gingival irritation are very common as a result of ill-fitting trays and the
subsequent leakage of peroxides. Tooth integrity is affected as
a result of urea degrading the enamel matrix, and hydrogen
bonds in matrix proteins becoming dissociated by the urea and
ammonium ions. Due to the redox reaction, there is often an
increase in the leakage of restorations, most notably amalgam.
Weakening of bond strength is a direct result of the oxygen
molecules causing a failure of resin to properly bond to dentin.
Cervical root resorption is more likely to occur following the
orthodontic treatment associated with bleaching. Finally, there
is even a psychological issue named bleachorexia that is caused
by a whitening obsession. With this excessive list of side effects
it is clear that such dangerous substances must be regulated to
some degree and not available over-the-counter as they currently are. It is a travesty that such harmful materials are accessible to minors and are not exclusively in adult’s hands.
Various methods have been mentioned throughout the course
of this work to help mitigate a number of the by-products of
bleaching. While long-term rebound effect is unchanged by the
form of bleaching (when power bleaching is done twice), the
form of peroxide does matter. CP is said to yield longer-lasting
results due to its slower and more stable release of oxygen
species. Laser heating doesn’t speed up the reaction rate and
only serves to increase tooth sensitivity and speed up enamel
erosion. Fluoride and potassium nitrate don’t mitigate tooth
sensitivity but decreasing the application time of bleach certainly can. In fact, usage of a novel electric powered bleach
showed that decreasing wearing time can also cause a decrease
in gingival and oral mucosal irritations.The best remineralization
agent is calcium phosphate and should be taken in conjunction
with whitening. Catalase helps remove residual oxygen species
and should also be taken while commencing bleaching. The catalase should help relieve some of the woes of weakened bond
strength and the leakage of amalgam restorations. Cervical root
resorption can be diminished when a lower concentration of
peroxide is used and laser treatment is avoided. Thus, the properly informed whitening patient can be shielded from some of
the by-products of bleaching if he/she is proactive in treating
them. However, the issues arise for patients who are not properly informed or are negligent in providing the proper care for
their teeth.

It is clear from the abundance of research provided in this
report, that while cheaper, whitening isn’t a safe alternative to
laminated veneers or crowns. Thus, those who can afford to do
so, should choose the more conventional route when looking to
make cosmetic repairs on teeth. The future of whitening seems
to lie in the ability of companies to create a cheaper system
that allows for shorter exposure time to peroxide. The Pearl
Brilliant White Ionic Teeth Whitening System which contains
9% HP and uses electrodes in the wall of trays to deliver an
electrical current, is definitely a positive start for making this
a reality. Ultimately this system needs to be tested more to
confirm that it really is effective, while decreasing the side effects. Furthermore, the hefty price tag doesn’t allow this brilliant technology to gain enough popularity.A cheaper alternative
must be created to allow all members of the populace to have
access to this newest advance in the field. Only when this comes
to fruition will whitening truly be a safe and cheaper alternative
to laminated veneers and crowns.
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Abstract
Many men experiencing hair loss often wonder: is there a cure? Can I get my hair regrown? This thesis addresses
these very issues, the anatomy of the pilosebaceous hair, the hair growth cycle, and the suggested causes of male male
pattern hair loss are examined. Finally, the Various drugs that have been suggested to reduce hair loss and even cause
hair regrowth are reviewed. After examining the various treatments, it can be concluded with reasonable certainty that
hair loss can be halted and often reversed by using FDA approved drugs finasteride and minoxidil. Other drugs such as
ketoconazole and dutasteride have also demonstrated effectiveness in treating hair loss, however no FDA approval has
yet to be issued, either due to lack of evidence demonstrating their efficacy, or due to concerns of negative side effects.
The major disadvantage of using hair loss drugs is that one must continuously use the drug to maintain its benefits. It
is therefore plausible to conclude that as of yet hair loss cannot be cured, rather its progression can be prevented as
long as one uses the drug.
Introduction
Hair loss, known medically as alopecia, is a very common phenomenon, affecting both males and females. Demographically,
it effects about half of males and a quarter of females by the
age of 50 (Vary , 2015) This makes it very likely we will be
affected by hair loss during our lifetime. Hair loss can manifest
itself in various forms, the most common being male pattern
baldness defined as the progressive loss of hair beginning in
some cases at puberty, and proceeding throughout adulthood
(Berman, 2015). Another form of hair loss is alopecia areata,
an autoimmune condition where the body mistakenly attacks
healthy hair follicles. Alopecia areata effects men, women and
children with hair loss occurring in the form of patches on the
scalp, and in extreme forms, a complete loss of hair (subtype
known as alopecia totalis) (Moskowitz , 2014). True, hair loss
is not a disease in a sense that it effects our physical wellbeing,
however, it is a condition which may cause severe psychological distress, particularly anxiety and depression upon the
affected individuals (Hunt, McHale, 2005). These psychological
effects, combined with the widespread prevalence of hair loss
make it imperative for us to find a cure. In this paper, the primary focus will be on exploring whether or not hair loss can
be prevented, and if hair lost hair can be regrown. Since hair
loss due to hormonal causes is the most prevalent and studied
form, it will be the focus of this paper.

Anatomy of the Hair Follicle
To get a better understanding of the mechanisms responsible
for hair loss, it is vital we discuss how hair growth occurs in
a healthy individual. In mammals, formation of the hair follicle
takes place during fetal skin development. Cells which form
the hair follicle, sebaceous and apocrine glands (responsible for
producing oils and sweat) are all derived from ectodermal stem
cells. In contrast, cells derived from mesodermal stem cells will
develop into the follicular dermal papilla and the connective
tissue sheath, while the neural crest derived melanocyte progenitors produce the pigmentary cells, which are responsible
for the coloring of hair (Fuchs, 2008).

Although hair follicles vary in shape and size, they all have the
same basic structure.The base of the follicle known as the papilla, is primarily composed of connective tissue and a capillary
loop which supplies nutrients to the hair follicle. Cell division at
the papilla is very rare (Pawilna, Ross , & Kaye, 2003).
Superficial to the papilla, lies the hair matrix, the site of hair
formation. In mammals the matrix contains trichocytes, the
cells responsible for hair production. These epithelial cells
produce modified keratin proteins, which contain ample
amounts of the amino acid cysteine. Cysteine has a reactive
sulfhydryl group which creates both inter and intra-chain
linkage within a protein structure, thereby giving hair high
tensile strength, and flexibility (Langbein & Schweizer, 2005).
Also, contained within the matrix are scattered melanocytes.
Just superficial to the matrix, lies the root sheath. The root
sheath is further subdivided into the inner and outer root
sheath. The inner sheath contains three different layers, a cuticle layer, Huxley, and Henle’s layer. The outer layer contains
the bulge, a stem cell rich area which supplies the entire
follicle with new stem cells. These stem cells are vital in the
healing process of an epidermal wound. Also, contained in
the outer sheath is the sebaceous gland, responsible for hair
lubrication. In the uppermost region of the outer sheath are
the attachment sites of the arrector pili, smooth muscles that
serve to help the hair maintain a vertical position (Ma & Yang,
2004). The entire unit consisting of the hair, hair follicle, pili
muscles and sebaceous gland is referred to as the pilosebaceous unit (PSU).

Hair Growth Cycle
There are three phases of hair growth, the anagen, catagen, and
telogen. The anagen phase is what is known as the growth phase.
During this stage the cells in the root divide rapidly.After dividing,
the cells produce a new hair that pushes the old hair out of the
shaft. At this time, the hair grows approximately 1cm every 28
days. The anagen phase is active for about 2-6 years.
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Individuals who have trouble growing their hair to a proper
length might have a short anagen phase, whereby their hair falls
out to a renewed anagen phase. In contrast, individuals who have
the ability to grow their hair exceedingly long are likely have a
growth phase lasting very long. It should be noted that auxiliary
hair such as that of the eyebrows, eyelashes and arms have a very
short growth phase, lasting 30-40 days. This is why we don’t have
eyelashes that are more than a few millimeters in length.
The catagen phase is a transitional stage, which lasts from two
to three weeks. At any given time about 3% of all hair are in this
stage. During the catagen stage, hair growth stops, and the outer
root sheath shrinks due to its detachment from the nutrient
rich capillaries. At this point, a hard, club begins to form at the
base of the hair, which is composed of hard keratinized tissue.
This club holds the hair in place for as long as three months.
The telogen phase is the resting phase and usually last for about
100 days on the scalp and longer for the hair of the eyebrow,
eyelash, arm and leg. During this phase the hair follicle is completely inactive, and the club becomes more solidified. If one
pulls out a hair at this stage, a hard, dry and solid root will be
visible. In a normal individual, about 25-100 telogen hairs shed
each day (Elzouki, et al. ,2012). People with androgenetic alopecia don’t have regrowth occurring at the same rate. Typically,
the hair loss begins above the temples and vertex of the scalp,
and as it progresses, a rim of hair remains at the side and the
back of the scalp.

Causes of Male Pattern Baldness
Androgens and their role in hair loss
Androgens (the hormones responsible for the characteristic
male appearance) play an important role in some, but not all
hair growth. During puberty, the body produces significantly
greater amounts of androgens to stimulate male development.
One of the more noticeable effects androgens have is on the pilosebaceous units in the pubis, axilla (armpit), and lower face. In
these regions, the hair goes from a fine, straight and almost colorless appearance, to a darker, thicker and curlier appearance.
Additionally, in the areas of the upper face and trunk, the pilosebaceous units respond to these same androgens, by drastically
increasing the size of the sebaceous gland, thereby increasing
the amounts of oils they produce (Alonso & Rosenfeld, 2003).
In the male body, the major bioavailable form of androgens is
testosterone. Testosterone can also be converted to a similar
compound know as dihydrotestosterone (DHT) by the enzyme
5α−reductase, which reduces the 4,5 double bond. DHT has a
significantly greater binding affinity and lower dissociation constant with the androgen receptor when compared to testosterone, hence DHT is a lot more potent. In men, approximately 5%
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of all testosterone molecules get converted by 5α−reductase
into DHT (French, et al., 1990).
The importance of DHT in males is clearly demonstrated in
individuals who have a deficiency in the 5α−reductase. Such individuals display phenotypical pseudohermaphroditism, a condition where the male genitalia and prostate are underdeveloped,
even though they have a genetic makeup of a male (ImperatoMcGinleyet al., 1979).
The androgen receptor is a 110kD protein with a ligand bonding domain, a DNA binding domain and two activation function
regions that confer transcriptional regulatory activity. When a
ligand binds to the androgen receptor in the cytoplasm, it exposes the nuclear localization signal. This allows it to dimerize
with another androgen receptor and then be transported to
the nucleolus. In the nucleus, the androgen receptor complex
binds to a specific region of DNA known as the hormone
response element, where it either up-regulates or down-regulates translation of specific genes. The effects of mediation by
the androgen receptor complex are highly variable (Alonso &
Rosenfeld, 2003).
It is widely believed that DHT is the major cause of baldness.
Paradoxically, individuals with a genetic predisposition to baldness
have an opposite response in some of their pilosebaceous units.
In such individuals, the units in the scalp revert from being thick
and darker in color, to being thin and lighter. However, the exact
mechanism as to how DHT causes baldness remains to be determined. Furthermore, we have yet to understand why DHT acts in
a paradoxical manner when affecting hair growth, creating baldness
in some areas while stimulating new hair growth in other areas.
Although no definitive theories exist, Ustuner (2013) has proposed that gravity might play a role in causing baldnesss. He seeks
to explain the unique pattern of manifestation in effected individuals by which is hair loss starts at the temples and the vertex of
the scalp and proceeds to other areas. Ustuner believes that the
weight of the facial tissue, which is supported by the scalp, causes
damage to the hair follicles after puberty. During youth, there is
sufficient fat tissue under the skin, which acts as a buffer to the
hair follicles, and protects them from scalp pressure. However,
this buffer gets diminished after puberty. The increase in DHT
levels causes the fat layer to becomes increasingly thinner, essentially losing its buffering ability. As a result, pressure in the hair
follicles increases causing follicular damage, eventually leading to
hair loss. He notes that women have a lower incidence of balding,
due to the effect estrogen has on maintaining the subcutaneous
fat, thereby preventing baldness until at least menopause (when
estrogen levels decrease) (Ustuner, 2013).
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Ustuner continues to say that resulting increase in pressure
weakens the follicle. To compensate for the increased pressure,
the follicle sequesters more DHT more testosterone to make
the hair follicle stronger. As a result, the subcutaneous fat layer
becomes even thinner, creating a vicious cycle. Ultimately, the
hair follicle becomes smaller and smaller, resulting in greater
amounts of hair loss. According to this theory, areas in the
front of the scalp should have greater pressure, due to greater
amounts of soft tissues (the face) pulling down the scalp. This
is consistent with the actual pattern observed (Ustuner, 2013).
One should be skeptical about this theory for several reasons.
First, Ustuner does not explain the mechanism of how testosterone decreases the subcutaneous fat in the scalp. Even though
there is a correlation between an increase in testosterone and
its derivatives and a decrease in subcutaneous scalp fat following puberty, it is not proof of causation. Additionally, Ustuner
does not address why or how testosterone causes an increase
in hair growth in axillary areas (paradoxical effect of DHT).

Prostaglandin D2 and their suspected role in
Hair Loss
Recently, there has been a new hypothesis as to what causes baldness. Researchers have found that individuals with
androgenetic alopecia have elevated levels of prostaglandin
D2 (PGD2) in areas of the scalp that are balding, while not
having elevated PGD2 levels in haired areas of the scalp in
the same individual. They note that in normal individuals,
PGD2 is elevated in the catagen (regression) phase. This
alludes to PGD2 having an inhibitory effect on hair, as the
catagen phase is the transitional stage where the hair begins
the process of falling out (Garza, et al., 2012). Additionally,
when researchers targeted prostaglandin synthase (enzyme
responsible for prostaglandin synthesis) in transgenic mice,
the mice displayed symptoms characteristic of androgenetic
alopecia due the increased synthesis of PGD2.

Genetic Factors
Many different genes have been suspected to play a role in hair
loss. Thus far, most genetic studies investigating genetic causes
have implicated the androgen receptor (AR) gene.This gene lies
on the X chromosome, and its biological identifier is Xq11-12
(Ellis , et al., 2001). This is very intriguing, since as we have mentioned above, the most widely accepted cause of male pattern
baldness is increased DHT levels. It would therefore be expected that the 5α−reductase gene be responsible for hair loss.

Treatments:
Finasteride (5α−reductase inhibitor)
In accordance with the theory that DHT is responsible for male
pattern baldness, a 5α−reductase inhibitor should reduce male

pattern baldness. Indeed, finasteride, a 5α−reductase inhibitor, has
been one of only two FDA approved drugs used to treat hair loss.
The recommended dosage for male pattern hair loss treatment is
1 mg/day taken orally. During trials conducted to determine the
efficacy of finasteride in treating male pattern baldness, a placebo controlled study was conducted with 42 healthy participants.
The trial demonstrated that administration of finasteride from
0.4 to 100 mg/day for up to 2 weeks significantly reduced the
mean serum DHT from a baseline level. The reduction reached a
maximum at the 1mg/day dosage. However, the study also found
that 14 days after drug withdrawal, DHT returned to baseline
levels. (Gormley, et al., 1990). In another study, individuals who
were taking 1mg/day finasteride had a mean reduction in DHT of
68.4% versus the placebo (Kaufman , et al., 1998).
In the phase III placebo-controlled studies, the effects of finasteride on hair regrowth was assessed. Three studies were conducted in this phase; all were randomized, double-blinded and
placebo controlled, and included 1879 male patients ages 18-41
years. All the individuals reported active shedding of hair at least
3 years prior to volunteering for the study. Hair loss among subjects ranged from mild to moderate. After categorically classifying subject’s hair loss based on severity, they were given either a
placebo or 1mg/day finasteride for 1 year. To detect whether or
not finasteride increased hair growth, a baseline hair count was
obtained before and after treatment, using macro-photographs
of a 5.1cm2 area of the leading edge of the vertex with hair loss.
After analyzing these photographs, finasteride was found to
cause significant progressive increase in hair counts in all areas
of the scalp studied (vertex, mid and frontal) during 12 months
of treatment. There was an 11% increase in hair count in subjects taking finasteride, compared to a 2.7% reduction in hair
count during the same 12-month period in placebo subjects.
Subjects taking finasteride for an additional year maintained
their hair count, while those on the placebo continued to lose
hair. After the 2-year period, 83% of those taking finasteride had
no further hair loss, compared to only 28% of those taking the
placebo. (Waldstreicher, et al., 1997).
Overall, tolerability was the same for both the placebo and finasteride receiving groups. The only difference was in sexual
function disorders which were reported in a higher percentage
in the group receiving finasteride. It should be noted that although there was a difference between both groups, the difference was relatively small, 3.8% in the placebo group and 2.1%
in the group receiving finasteride. Additionally, of the subjects
reporting sexual disorders during therapy, many cases were
resolved even though they continued taking finasteride. All
subjects who withdrew from the trial due to sexual disorders
reported that the problems were resolved after discontinuing
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the drug (Waldstreicher, et al., 1997). Based on these studies, it
appears that finasteride does indeed reduce hair loss in most
men. And since finasteride causes hair regrowth by altering
DHT levels, it supports the DHT theory of baldness.
More research has to be carried out to determine whether
there is a link between male breast cancer and the use of finasteride, as has been suggested by the UK Medicines and
Healthcare Products Regulatory Agency. They have suggested
that male breast cancer might be linked to the decrease in the
ratio of testosterone to estrogen when taking finasteride. For
individuals using finasteride to treat hair loss, this suggestion
should be taken with a bit of skepticism, as a majority of cases
of male breast cancer was found in males taking the 5mg/day
dose as a form of treatment for benign prostatic hyperplasia. In
contrast, only a small percentage of prostate cancer was reported in individuals taking the 1mg/day dose suggested for hair loss
treatment (Shenoy & Prabhakar, 2010). However, as one must
continue using the drug to prevent further loss of hair, there is a
need for long term studies of possible side effects.
It should also be noted that non-Caucasian participants appeared to have less regrowth of hair compared to Caucasians.
However, one has to be cautious in interpreting this, since only
a small portion of the study subjects were non-Caucasian. To
definitively state that non-Caucasians experienced less hair regrowth, future studies conducted must include a representative
number of non-Caucasian subjects.

Dutasteride
Similar to finasteride, dutasteride is also a 5α−reductase inhibitor,
however, dutasteride inhibits not only type II, but also type I forms
of 5α−reductase. Scientists don’t exactly know the effect type I
5α−reductase inhibitor has on hair loss, since no deficiency has
been found for it. However, evidence suggests that dutasteride is
three times more potent than finasteride in inhibiting type II, and
more than 100 times more potent in type I enzyme. (Clark , et al.,
2004). This would suggest that dutasteride would have a greater
ability preventing hair loss, and promoting hair regrowth. Indeed,
dutasteride has been found to decrease serum levels of DHT
by more than 90% when compared to only 70% in finasteride.
(Dallob, et al., 1994).
In 2002, the FDA approved dutasteride as a treatment for benign
prostatic hyperplasia. Phase trials were also conducted on its use
as a treatment for male pattern baldness. During the phase II
trails, researchers found increased hair growth on the scalp. They
also found that a 2.5mg dosage of dutasteride was more effective
than a 5mg dosage of finasteride (Olsen , et al., 2006). However,
the phase III trials were put on hold due to concerns of side
effects. For this reason, one should be hesitant in using this drug.
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Minoxidil (Vasodilator)
Minoxidil, the second of only two drugs the FDA approved for
treating hair loss, was initially developed as a treatment for ulcers. When minoxidil was applied to dogs during the trail phase,
the ulcers did not improve, however, minoxidil was found to be
a strong vasodilator. As a result, the FDA approved minoxidil
tablets as a treatment for high blood pressure in 1979 (Conrad
, 2008). Initially, when studies on the effectiveness of minoxidil
as a vasodilator in humans were conducted, researchers found
unexpected hair growth. That is when it occurred to researchers that minoxidil might be an effective treatment for hair loss
(Gilmore, et al., 1970)
Although the mechanism of minoxidil’s ability to cause hair
growth is poorly understood, some theories have been suggested. Minoxidil might increase hair growth by either shortening
telogen or prolonging the anagen phase. Others propose that
minoxidil is a potassium channel opener. When the potassium
channel opens, it causes a hyperpolarization in cell membranes,
this widens the blood vessels surrounding the hair follicle,
thereby allowing more oxygen and nutrients into the follicle
(Goren, et al., 2015).
In the 1980s, studies reported that a 2% topical solution of minoxidil reduced baldness in about 50% of patients. Although the
study found that few mature terminal hairs were regrown, the
number of fine, non-pigmented villus hairs were reduced. These
studies acknowledged that the ideal candidates for minoxidil
therapy were those who had been bald for less than five years,
and whose baldness was less than 10cm in diameter and located
on the vertex.They found that minoxidil was not useful for frontal hair loss. Additionally, patients who discontinued treatment
showed a rapid loss of the newly regrown hair. After 3 months
of discontinuing therapy, their hair count was below baseline
levels (Savin , 1987).
After getting approved by the FDA as a treatment for hair loss
in men, minoxidil became available under the name Rogaine,
and was obtainable only by prescription. In 1996, Rogaine was
approved for over-the-counter sale, and for the production of
generic versions. Eventually a 5% topical solution was approved
by the FDA (Conrad , 2008).
Two studies have been conducted comparing the 2% versus the
5% solution. One of the studies measured hair mass before and
after a two-year period. This study found a greater hair mass in
individuals taking the 5% solution. The difference was most apparent early in the study. After taking the 5% solution for five
months, these individuals experienced a 55% increase in total hair
mass compared to the baseline, while those on the 2% solution
only experienced a 25% increase. After the end of the 2-year
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period, the 5% group had an increase of 25% over the baseline,
while those on the 2% had only 15% (Price, 1996). The second
study found that the 5% minoxidil produced a significantly greater
amount of non-villus hair by count as compared to the 2% group.
They also found that patients using the higher dosage had an increased likelihood of noticing more hair coverage on the scalp in
their assessment of treatment benefits (Trancik, 1998).
Generally, minoxidil is well tolerated, however, some side effects
have been reported. The most frequent side effect is itching, redness, or irritation of the scalp in the treated area. Unwanted hair
growth elsewhere on the body has also been reported. Some individuals reported exacerbation of hair loss after applying minoxidil.
Severe allergic reactions have also been reported including, rash,
hives, difficulty breathing, tightness in the chest, swelling of the
mouth, face, lips, or tongue, chest pain, dizziness, fainting, tachycardia, headache, sudden and unexplained weight gain, and swelling of
the hands and feet (Rogain Side Effects, 2015). Overall, it seems
safe to say that minoxidil is a somewhat effective treatment for
male pattern hair loss, however, compared to finasteride, it is less
effective but has the advantage of being a topical.

Ketoconazole (anti-fungal)
Ketoconazole, a common anti-fungal shampoo widely used in treating seborrheic dermatitis (dandruff), has also been suggested to
contain hair regrowth properties. Recently, a study demonstrated
that individuals applying a 2% solution of ketoconazole produced
comparable levels of hair growth when compared to those using 2%
minoxidil. Both groups achieved greater levels of hair growth compared to those using un-medicated shampoo (Pierard-Franchimont,
et al., 1998). Similar results were obtained when treating model
mice with androgenetic alopecia with 2% ketoconazole, when compared to the placebo group (Jiang, et al., 2005).
Why ketoconazole causes hair regrowth is not clearly understood. Some have suggested that ketoconazole plays a role in
local disruption of the DHT pathway. They have suggested that
when used in combination with finasteride, it may have a greater affect in reducing DHT levels compared to using finasteride
on its own. (Perez, 2004). Its effect on DHT has been used to
explain why some individuals using ketoconazole experience
gynecomastia (enlargement of the breasts) (Wolverton , 2002).
Clearly, it seems like ketoconazole has some hair regrowth abilities, however, there is a need for more studies to be carried
out to demonstrate how effective it is compared to placebo
and other treatments. Additionally, more research needs to
be done on the mechanism behind how it causes hair growth.
Finally, studies have to demonstrate whether or not using ketoconazole for an extended period of time is safe.

Low-level Light Therapy
Use of a ruby red laser (694nm) , resulted in increased hair
growth in mice who had their backs shaved (Mester, et al.,
1968). Although light therapy has been shown to effectively reduce inflammation, improve wound healing and reduce stroke
symptoms, the mechanism behind it is poorly understood. Some
have hypothesized that the light increases levels of ATP synthesis in the mitochondria.There has been evidence that there is an
increase in activity in complexes II and V in the electron transport chain (Oron , et al., 2007).
Many light therapies are marketed as treatments for hair loss.
Typically, these devices are brushes or combs that have a red
light shining out of the tips onto the scalp. Such devices are
available for purchase over the counter. So far only one such
device has been approved by the FDA as not being harmful,
but does attest to its ability to treat hair loss. Such approval is
sought after, as using certain wavelengths of light can be harmful.
Companies have capitalized on the little research showing hair
regrowth abilities and have produced light therapy devices for
consumers, despite the little research that has been conducted
to determine the safety and efficacy of it. As a consumer, one
must therefore be very skeptical of buying such light therapy
devices. More research must be done before anything definitive
can be said about using light therapy to treat hair loss.

Discussion
In light of research indicating that drugs can prevent further
progression of hair loss, we may effectively conclude that hair
loss can be treated. We cannot however conclude that hair loss
can be cured, for a cure implies a reversal of a problematic medical phenomenon. Hair loss as of yet cannot be cured because
the effectiveness of hair loss drugs is only for as long as they
are administered. To find a cure, a definitive theory explaining
the causative mechanisms behind hair loss is necessary. Once
we understand the mechanism behind hair loss, most certainly
a cure will follow.
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Abstract
Vitamin D deficiency, in an increasingly modernized world, is a major global health issue and so is major depressive disorder
(MDD) and its high fatality risk. Studies suggest that there may be a connection between the two. Several studies have
found a connection between low levels of vitamin D and higher rates of major depressive disorder, depressive symptoms
and suicidal ideation. Specifically, lower concentrations of vitamin D was seen in the subgroup of patients with suicidal
thoughts when comparing with non-suicidal depressed patients. A likely reason for this may be the well- researched role
vitamin D plays in regulation of inflammatory cytokine markers in the brain. Elevation of these proinflammatory cytokines
is shown to be a major contributing factor to depression and suicidality. Therefore, a lack of vitamin D contributes to an
increase in inflammation and thereby an increase in the risk of depression and suicide. Thus, increasing vitamin D levels
by supplementation or sun exposure, may decrease depressive symptoms. Because this research is recent, there are few
studies assessing the possible benefits and limitations of using vitamin D as a treatment method.
Introduction
Vitamin D₃ is a fat soluble vitamin, stored mainly in the liver
and adipose tissue. It is primarily obtained by the conversion of
cutaneous 7-dehydrocholesterol to previtamin D₃ by sunlight,
specifically Ultraviolet (UV) B radiation with a wavelength of
290–320 nanometers. Previtamin D₃ then spontaneously isomerizes to vitamin D₃, or cholecalciferol.Vitamin D3 is biologically
inert and must undergo two hydroxylation to be biologically
active. The first hydroxylation occurs in the liver, by 25-hydroxylase, converting vitamin D3 to calcidiol, or 25-hydroxyvitamin
D [25(OH)D]. The second hydroxylation occurs by 1α-hydroxylase, found primarily in the kidneys, although recent research
found this enzyme in many other tissues. The second hydroxylation converts the 25-hydroxyvitamin D to the biologically-useful calcitriol, or 1,25-dihydroxyvitamin D [1,25(OH)2D]
(Vitamin D: Fact, 2016).
Besides for obtaining vitamin D by sun exposure, vitamin D can be
obtained by food. However, very few foods in nature contain vitamin D.Therefore, a better way of obtaining vitamin D is from cholecalciferol-fortified foods or supplements (Vitamin D: Fact, 2016).
Serum concentration of 25-hydroxyvitamin D is the best indicator of vitamin D status, because it reflects vitamin D obtained
by sun exposure and ingestion. It also has a fairly long circulating
half-life of 15 days and its concentration is not affected by other
metabolites. However, it does not indicate how much vitamin
D is stored in body tissues. In contrast, 1,25-dihydroxyvitamin
D has a short circulating half-life of 15 hours and its levels are
closely regulated its own concentration and by hormones and
electrolytes like parathyroid hormone, calcium, and phosphate.
Additionally, levels of 1,25(OH)2D only decreases when vitamin
D deficiency is severe. Therefore, 25-hydroxyvitamin D levels
are used to assess sufficiency (Vitamin D: Fact, 2016).
There is considerable discussion of what serum concentrations
of 25-hydroxyvitamin D indicate vitamin D deficiency, adequacy
for bone health and optimal health overall. As of now, there
is no specific cut points established by a scientific consensus

process. However, the committee of the Institute of Medicine,
based on its review of data of vitamin D needs, have concluded
that there is a risk of vitamin D deficiency at serum 25(OH)
D levels of less than 30 nmol/L (<12 ng/mL). Additionally, some
people are potentially at risk for inadequacy at concentrations
ranging from 30-50 nmol/L (12–20 ng/mL). They stated that 50
nmol/L is the serum 25-hydroxyvitamin D level that is adequate
for 97.5% of the population. Only at concentrations of greater
than 125 nmol/L (>50 ng/mL) is there potential adverse effects
of overdose (Vitamin D: Fact, 2016).
Cutaneous vitamin D levels are mainly dependent on climate,
overall skin exposure, skin melanin content and age. Residing
in a climate closer to the equator results in more year-round
sun exposure and more vitamin D synthesis. Although surprisingly, geographic location does not consistently predict average
serum levels in a population. Opportunities exist to form vitamin D from exposure to sunlight during the spring, summer, and
fall months even in the far north or south, and it can be stored
in fat for periods of little sunlight. Darker skin absorbs less
sunlight and, therefore, more melanin reduces the production
of vitamin D. Perhaps, this characteristic may contribute to the
consistency in average serum levels of those near the equator
and those further away, because those who live near the equator generally have a darker skin tone that synthesis less vitamin
D than those farther away with a lighter skin tone. Vitamin
D synthesis may also decline with age because skin synthesis
declines (Johnson, 2016).
Major depressive disorder (MDD) is a common disorder and
leading source of disability worldwide. It is a major global health
problem, with more than 50% of all suicides contributed to
clinical depression (Bay-Richter, Janelidze, Hallberg, & Brundin,
2011). Classically, the prevailing hypothesis on the cause of major
depression was a deficiency of monoamines, a class of neurotransmitters and neuromodulators, like serotonin. Therefore,
current available medications for major depression mainly target monoamine pathways. However, research has not shown
a consistent relationship between serotonin and depression
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(Gardner & Boles, 2011). And although relatively affective, 30%
of depressed patients do not achieve remission even with multiple, monoamine-regulating, treatment trials (Miller, Maletic, &
Raison, 2009). Additionally, 50% to 80% of all patients treated for
major depression will experience relapse (Bay-Richter, Janelidze,
Hallberg, & Brundin, 2011). These monoamine regulating drugs
can have serious side effects, which include worsening of depressive symptoms and suicidal ideation. Therefore, it is imperative
to find novel pathways involved in depression and consequently
more effective treatments for those suffering.
Historically, in literature, and in art and religion, happiness and
positivity have been associated with summertime, daylight, and
sunny and open landscapes. In contrast, fear and gloom have
been associated with winter, night and dark and polluted urbanscapes. At the height of early industrialism, in such polluted
cities, rickets, which is extreme vitamin D deficiency was first
recognized. Among the symptoms of rickets, mental symptoms
were also described and Florence Nightingale stated: “People
say the effect [of sunlight] is on the mind. So it is, but the enlightened physician tells us it is on the body too.” (Humble, 2010)
Mental disturbances caused by reduced sun exposure seemed
self-evident that no one seemed to note the mental health benefits of rickets treatment, which was primarily to increase sun
exposure. Because of the awareness of adequate sun exposure,
rickets disappeared as a public health problem. Nevertheless,
from the 1950s and on, with increasing modernization, the time
spent indoors increased for all ages worldwide. Additionally,
since the 1980s, the public is being warned about the dangers of
UV rays and its contribution to malignant melanoma. Therefore,
people have developed concern of excessive sun exposure and
are applying sunscreen and covering up more when they are
outside. At the same time, as these changes are taking place, the
incidence of depression, especially in children and adolescents,
has become more and more prevalent in the United State and
Europe (Humble, 2010). Additionally, it is a long, well-known and
perplexing observation that death by suicide is highest in the
springtime for people living in temperate climates, which is also
when vitamin D levels are the lowest in the population (Umhau
et al., 2013). Is there a correlation between these two observed
phenomena of depression and vitamin D synthesis, and what
would be there relationship?

Materials and Methods
Materials for this comprehensive review were obtained from
Touro College’s online library, PubMed, PubMed central,
Proquest, National Institute of Health website and Merck
Manual website. The material consisted of clinical research papers, peer-reviewed journal articles and clinician-directed informational reports. The material was reviewed, critically analyzed
and compiled to answer research questions.
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Discussion
Vitamin D and Inflammation:
Classically, Vitamin D is associated with bone health. Vitamin
D aids calcium absorption in the gut and maintains adequate
serum calcium and phosphate levels for normal mineralization
of bone (Vitamin D: Fact, 2016). It is also needed by osteoblasts
and osteoclasts bone growth and repair. Vitamin D deficiency
was mostly associated with rickets and osteomalacia at extreme
deficiency. Rickets is a disease in children where vitamin D deficiency leads to bones not being able to properly mineralize,
which results in soft bones and skeletal deformities. In adults,
vitamin D deficiency can lead to osteomalacia, or weak bones
(Vitamin D: Fact, 2016).
Recently, many other functions of vitamin D have been discovered and vitamin D receptors have been found in many tissues.
One of the most significant findings is the function of vitamin
D in immune system modulation. There is an increasing number of studies that demonstrate the importance of vitamin D in
the reduction of inflammation and the association of vitamin D
deficiency with increased inflammation (Peterson & Heffernan,
2008). Most of the known effects of vitamin D are facilitated
through vitamin D receptors (VDR). These vitamin D receptors
have been found extensively in immune system cells, specifically
in T lymphocytes and macrophages. Furthermore, macrophages
have been found to express 1α-hydroxylase, which is the enzyme that is responsible for the final step in synthesizing biologically-active vitamin D. Additionally, they have been found to
express 24-hydroxylase, the major degrading enzyme of vitamin D. This means that these cells can regulate the production
and secretion of vitamin D in their own vicinity (Peterson &
Heffernan, 2008).
Additional evidence now suggests that vitamin D insufficiency
may play a role in immune system dysfunction and low 25-hydroxyvitamin D serum levels are shown to be associated with
autoimmune diseases like multiple sclerosis, Type 1 diabetes
and rheumatoid arthritis. Recently, this insufficiency has been
correlated to macrophage dysfunction, such as impaired chemotaxis, phagocytosis and increased production of proinflammatory cytokines. Proinflammatory cytokines are produced
predominantly by activated macrophages. These cytokines take
part in cell signaling and up-regulation of inflammatory reactions. Vitamin D has been shown to reduce inflammation by
down-regulating the expression of monocyte toll-like receptors
(TLRs), which are known to activate inflammation and aggravate
autoimmune disease and sepsis (Peterson & Heffernan, 2008).
In light of the research, Peterson and Heffernan (2008) sought
to investigate the relationship between serum vitamin D status
(25(OH)D) and inflammatory markers in 69 healthy women.
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They recruited people with high UVB and minimal UVB exposure, as assessed by a screening questionnaire, to obtain a
range of serum levels. Volunteers were excluded for multiple
factors, including, if they took a vitamin D supplement, had a
current or previous medical condition or took medication affected immune function. The results revealed that serum TNFα, a proinflammatory cytokine, was significantly lower in the
group of women with high UVB exposure, after controlling for
multiple factors. However, there was no significant statistical
difference shown between the two groups in regards to other
proinflammatory cytokines, like IL-10, CRP, IL-6. Serum TNF-α
concentrations are increased in several diseases like multiple
sclerosis, inflammatory bowel disease, rheumatoid arthritis,
heart disease and osteoporosis, and lowering TNF-α concentrations through sufficient vitamin D levels may improve disease
outcomes. The main limitation of this study was the small sample size. Additionally, women who frequently tan are characteristically different from non-tanners and may engage in behaviors
that can affect the study outcomes. This study shows a negative
correlation between vitamin D status and TNF-α concentration
in healthy individuals. More research is needed to determine if
vitamin D can be used as a therapy in inflammatory diseases.
A case where vitamin D deficiency seems to contribute to
immune modulation, is in diabetic foot infection. Diabetic foot
infection is a reflection of a diabetic patient’s altered immune
system. In an infectious state, pro-inflammatory cytokines are
released in the body, such as IL-1β, IL-6, interferon-γ (IFN-γ)
and TNF-α, or chemokines such as IL-8. To counteract these
factors and avoid a hyper-inflammatory state, the body releases
anti-inflammatory cytokines such as IL-10. In a diabetic patient,
several factors lead to decreased wound-healing abilities, including impaired cytokine production. This abnormal wound healing
is attributed to immune dysregulation because of vitamin D deficiency in addition to hyperglycemia (Timms et al., 2002).

correlated with IL-1β as well as IL-6 levels and moderately negatively correlated with TNF-α levels, but not correlated with
IFN-γ levels. In this study, diabetic patients with foot infection
serve as a model for immune system abnormality resulting from
hyperglycemia and infection, with increased pro-inflammatory cytokine concentrations. The results of the present study
showed that elevated cytokine responses occur as a factor of
vitamin D deficiency in patients with diabetic foot infection.
Vitamin D deficiency, particularly when serum levels were very
low, intensified inflammatory cytokine release in patients with
diabetic foot infection.
Because of this increasingly strong correlation and possibly
causation of vitamin D deficiency to amplified inflammation, and
to try to prove causation more visibly, Hoe et al. (2016) recently
performed a study ex vivo. They studied the effects of 1,25-dihydroxyvitamin D, the active metabolite of vitamin D, on peripheral blood mononuclear cells (PBMCs) and purified immune
cell subsets isolated from healthy patients, when they exposed
those cells to stimulation with Gram-positive heat-killed pneumococcal serotype 19F (HK19F) and Gram-negative Escherichia
Coli serotype 055:B5 derived lipopolysaccharide (LPS) bacterial
ligands. They found that in 1,25(OH)2D3 pretreated samples
compared to non-treated, for both ligands, 1,25(OH)2D3
suppressed proinflammatory cytokines, like TNF-α, IFN-γ and
IL-1β, and chemokine IL-8, in peripheral blood mononuclear
cells (PBMCs) and TNF-α and IL-1β in CD14+ Monocytes.
Anti-inflammatory IL-10 was increased in HK19F-stimulated
monocytes. Additionally, when comparing the blood samples of
the healthy subjects, they found that levels of HK19F-specific
IFN-γ were significantly higher in vitamin D-insufficient adults
(<50 nmol/L) compared to sufficient adults (>50 nmol/L). This
study suggests Vitamin D causes modulation of inflammation of
the immune system response which is critical for host defense.

Inflammation and Depression
Another study, investigating the relationship between vitamin D
deficiency and increased inflammatory cytokines, was done by
Timms et al. (2002), by evaluating the influence of vitamin D on
the concentrations of IL-1β, TNF-α, IFN-γ and IL-6 in patients
with diabetic foot infection. Subjects were 112 diabetic patients
with diabetic foot infection while 107 diabetic patients with no
evidence of infection served as controls, additionally, 40 healthy
subjects were included in the study. Vitamin D deficiency, a
serum 25-hydroxyvitamin D < 50 nmol/l, was found in 71.4% of
the diabetic foot infection patients, 61.6% of the diabetic controls and 48.6% of the healthy volunteers, but severe deficiency,
with a serum 25-hydroxyvitamin D of < 25 nmol/L, was mostly
found in diabetic foot infection patients than in diabetic controls
and healthy volunteers. In both patients and controls, 25-hydroxyvitamin D levels was found to be significantly negatively

The progression and complications of many diseases and disorders, like cardiovascular disease, diabetes and cancer, are being
increasingly attributed to inflammatory dysfunction. Additionally,
this theory of disorder is being extended to neuropsychiatric
disorders, with mounting evidence suggesting that defective alterations of the immune system seen in psychiatric patients may
contribute to their disorders, and with mounting evidence of
inflammation contributing to major depressive disorder. Patients
with major depression have been found to exhibit elevated
proinflammatory cytokines, like IL-1β, TNF-α and IL-6, which
have been shown to interact with areas known to be involved
in depression, including neurotransmitter metabolism, neuroendocrine function, and neural plasticity. Furthermore, psychosocial
stress, a common precipitator to major depression, has been
shown to have the ability to stimulate inflammation, owing to
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the fact that it activates sympathetic nervous system pathways.
Moreover, depressed patients with increased inflammatory markers have been found to have greater resistance to treatments, and
in studies, antidepressant drugs have been found to be correlated
with decreased inflammation (Miller, Maletic, & Raison, 2009).
Recurrent coinciding comorbidities and drug efficacies suggest
that depression is part of a group of related conditions, all of
which are associated with inflammation dysfunction. They are
sometimes referred to as the “affective spectrum disorders”,
and include migraine, irritable bowel syndrome, chronic fatigue
syndrome, fibromyalgia and generalized anxiety disorder, among
many others. Based on current knowledge, these diseases, including depression, seem to be a function of three connected
abnormalities: monoamine dysfunction, increased inflammation,
and mitochondrial disorder (Gardner & Boles, 2011)
To test if inflammation may correlate or even cause major
depression, several studies performed on animals who have
been injected with the endotoxin lipopolysaccharide (LPS) to
generate inflammation, showed that these subjects subsequently developed depressive-like symptoms. In clinical practice, it
has been seen that patients treated with interferons and interleukins, to promote inflammation against certain forms of
cancer and viral infections, like Hepatitis C, frequently develop
depression. To further investigate this relationship Bay-Richter,
Janelidze, Hallberg, & Brundin (2011) induced inflammation in
rats by administering Escherichia coli serotype 055:B5 lipopolysaccharides (LPS) intraperitoneally for four days.They measured
their levels of cytokine markers at the state of sickness and
then at the state of depressive-like behaviors. They also measured mRNA transcription of cytokines in specific brain areas
related to depression as well as levels of cytokines in serum
and cerebral spinal fluid. Cyclooxygenase enzymes, inflammatory stimulating COX-1 and COX-2, have previously been shown
to correlate with depressive-like behavior, thus, it is suggested
that proinflammatory cytokines can induce depressive-like behavior by activating prostaglandins, and inflammation, through
the cyclooxygenase enzyme. Therefore, they also measured cyclooxygenase enzymes in the brain of the mice. This is the first
published study examining the relationship between proinflammatory cytokines and cyclooxygenase enzymes in the blood,
CSF and depression-related brain areas and their capacity to
cause sickness and behavioral changes.
In this study, they found that there was a clear distinction between the phase of sickness, which is 2 hours after injection
of lipopolysaccharides, and the phase of depressive symptoms,
which is 24 hours after injection, for cytokines, cyclooxygenase
enzymes and mRNA transcription of cytokines. During the sickness behavior, IL-1β and IL-6 were elevated in the blood, IL-1β
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was elevated in the CSF, and TNF-α was elevated in the striatum
of the brain. Also, IL-1β mRNA transcript was increased in the
frontal cortex and hippocampus. Curiously, in this phase, IL-6
and COX enzymes were decreased in the hippocampus. After
24 hours of injection, the rats did not show signs of sickness but
began displaying depressive symptoms in the forced swim test.
This test is used on rodents to evaluate depression and is used
when assessing antidepressant drugs and therapies. During the
depressive phase of behaviors, the transcription of TNF-α mRNA,
IL-6 levels and COX enzymes levels shifted back to normal levels in all brain areas, but the cytokine IL-1β was still significantly
elevated in the frontal cortex and hippocampus and there was
an increase in the concentration of IL-1β in the cerebral spinal
fluid. This increase was only found in the CSF and not in blood
serum.This may explain why studies measuring the serum level of
cytokines in patients with major depressive disorder, did not find
any significant difference when comparing depression levels with
normal levels. In this study, they found that Lipopolysaccharideinduced depression is primarily associated with the increase of
IL-1β. This cytokine remains elevated in the brain even after the
initial inflammatory phase and continues to contribute to a depressive-like phenotype in the rats.This suggests that a short term
immune inflammatory response may lead to long term changes
in transcription of inflammatory markers and that transcription
levels may even increase after the initial immune response (BayRichter, Janelidze, Hallberg, & Brundin, 2011).
Although, elevated inflammatory markers are found in many patients with psychiatric disorders, there is no clear differentiation
or explanation why some patients have elevated cytokine concentrations and some do not. Perhaps, there is a specific subgroup
of patients that will display signs of inflammation. To advance and
investigate if the phenomenon of increase cytokine concentrations in psychiatric patients is specific to a subgroup of depressed
patients, Janelidze, Mattei, Westrin, Traskman-Bendz, & Brundin
(2011) designed a study dividing their subjects by non-suicidal
and suicidal patients. In this study, they compared plasma cytokine
levels in 47 treated and untreated patients with depression that
had attempted suicide, 17 untreated patients with a diagnosis of
major depressive disorder that did not have any suicidal ideation
and 16 somatically healthy controls with no current or previous
history of neuropsychiatric disorder. They found statistically significant elevated plasma concentration of proinflammatory cytokines IL-6 and TNF-α and decreased plasma concentrations of
anti-inflammatory cytokine IL-2 in the suicide attempters, compared to the non-suicidal depressed patients and healthy controls. Elevated cytokines were seen in suicidal patients, regardless
if they had received treatment or not. Although a limitation of
this study is that the duration of the disorder and duration of
treatment were not considered. Interestingly, these patients with
elevated cytokines did not show any signs of systemic or local
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infection or inflammation.This suggests that inflammation seen in
depressed patients is specific to those that are suicidal, although
it may also be specific to different subgroups of depression too.
Furthermore, it suggests that these elevations are associated
and may contribute to suicidal ideation. Because this study used
patients with untreated major depression, one group it did not
control for specifically, is patients with treatment-resistant depression, and therefore, perhaps increased cytokines is seen in all
patients with treatment-resistant depression, not only those who
have attempted suicide. Evidence of abnormal cytokine elevations
were observed in suicidal patients, compared to non-suicidal
depressed patients and healthy controls, and may contribute to
suicidality.

fluctuation and its neuropsychiatric effects. In summation,
Lindqvist et al. found that inflammatory cytokines were directly
correlated with the presence and extent of suicidal thought and
behavior and the degree of violence of a suicide attempt.

As the mechanism that causes depression and suicide is located in the brain, it is important to understand if these systemic
inflammatory changes relate to changes in the central nervous
system. Lindqvist et al. (2009) tested the proinflammatory cytokine profile of the cerebral spinal fluid (CSF) of 63 institutionalized patients who had recently attempted suicide compared to healthy controls. They also evaluated if there was a
difference in the cytokine profile of patients who had attempt a
violent method of suicide compared to the patients who used
a nonviolent method. The patients underwent a “wash-out”
period where they discontinued all antidepressant and antipsychotic medication until there was no trace of it in their blood.
Depressive symptoms were assessed using the MontgomeryÅsberg Depression Rating Scale (MADRS) and suicidal ideation
was assessed using the Suicide Assessment Scale (SUAS). They
found that the patients who had attempted suicide had higher
levels of cytokine IL-6 in their cerebral spinal fluid to healthy
patients, and the violent suicide attempters had the highest concentration of IL-6. They also found that CSF IL-6 had a positive
correlation with intensity of depressive symptoms in all suicidal patients. Additionally, they found that IL-6 levels correlated
positively with current suicidal ideation and suicidal symptoms,
as in patients expressing a “wish to die” and “preoccupation
with suicidal thoughts.” These results suggest that, as discussed
previously, IL-6 may have specific relevance to suicide. They did
not find any significant difference in proinflammatory cytokine
IL-1β, TNF-α, and IL-8 between the groups studied. Lindqvist et
al. then went further to try to determine a mechanism of how
these abnormalities may contribute to suicidality. They compared levels of cytokines with known biomarkers of depression
and suicide and found that both IL-6 and TNF-α was related to
increased levels of 5-HIAA, which is a metabolite of serotonin,
and HVA, which is a metabolite of dopamine, in the fluid of the
patients who attempted violent suicide methods. This suggests
that proinflammatory cytokines may modulate monoamines in
the central nervous system. Further, longitudinal studies would
be helpful in studying the effects of cytokine and monoamine

The presence of vitamin D receptors (VDR), in the central nervous system was first discovered in 1982 by Stumpf, Sar, Clark,
and DeLuca. And nowadays, there is significant evidence of vitamin D’s presence and actions on different parts of the brain
and nervous system functioning. There is increasing evidence
that the vitamin D receptor (VDR) mediates transcription of
more than 1,000 genes (Umhau et al., 2013). Calcitriol is known
to function in the regulation of neurotransmitters, specifically
dopamine, adrenaline, noradrenaline and acetylcholine, regulates
several neurotrophic factors of the central nervous system, by
enhancing nerve growth factor (NGF) and glial derived neurotrophic factor (GDNF), and assist with anti-oxidative properties
in the brain (Humble, 2010). Many of the effects that vitamin D
has on the brain, share pathways with factors, when abnormal,
are known to be associated with several neuropsychiatric disorders including major depressive disorder (Humble, 2010). Based
on this, inadequate levels of vitamin D may lead to changes in
the central nervous system that may interfere with brain function and contribute to mood disorders.

Vitamin D and Depression
As discussed previously, there is strong evidence that vitamin
D deficiency may be contribute and cause immune system dysfunction, including elevated inflammatory markers. And elevated
inflammatory markers may play a role in depression with suicidal ideation. Therefore, there are many that suggest that vitamin
D deficiency may be a contributing factor in those who suffer
from suicidal thoughts accompanying major depressive disorder.

As depression is underdiagnosed in non-institutionalized healthy
populations and subclinical depression and chronic low mood is
common in older adults, and is a factor in morbidity, mortality
and quality of life, one study seeking to clarify if vitamin D may be
associated with depression in healthy adults was done by Lee et
al. (2011). Lee et al. used baseline data from the European Male
Ageing Study (EMAS), a cohort study of male aging in Europe, to
determine whether concentrations of serum 25-hydroxyvitamin
D were associated with levels of depression in a large sample
size of 3151 subjects, well-characterized, community-dwelling
sample of middle-aged and older men with a mean age 60 ± 11.
Subjects were assessed on social issues, lifestyle behaviors, and
any related comorbidities, like heart conditions, pituitary disease, diabetes, and cancer. Depressive symptoms were assessed
using the Beck Depression Inventory-II (BDI-II). Their results
found that serum vitamin D concentrations were significantly
lower in men with depressive symptoms, scoring ≥14 on the
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BDI-II, 10 nmol/L decrease in 25-hydroxyvitamin D was associated with an average increase of 5.2% in the BDI-II score. Even
after adjusting for age, smoking, alcohol consumption, physical
activity, BMI, comorbidities and adverse life events, there was
still a significant difference in serum vitamin levels. Additional
adjustment for season did not change this inverse association.
Only 22 men (0.7%) reported taking vitamin D supplements and
exclusion of these men did not change the results. A major limitation of this study, is its difficulty in assessing causality or even
if vitamin D contributes to depression. It may be that vitamin D
insufficiency may just be a ‘risk marker’ of general poor health
and lifestyle. Depressive behaviors of decreased physical activity
and exposure to sunlight may by itself lead to lower vitamin D
levels. Lee et al. did attempt to adjust for this factor by assessing
if physical activity can contribute to low vitamin D levels but
this adjustment does not measure sunlight exposure or rule out
reverse causality. The main strengths of this study is their large
sample size of healthy subjects of similar origin and uniform
methods of assessing depressive symptoms. Their study did find
an inverse relationship between serum vitamin D levels and depressive symptoms, mostly independent of confounding factors.
To further this relationship and see if low vitamin D levels is a
conclusively a predisposing factor of suicide, Umhau et al. (2013),
did a case-control study of 25-hydroxyvitamin D concentration,
of serum samples stored in the Department of Defense Serum
Repository, of deployed active-duty service members who had
subsequently committed suicide. 495 subjects were selected
from the Armed Forces Health Surveillance Center (AFHSC)
who had officially verified suicides occurring between 2002
and 2008 and had blood sampled within 24 months of death.
Controls were randomly selected from the same data bank, and
were matched as taking the blood work within 12 months of
those who had committed suicide, to minimize for any temporal changes in military environment. They found an increased
risk of suicide in lower levels of serum 25-hydroxyvitamin D,
and all those who committed suicide has a seasonally adjusted
levels below 20 ng/mL. Additionally, they found that 30% of the
suicides assessed occurred in those in the lowest levels of vitamin D status. When they graphed the data, they found a curve
that is characteristic of nutritional intake, which appears to have
benefit until a threshold is reached and after that, any additional
enrichment shows little benefit. Meaning, that if sufficient nutrient input is reached then further input will have no effect
on outcomes. Which is important when considering Vitamin
D supplementation as a treatment method, as discussed later.
One limitation of this study, is that vitamin D levels were not
measured at the time of suicide but sometimes months before.
This problem is lessened by the fact that vitamin D levels are
shown to be correlated up to 3 years apart. Perhaps, active-duty service members may have a higher risk of suicide because
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they often work at night and are excessively covered up in the
daytime, therefore, their reduced sun exposure and subsequent
reduced vitamin D synthesis contributes to their suicidality. In
this study, vitamin D status before suicide attempt was inversely
correlated with suicide risk in a large sample size of a specific
subset of the population with a general high risk of suicide.
Suicidal ideation may be sudden and in most cases, the first
thoughts of suicide often occur less than 10 minutes before the
suicide attempt. In a young, and somewhat aggressive, population like military service members, impulsivity may contribute
to their risk of suicide. There seems to be a link between vitamin D and impulsivity, as vitamin D increases proinflammatory
cytokines in the brain. Proinflammatory cytokines reduces serotonin activity which is long associated with impulsive suicide
(Umhau et al.,2013). As discussed in detail earlier, perhaps, this
effect of vitamin D is the mechanism by which vitamin D deficiency contributes to higher suicide rates.
Is present vitamin D concentration associated with suicide attempt? As a similarly designed study discussed previously, done
by Janelidze, Mattei, Westrin, Traskman-Bendz, & Brundin (2011)
to show that increased inflammatory cytokine concentration
of IL-6 and TNF-α contributes to suicide risk, Grudet, Malm,
Westrin, & Brundin (2014), takes it a step further, to see if vitamin D concentrations, which also contributes to increased
inflammatory cytokine concentrations, differ in suicidal depressed patients compared to non-suicidal depressed patients.
They included a total of 59 patients who had attempted suicide,
and had two control groups of 17 untreated patients with major
depressive disorder who had no suicidal ideation and 14 somatically and psychiatrically healthy patients.They found a significant
difference in serum 25-hydroxyvitamin D levels between groups,
with the suicide attempters have a significantly lower mean vitamin D concentration, of 47 ± 20 nmol/L, than the non-suicidal
patients, 62 ± 27 nmol/L, and healthy patients, 65 ± 26 nmol/L.
Additionally, 58% of patients in the suicidal group had a clinical
vitamin D deficiency of below 50 nmol/L, compared to 30% in
the other two control groups.When comparing vitamin D levels
and inflammatory cytokines in all groups, they found a correlation between 25-hydroxyvitamin D serum concentrations and
proinflammatory cytokine serum concentration of IL-1β. They
did not find a statistically significant correlation between vitamin
D and cytokines IL-6 and TNF-α in all groups. When comparing
individual groups, they found an inverse association between
25-hydroxyvitamin D and IL-1β in the patients who attempted
suicide and an inverse association between 25-hydroxyvitamin
D and IL-6 in the non-suicidal depressed patients. In conclusion,
they found a negative correlation between vitamin D levels and
suicide risk and a negative correlation between vitamin D levels
and proinflammatory cytokines. The cross-sectional design of
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this study does not allow any conclusions whether low vitamin
D status can be a direct contributing factor of suicide, but based
on previous knowledge of the mechanism of 1,25-dihyroxyvitamin D on brain function and regulation, there is considerable
evidence to suggest a direct causality.
Vitamin D deficiency is common in the modern world and
Vitamin D supplementation is relatively inexpensive nutritional
additive. If this vitamin D insufficiency has a direct contribution
on depression and suicide, can vitamin D be used a treatment
to reduce depressive symptoms and stop the epidemic of depression and suicide worldwide?
As a vitamin D intake is an easy nutritional therapy, BertoneJohnson et al. (2011) seeks to clarify if vitamin D supplementation can prevent or treat depression. They patients used for
this study were part of a large and diverse sample size that
was tracked for a long period of time. The subjects used for
this study were part of the observation study (OS) component of the Women’s Health Initiative (WHI) This is a database
composed by the National Institute of Health which allowed
Bertone-Johnson et al. to follow the health of 81,189 postmenopausal women over an 8-year period. Baseline intake was
assessed by asking patients about diet and any vitamin D supplementation and estimates of total solar irradiance was calculated based on the geographic location of the clinic centers
and controlled when interpreting the results. At each clinic
visit, depressive symptoms were assessed using the Burnam
8-item scale for depressive disorders. When controlling for
confounding factors, they found that lower vitamin D intake
of <100 IU/day had a strong inverse correlation in women
who met criteria for prevailing depressive symptoms at the
baseline visit. And the reverse was also true, those patients
with a substantial intake of vitamin D was associated with a
lower prevalence of depressive symptoms. This effect seemed
to have a threshold, as those positive effects of increased intake was only shown in patients who consumed 400 to <800
IU/day and an intake of ≥800 IU/day was not associated with
decreased risk of depression. At year 3 of the study increased
vitamin D intake was correlated with lower risk of depressive
symptoms in patients with no evidence of depression at baseline. A limitation of this study, is that it did not measure serum
25-hydroxyvitamin D levels in conjunction with intake levels.
This is important as the effects of vitamin D intake on serum
vitamin D levels may differ in individuals. Individuals may differ
in the processing of vitamin D ingestion; these differences are
in part because of genetic factors, vitamin D metabolism and
general dietary intake. This study saw an inverse relationship
between vitamin D intake and depressive symptoms in older
women.

One study, looking at the direct effects of vitamin D supplementation on depressive symptoms in conjunction with metabolic profiles, c-reactive protein (CRP), an inflammatory marker,
and oxidative stress. Sepehrmanesh et al., (2016) performed a
randomized, double-blind, clinical trial in performed in Kashan,
Iran, from October 2014 to December 2014. They included 36
patients, ages 18–65 years, equal parts men and women, diagnosed with major depressive disorder and randomly assigned
18 of them to receive a single capsule of 50,000 IU vitamin D
weekly and 18 patients to receive a placebo weekly for 8 weeks
in total. The Beck Depression Inventory (BDI) was used to assess depressive symptoms before and after supplementation. As
expected, after 8 weeks, changes in vitamin D concentrations
were greater in the vitamin D group than in the placebo group.
The group taking vitamin D supplements had improved insulin
function and decreased oxidative stress than the patients that
took a placebo. No changes were seen in c-reactive protein levels between both groups. This may be because of the duration
of the study or the specific inflammatory marker studied, as different inflammatory markers have been found to be associated
with vitamin D deficiency and depression. But most importantly,
this study found that the patients taking vitamin D supplements
had significant decreased depressive symptoms, and decreased
BDI total scores, post-nutritional therapy compared to before.
As all these patients had vitamin D deficiency of less than 20
μg/L at the start of this study, it is not possible to assess if the
effects of supplementation are seen only in vitamin D deficient
individuals or this therapy may also be useful in those who have
clinically sufficient levels of vitamin D. Perhaps the beneficial effects of supplementation can be explained by the fact that both
groups had a low baseline mean serum 25-hydroxyvitamin D
level. Therefore, a relatively short supplementation period was
effective in lowering depressive symptoms. Overall, vitamin D
supplementation had a positive effect on lowering depressive
symptoms in patients with major depressive disorder.

Conclusion
Vitamin D status seems to be directly linked to mood disorders and particularly major depression. A mechanism for this
association is demonstrated in detail, as both are correlated
to inflammatory cytokine status. Vitamin D deficiency is associated with an elevation of proinflammatory cytokines because
vitamin D modulates and prevents uncontrolled inflammation
systemically and in the central nervous system. This elevation of
proinflammatory cytokines may have adverse psychiatric effects.
It can contribute to depressive symptoms and even suicide.
Patients with suicidal thoughts specifically, seem to have abnormal proinflammatory cytokines and lower levels of vitamin D in
their body, than patients with major depression that do not have
suicidal thoughts.
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As the conceptual understanding of vitamin D’s activity as a
neuro and immune modulator on the brain is an innovative and
relatively new area of study, there are few direct-link studies on
how the supplementation of vitamin D may reduce instances of
major depressive disorder and suicide risk. Vitamin D supplementation treatment for major depressive disorder should be
tested in a larger sample size, in patients with clinically sufficient
vitamin D status, and for longer periods of time.Additionally, this
treatment should be tested in patients with suicidal ideation, as
this is the subgroup that has been differentiated to be effected most by vitamin D deficiency. Furthermore, studies should
assess the difference between treatments that raise vitamin D
levels by intake versus UV ray exposure. Perhaps, vitamin D status and its effects may differ when synthesized naturally in the
skin with direct access to subcutaneous fat for storage and the
bloodstream, in contrast the supplementation being first processed in the gastrointestinal tract. Vitamin D as a treatment
method for major depressive disorder is a new and exciting area
of research that may impact the global population tremendously due to the large number of people suffering of depression
worldwide. More research on the effectiveness and limitations
of this treatment should be done to maximize its impact.
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Abstract
In recent years, science has made great strides in its understanding of the microbiome, discovering that it plays a role in
regulating many body processes. One area of study is the microbiomes interaction and influence on host metabolic processes. Studies using both mice and humans have established a clear correlation between obesity and the composition of
the microbiome, identifying a microbiome unique to obese individuals. Furthermore, experiments with germ-free mice
have shown that the microbiome effects host metabolism, causing germ free mice to increase in mass when inoculated
with normal microbiota. Inoculation with microbiota from obese mice yielded greater increases in mass, showing the
obesogenic effect of the microbiota. The mechanisms through which the microbiome can contribute to obesity are enhanced extraction of energy from food, and increased capacity for nutrient uptake in the gut, and alteration of metabolic
pathways by suppressing fasting induced adipose factor and decreasing AMPK activity. Many of these pathways show
increased activity in obese mice. The enhanced energy extraction coupled with greater deposition of fat mediated by
altered metabolic pathways can contribute to obesity.
The role of the microbiota in obesity, combined with decades-old observations that antibiotics, particularly early in life,
increased the weight of livestock, led to a hypothesis that antibiotics can disrupt the development of the microbiome,
causing metabolic changes, leading to obesity. Recently, this hypothesis has been tested, both in studies utilizing mice, and
in many epidemiological studies. This paper will evaluate the available evidence to determine if exposure to antibiotics
early in life can lead to increased incidence of obesity later.
Introduction
In 1671 when Antony van Leeuwenhoek first spied “animalcules,” now known to us as single cell organisms, through his
homemade microscope, he set into motion a centuries long
scientific endeavor to discover, describe, catalogue and gain
a deeper understanding of the vast microbial world that surrounds us. This laid the groundwork for the development of
the germ theory by Louis Pasteur and Robert Koch over the
course of the 1860’s and 1870’s. Germ Theory, the theory that
many diseases are caused by microbial agents, revolutionized
medicine leading to many advances such as the disinfecting
of wounds, the appreciation of the need for a sterile environment during surgery, and in 1921 the fortuitous discovery
of penicillin by Alexander Fleming. Germ theory also had a
profound influence on the attitudes of medicine and society
at large towards “germs.” Although only a tiny fraction of
microbes are pathogenic, they became indelibly associated,
both in the popular imagination and in medical practice, with
sickness and disease. This focus on microbe pathogenicity has
yielded tremendous benefits to public health, in fact antibiotics
were among the primary drivers of rising life expectancy in
developed countries in the mid twentieth century (Armstrong,
1999), but antibiotics, for all their benefits, came with costs as
well, namely their effect on the native flora.
Discovery of the body’s native flora began in the mid 1880’s
when an Austrian pediatrician, Theodore Escherich, observed
the eponymously named Escherichia coli in the stool of healthy
children. Discovery continued apace and the realization set in
that there was a large, diverse, community of microbes that
colonized the skin, nasal and oral cavities, and the urogenital
and gastrointestinal tracts of healthy people, making up their
native flora. As early as the 1970’s there was already an idea

of the number of microbes, then estimated to number roughly 1014, living primarily in the gastrointestinal tract, and some
idea of ecology of this diverse community (Savage, 1977). Until
relatively recently, it was assumed that the microbes living in
the colon lived a largely commensal existence, dining on food
indigestible to the human host but not interacting with the
host in any meaningful way. With this understanding collateral
damage to the gut bacteria because of antibiotics was no great
concern, with the worst-case scenario being an unwanted
bloom of C. Difficile. However, in recent years and particularly
since the launch of the Human Microbiome Project, an entirely
different picture has emerged, one that includes many symbiotic relationships between the native flora and the host, in
fact so enmeshed is the host-symbiont relationship, that they
have been described as one “supraorganism (Turnbaugh, et al.,
2007). This new understanding demands a closer look at the
possible effects of antibiotics on our microbiome.
This paper will explore the possible link between antibiotics
and obesity. First it will lay the groundwork with a thorough
exploration of the literature linking the state of the microbiome to obesity as well as an understanding of the underlying mechanisms. Then it will consider the evidence that a
disturbance of the microbiota through antibiotic treatment
can cause obesity along with proposed causative mechanism.
Finally, it will propose ways to mitigate the effects of the antibiotic treatment.

Methods
Information for this paper was obtained primarily through online searches utilizing google scholar as well as well as numerous
databases accessed through Touro college’s library system.
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Definition of “Core Microbiome”
The first step to determining if obesity is associated with an
altered microbiome is establishing the baseline values defining
what a “normal” gut microbiome looks like. This task is complicated by the wide diversity of gut microbial populations found
across different geographical areas and cultures, and even within
communities and cultures. In fact, in one study “there was not
a single abundant (deﬁned as >0.5% of the community) bacterial species shared by all 154 individuals” involved in the study
(Turnbaugh P. J., 2009) . However, if one looks at the microbiome
on the level of phyla, a strong pattern begins to emerge, with
bacteria from the phyla Firmicutes and Bacteriodetes representing, in one study, 92.6% of the microbiota (Ley, et al., 2006).
These 2 phyla and their respective ratios can serve as one definition of a core microbiota.
Another way of defining the core microbiome is, rather than
focusing on the species or phyla present, focusing on the various genes present. Various studies utilizing this methodology
have found that regardless of the vast diversity of the microbial
makeup of the gut flora, there exists a “wide array of shared microbial genes, comprising an extensive, identifiable ‘core microbiome’ at the gene, rather than at the organismal lineage, level”
(Turnbough, et al., 2009). While both definitions are useful, this
paper will primarily utilize the second definition of the microbiome as a set of genes rather than ratio of different bacterial
phyla. The reason for this is that a focus on genes can better
illuminate any products of the microbiome that may affect host
metabolic pathways, possibly contributing to obesity.

Association of Obesity with Altered Microbiome
Having established a baseline microbiome, we can now explore
any obesity associated changes that may occur. First, we will explore the changes in the ratio of Firmicutes and Bacteroidetes
associated with obesity.
In one experiment, mice heterozygous for obesity ob/+ (due to
a defective leptin gene) were mated producing litters consisting
of a mix of obese (ob/ob) and lean (ob/+ and +/+) phenotypes.
Microbial ecology in the gut, specifically the ratio of Firmicutes
to Bacteroidetes, which is typically similar among members of
a family living together, was found to be consistent in the heterozygous mothers as well as the ob/+ and +/+ children. In the
homozygous ob/ob mice of the same litter however, a sharp
increase in abundance of Firmicutes relative to Bacteroidetes
was observed (Ley, et al., 2005). This shows a clear correlation
between obesity and the composition of the gut microbiome.
In another experiment, 12 obese individuals were randomly
placed on either a fat or carbohydrate restricted diet and their
gut microbiota was monitored over the course of a year for any
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discernible shift in the microbiota as they lost weight. Initially,
obese people had more firmicutes and fewer Bateroidetes than
lean controls. However, over the course of the year as their
weight dropped, the ratio of Firmicutes to Bacetoidetes began
to more closely resemble a typical lean profile (Ley, et al., 2006).
Together, these two studies, encompassing both mice and men
and showing both an increase in abundance of Firmicutes as an
obese phenotype was acquired in the mouse experiment and
a decrease in its abundance as weight was lost in the human
experiment, firmly establish that obesity is associated with an
altered microbiome.

Can the Gut Microbiome Cause Obesity?
Having established a strong correlation between obesity and altered gut microbial ecology, we can now explore the possibility
that the microbiome can be a causative agent in obesity.
There seems to be good experimental evidence, at least with
mice, that this is the case.
In one experiment, mice were divided into three groups. One
group was raised “Germ Free” meaning that their gut was sterile. Another group consisted of regular, conventionally raised
mice, and acted as a control. A third group was initially raised
germ, free but subsequently inoculated with gut bacteria at 7-10
weeks by spreading a suspension of cecal content from the control group mice on their fur. Comparison of germ free and regular mice at 8 to 10 weeks found that regular mice had 42% more
body fat than their germ-free companions and had epidydimal
fat pads weighing 47% more, all while eating 29% less food. After
a 14-day colonization, a process known as conventionalization,
the third group of mice experienced a dramatic 57% increase in
total body fat and a 61% increase in epididymal fat pad weight
all while their chow consumption decreased to that of the normal mice (Backed, et al., 2004). This experiment shows that gut
microbiota has a powerful effect on metabolism and fat storage.
The initial low-fat state of the germ-free mice even with their
above average food intake and their dramatic increase in fat,
even in the face of decreased chow consumption, as they were
conventionalized, indicates that a normal microbiome plays a
key role in regulating fat in mice.
Having established the effects of a normal microbiome, let us examine the effects of an obese one.Toward this end, an experiment
was constructed in which germ-free mice were colonized by gavage (meaning they were fed by tube) with the cecal contents of
either wild type +/+ or genetically obese ob/ob (leptin deficient)
mice. In the 14-day period following the colonization food consumption in the (ob/ob) and (+/+) transplanted groups was not
statistically different (55.4±2.5g for ob/ob against 54.0±1.2g for
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+/+) and they both ate the same type of chow (no difference in
caloric density). Despite this, the mice colonized with ob/ob microbiota exhibited a significantly greater increase in body fat than
those colonized with +/+ microbiota with the ob/ob colonized
mice increasing body fat by 47±8.3% and the +/+ colonized mice
increasing by just 27±3.6% (Turnbaugh,et al., 2006).
The dramatic difference in body fat between the two groups
strongly indicates that the obese microbiome causes greater
adiposity, and gives rise to the possibility that the microbiome
can play a role in its development.

Mechanisms of Microbiome Influence on Adiposity
The classic, somewhat simplistic understanding of the development of obesity is to take the calories of the food eaten,
subtract calories burned by both the basal metabolic rate and
any additional energy expenditures for various activities, and
assume that the remainder is stored as fat in adipose tissue
throughout the body. Our exploration of the mechanisms
through which the gut microbiota increase adiposity will illuminate several ways that this seemingly straightforward and
commonsense equation can be altered.
One mechanism proposed is that all microbiomes increase the
bodies capacity for energy harvest from food eaten by excreting exoenzymes that break down polysaccharides that the host
is unable to metabolize. Once degraded into monosaccharides
and short chain fatty acids, both the bacteria and the host
readily take up the product, accruing extra calories to the host
from the same food. It is further hypothesized that the changed
obese microbiome performs these tasks more efficiently extracting even more calories from the same unit of food with the
host reaping some of the benefits. This hypothesis is buttressed
by numerous lines of evidence.
The first of these is a simple comparison of the energy remaining in the feces of regular mice as opposed to genetically
obese mice. Bomb calorimetry showed that ob/ob mice have
significantly less energy remaining than regular mice, yielding 3.2
kcal/g compared to 3.4 in regular mice (Turnbaugh, et al., 2006).
This is simple, clear, empirical evidence that an obese microbiome harvests more energy than a standard, lean microbiome.
Another line of evidence involves a genetic analysis of the microbiome, specifically of genes encoding enzymes that catalyze
the breakdown of polysaccharides indigestible to their hosts.
In one study, a sequencing of 18 Human microbiomes identified
genes for 156 carbohydrate- active enzymes, which are enzyme
families that break down carbohydrates, including 77 glycoside
hydrolase, 21 carbohydrate-binding module, 35 glycosyltransferase, 12 polysaccharide lyase and 11 carbohydrate-esterase

families. These genes consisted of fully 2.62±.013% of all the
microbial genes sequenced, a higher percentage than any other
identified group of genes. Furthermore, an analysis of lean and
obese twins found that the obese twins had a microbiome that
was significantly enriched in genes coding for carbohydrate,
lipid, and amino acid metabolism as compared to that of their
lean twins (Turnbough, et al., 2009).
Mice studies have yielded similar results, with ob/ob mice
having microbiomes containing more genes coding for various
carbohydrate-active enzymes as compared with their lean littermates. A predicted result of this would be an increased concentration of the products of bacterial fermentation of these
polysaccharides, such as butyrate and acetate, in the cecum
of the ob/ob mice. This prediction was borne out, with cecal
butyrate concentration of obese mice double those of lean
mice and acetate levels 20% higher (Turnbaugh, et al., 2006).
Interestingly this same study also found a greater abundance
of archaea in the obese mice than their lean counterparts.
Archaea oxidize the hydrogen produced as a by-product
of fermentation by gut bacteria, turning it into methane. By
removing a product of the fermentation reaction, they increase its efficiency, serving to further enhance energy extraction by the obese microbiome. Indeed, in a study of mice
colonized with archaea commonly found in the human gut,
Methanobrevibactor smithii and B. thetaiotamicron, a significant increase in the efficiency of bacterial polysaccharide fermentation leading to an increase in adiposity in the mice was
observed (Samuel & Gordon, 2006)
In addition to increasing energy extraction from food, there is
also evidence that the microbiome increases the hosts capacity
for uptake of nutrients in the gut. In one experiment, germ-free
and conventionalized mice were fed a glucose solution. After fifteen minutes, the level of glucose uptake was found to be twice
as high in the conventionalized mice as in the germ-free ones
(Backed, et al., 2004). Additionally, the microbiome is essential to
the development of the capillary network to transfer these nutrients from the intestines to the hepatic portal vein. Germ-free
mice were found to have arrested development of this capillary
network, and upon conventionalization, developed it to normal
levels within ten days (Stappenbeck & Hooper, 2002).
These lines of evidence collectively paint a picture of a microbiome that extracts more energy from food by breaking down
complex polysaccharides that the host is unable to metabolize
on his own and amplifying the hosts ability to absorb the resultant monosaccharides, providing one possible mechanism for
the microbiome to contribute to obesity.
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Another mechanism proposed is that the microbiome modifies
cell signaling pathways to increase fat storage, that is, to direct
more of the energy harvested toward adipocyte storage rather than other metabolic functions. Two metabolic pathways are
involved, one of which involves fasting-induced adipose factor
(Fiaf) which is a lipoprotein lipase inhibitor (Backed, et al., 2004).
Lipoprotein lipase facilitates deposition of fat in adipocytes. Fiaf,
which inhibits it, is a crucial regulator of this process. Fiaf is produced by brown and white fat, the liver, and the intestine. The
microbiome suppresses the production of Fiaf in the intestinal
epithelium, thereby increasing the activity of lipoprotein lipases,
resulting in more triglycerides being incorporated into adipocytes.
Experimental evidence for this machanism comes from a study
that compared regular germ-free mice, germ-free mice incapable of producing Fiaf (Fiaf-/-), and conventionalized mice both
with and without the Fiaf gene. The regular germ free mice,
as expected were the leanest. Germ free Fiaf-/- mice however, were found to have nearly the same amount of fat as their
conventionalised wild type peers. Furthermore, a conventionalization of the germ free Fiaf knockout mice yielded a minimal
increase in body fat of 10±8% versus 55±16% for the wild type
germ free mice. Conventionalization of heterozygotes (Fiaf +/-)
yielded an intermediate result, consistant with the hypothesis.
Additionally comparison of mRNA of conventionalised and
germ free wild type mice revealed camparitively less Fiaf expression in the small intestines of the the former, expression
elswhere though was unaffected (Backed, et al., 2004). Other
studies have had similar findings, including one that found that
while regular germ free mice were resistant to obesity induced
by consuming an “american diet” in their case chow with higher
fat content and more easily digested sugars, Fiaf -/- mice had
lost this resistance (Backhed, et al., 2007). These findings point
to fasting induced adipose factor as a major component of the
microbiomes contribution to adiposity.
Another pathway involves levels of AMP-activated protein kinase, or AMPK (Backhed, et al,. 2007). AMPK is a key enzyme
regulating metabolism, serving as the lynchpin of a complex web
of metabolic pathways maintaining proper ATP levels. AMPK
ramps up energy production in response to metabolic stresses.
It is triggered primarily, as its name indicates, by an increased
ratio of AMP to ATP, but also by numerous other factors such as
an elevated ratio of NAD to NADH, and the hormones leptin
and adiponectin (Kahn, et al,. 2005) .The microbiome is thought
to decrease AMPK activity, leading to lower energy expenditure,
with more calories remaining to be deposited as fat.
Evidence for this mechanism is based on a number of observations. The first is that germ free mice were found, using an
immunoblot assay, to have phospho-AMPK, which is the active
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form, at concentrations 40% percent greater than their regular
peers in their gastrocnemeus muscles. Consistant with these
findings AMP levels in the germ-free mice were foud to be 50%
higher. Additionally, many other enzymes involved in the fatty
acid oxidation pathway triggered by AMPK showed fluctuations
consistant with increased fatty acid oxidation. In this pathway,
AcetylCoA carboxylase converts Acetyl CoA to Malonyl CoA,
Malonyl CoA inhibits carnitine-palmitoyl transferase-1 (Cpt1),
which catalyzes the rate-limiting step for uptake of long chain
fatty acids by mitochondria, AMPK phosphorylates AcetylCoA
carboxylase, inhibiting it and thereby increasing fatty acid
oxidation (Kahn, et al, 2005). A 43% increase in the levels of
phosphorylated AcetylCoA carboxylase was found using an
immunoblot assay and a 17% increase in the level of Cpt1 was
found with a biochemichal assay, in germ free over that of regular mice,both consistant with increased fatty acid oxidation
(Backhed, et al,. 2007).
Collectively, these lines of evidence paint a picture of a microbiome that acts on both sides of the energy equation, harvesting
more energy from food through greater polysaccharidase activity, conserving more of that energy through, and depositing a
greater portion of it as fat.

Can Antibiotics Contribute to Obesity?
Having gained some appreciation of the influence of our microbiota on our metabolism and its role in promoting adiposity,
we can now explore the role of antibiotics on this complex
system. Specifically, we will explore whether the disruption to
the microbiota caused by antibiotics, particularly early in life, can
affect the body mass of the host later in life by either promoting
or inhibiting weight gain.
There is extensive evidence that antibiotics promote weight
gain, from veterinary medicine, animal models, and epidemiological studies.
In the 1950’s Veterinary scientists showed that giving pigs (Taylor
& Gordon, 1955) and other livestock (Jukes & Williams, 1953)
sub-therapeutic doses of antibiotics increased their growth
causing them to gain more weight without increasing feed
consumption. It subsequently became common practice among
farmers to mix low doses of antibiotics into the feed of pigs,
cows, sheep, and poultry, increasing their weight, a practice that
continues to this day. The effect on weight gain is significant, a
meta-analysis of numerous studies gauging the weight boosting
effects of adding antibiotics to feed in pigs found an increase in
weight gain of up to 15% and an increase in feed efficiency (an
industry term for amount of meat produced per unit of feed) of
up to 6%.The strongest effects were found when the antibiotics
were given from birth with lesser, though still significant effects
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found if they were given at later dates (Hays, 1969). Evidence
that the weight gain is connected to disruption of the microbiota comes from experiments with germ free chickens. Germ free
chickens given feed containing antibiotics that had a growth promoting effect on regular chickens showed no similar increase in
growth from the treatment (Coates, 1963), indicating that the
weight gain is a result of modulation of the microbiome. These
veterinary studies on regular and germ free animals, combined
with the everyday experience of farmers for the last 70 years
provide one line of evidence that antibiotic use has a role in
weight gain. Importantly, as the data showed, the effect is greatly
magnified in early life, suggesting that the early microbiome may
be particularly vulnerable to whatever disruption causes the
weight gain, a theme that will be expanded on shortly.
More evidence comes from experiments with model organisms,
namely Mus Musculus, the mouse. Additionally, these experiments shed light on the magnified effects of antibiotics found
in early life.
In one experiment the effects of sub-therapeutic antibiotic
treatment (STAT) was tested on mice to attempt to replicate its
observed effect on farm animals and gain some insight into its
mechanisms. In the experiment mice were exposed, starting at
weaning, to various common antibiotics by putting them in their
drinking water at sub-therapeutic levels, and were compared
to a control group using various metrics. After a seven-week
exposure, the STAT mice were found to have greater fat mass
than the control group as well as a significantly higher percent
body fat. Curiously although fat mass was greater in the STAT
mice, total mass was not significantly greater at seven weeks,
though later measurements taken from 8 to 26 weeks did show
increased mass in the STAT mice (Cho, et al., 2012).
Utilization of other metrics allows for a deeper understanding
of the processes driving the adiposity of the STAT mice. One
important measure taken was the level of Gastric Inhibitory
Polypeptide (GIP). GIP, a hormone secreted by K cells in the
small intestine, stimulates lipoprotein lipase activity, increasing
fat storage and contributing to adiposity (Miyawaki, et al., 2002).
GIP levels were found to be substantially elevated in STAT mice
(39.1±2.5 pg/ml) compared to the controls (24.4±4.2 pg/ml).
This provides a possible mechanism for the observed increase
in adiposity.
Microarray analysis of differential gene expression in hepatic tissue yielded deeper insights into the metabolic changes wrought
by STAT. Comparison of STAT and control mice found upregulation of pathways for lipogenesis and triglyceride synthesis in the
STAT mice, further contributing to adiposity.

Examination of the gut bacteria in the STAT mice yielded further insight. Although the overall number of bacteria did not
change significantly, the composition of the microbiome did
change, with the abundance of Firmicutes increasing relative to
that of Bacteroidetes, which, as discussed earlier, is typical of
obese microbiomes. Additionally, examination of the cecal contents of the STAT mice found higher levels of butyrate and acetate, suggesting increased energy capture through fermentation
of complex carbohydrates indigestible to the mice, as discussed
earlier. Supporting evidence came from metabolic cage experiments showing no difference in caloric intake but a lower caloric output in fecal pellets in STAT mice compared to controls
(Cho, et al., 2012).
Taken together, these measurements paint a picture of antibiotics changing the composition of the microbiome, leading to
metabolic changes causing adiposity and weight gain, and suggest
that perhaps antibiotics can contribute to obesity in humans as
well.

Increased Effect in Early Life
Greater weight gain was observed in farm animals when STAT
was started earlier in life. Mouse studies have explored the importance of the timing of antibiotic exposure further, experimentally confirming these observations and expanding upon
them. They found that early life is a critical time in metabolic
development and exposure to antibiotics at this sensitive stage
can permanently alter host metabolism.
Evidence for these claims comes from an experiment comparing
mice started on low dose penicillin (LDP) at weaning (LDP-w) to
mice where LPD was started shortly before birth(LDP-b) so that
the initial colonization with maternal microbiota would be altered.
A control group was maintained that was not exposed at all.
The experiment found that earlier administration of antibiotics
did have amplified effects.The growth rate for LDP-b was greater than the control, the fat mass as well as the total mass of
adult LDP-b male mice was greater than that of LDP-w mice and
the control (Cox, et al., 2014), demonstrating enhanced effects
of earlier antibiotic administration. Sexual dimorphism was apparent in the results with the females experiencing lesser if any
effects, a finding that remains unexplained. Metabolic differences
between the LDP-b and LDP-w mice were found as well with
the LDP-b mice having greater expression of genes involved in
adipogenesis than LDP-w mice.
The mammalian early microbiome is a dynamic, changing environment typically showing a pattern of succession as different taxa first dominate then diminish (Pantoja-Feliciano, et al.,
2013). Altered representation of some of these taxa has been
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associated with obesity (Kalliomaki, et al,. 2008). Typically,
Lactobacillus is prominent in nursing animals, as was indeed the
case with the controls. The LDP-b mice however, showed much
lower levels of Lactobacillus, as well as other groups whose population typically peak in early life such as Candidatus Arthomitus
and Allobaculum (Cox, et al., 2014). Although the precise roles
of these microbes are not known, their suppression by LDP and
the dramatic phenotypic effects that follow suggest some role
in metabolic development.
In an experiment with worrying implications for human obesity,
some LDP mice were switched to high fat diet at 17 weeks, and
were compared to control groups with just a high fat diet or
just LDP. The growth promoting effects of LDP were accentuated by the high fat diet producing fat and weight gain surpassing
that produced by the high fat diet or LDP alone.
More worrying still, the metabolic effects of LDP lasted into
adulthood even after treatment finished. Mice that received LDP
for only four weeks after birth still experienced greater fat and
total mass accumulation from 6-20 weeks. This weight gain persisted even though the microbiota had appeared to normalize.
Finally, to demonstrate that the metabolic and phenotypic
changes observed were a result of an altered microbiota
and not some direct effect of the penicillin, cecal microbiota
were transferred from 18-week-old control and LDP mice to
3 week germ-free mice. The mice inoculated with the LDP
microbiota increased total mass and fat mass at a faster rate
(.078 g/day total mass and .058 g/day fat mass faster) than
those inoculated with the normal microbiota (Cox, et al.,
2014).
These studies provide convincing evidence, as much as can be
inferred from model organisms, that antibiotics contribute to
obesity through disruption of the microbiota, and that early life
is a particularly sensitive time when disruption of the developing
microbiome can have long lasting metabolic effects.

Epidemiological Studies
The findings in model organisms that antibiotic exposure, particularly in early life, can lead to obesity, have important implications for human health. However, results in model organisms
do not always translate into results in humans. Since ethical
concerns preclude the types of randomized, controlled studies
routinely performed with model organisms from being done on
humans, we must rely on epidemiological evidence. Fortunately,
there are a wealth of well-constructed epidemiological studies
demonstrating that antibiotic exposure in infancy is correlated
with obesity later in life.
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In a study involving 28354 mother baby pairs from the Danish
National Birth Cohort, antibiotic exposure in the first six
months of life was correlated (with an odds ratio of 1.54,
well above the threshold for showing correlation) with an increased risk of being overweight at 7 years (Ajslev, et al., 2011).
Supporting these findings are results from a study utilizing
11532 children from the Avon Longitudinal Study of Parent and
Children. This study examined antibiotic exposure during three
early-life time windows, 6< months, 6-14 months, and 15-23
months. Exposure under six months was, once again, strongly
correlated (p<.001) with increased body mass at 10, 20, and
38 months. However, exposure from 6-14 months showed no
effect and exposure at 15-24 showed a modest weight gain at 7
years (Trasande, et al., 2013). A Canadian study combining data
from health records and a Canadian longitudinal birth cohort
study further bolstered these findings. The study found that
children who received antibiotic treatment in the first year of
life were more likely to be overweight at ages 9 and 12 than
their untreated peers (32.4% overweight if exposed vs. 18.2%
if not). Additionally, researchers noted a greater prevalence of
elevated central adiposity, a precursor of metabolic syndrome,
among the treated children (Azad, et al, 2014). A longitudinal
study in the USA (Bailey, et al., 2014)and a global cross sectional
study (Murphy, et al., 2013) found similar results as well. Several
the studies (Trasande, et al., 2013) (Murphy, et al., 2013) found a
strong sexual dimorphism, with the effect much greater in boys,
and nearly all the studies showed some difference between girls
and boys, with the boys seeing greater weight gain than the
girls, a finding that while replicated many times in both model
organisms and in humans, has not been satisfactorily explained.
The collective weight of these epidemiological studies gives
great credence to claims that antibiotics contribute to obesity.

Mitigating the Effects of Antibiotics
Even with all the evidence of detrimental side effect of antibiotics, stopping their use is obviously not an option. Antibiotics
are a cornerstone of modern medicine, without which life expectancy would surely drop precipitously. However perhaps a
bit of restraint in prescribing antibiotics to children is in order.
Rates of antibiotic prescriptions in the USA are unnecessarily
high, with some analyses finding that fully half of all antibiotic
prescriptions written are unnecessary (Nyquist, et al., 1998).
Although antibiotic prescription rates among children and adolescents have dropped since that finding (Lee, et al., 2014), prescription rates in the USA are still high compared to some other
countries. In Sweden, for example, antibiotic use is 53% lower
than in the USA (Ternhag & Hellman, 2010). This indicates that
prescription levels can still be lowered significantly without adversely effecting public health. While some antibiotic exposure
may be unavoidable for many children, even merely reducing the
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number of rounds of antibiotics they take reduces their chance
of developing obesity later in life (Bailey, et al., 2014).
One final action possible to mitigate the obesogenic effects of
antibiotics on children is to prescribe narrow spectrum antibiotics when possible. One study, despite finding significant
correlation between broad-spectrum antibiotics in the first two
years of life, found no such correlation for narrow-spectrum
antibiotics (Bailey, et al., 2014).

Conclusions
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In conclusion, the evidence for an obesogenic effect of early-life
exposure to antibiotics is substantial and convincing. The many
mouse studies demonstrating the influence of the microbiome
on metabolism and its role in obesity give ample reason to suspect that perturbations of the microbiome with antibiotics may
have some effect on obesity. The evidence from farm animals,
mice, and epidemiological studies serve to confirm that suspicion, showing that antibiotic exposure in infancy contributes to
one’s chances of developing obesity later in life.
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